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General Introduction 
 
 
Active compound screening 
 
Compound activity screening is common practice in drug discovery 
and it is often performed in high throughput fashion to facilitate the 
screening of large numbers of compounds to be processed [1]. 
Compound screening is usually performed in a broad variety of different 
assays among which are cellular and biochemical assays. While 
biochemical assays usually only give information regarding the affinity of 
compounds towards target macromolecules they are screened for, they 
can be performed at a much higher throughput with less complexity than 
cellular assays [2]. On the contrary, cellular (e.g. signal transduction) 
based assays provide much information about the biological activity of a 
compound on cells and therefore more closely resemble the effects 
compounds may exert in the body [3]. A drawback of cellular assays, 
however, is the cumbersome and continuous production of viable cells, 
while the target proteins needed in biochemical assays usually can be 
stored easily and efficiently in freezers until use. This is why initial 
screening procedures encompass affinity screening to reduce the 
compound pipeline into smaller libraries with “higher affinity compounds”. 
After the first screening process of large libraries, the initial hits found in 
the libraries present a small fraction of the original libraries rendering 
them more suitable for further cell based screening.  
While radioligand based affinity assays were the primary assays in 
the past, the use of radiolabeled tracer molecules and the heterogenicity 
of the assays render them less suitable for high throughput 
automatisation than e.g. fluorescence based assays. This resulted in the 
development of fluorescence based assays in all areas of drug 
discovery. Examples such as time-resolved fluorescence resonance 
energy transfer, fluorescence anisotropy, fluorescence correlation 
spectroscopy, fluorescence fluctuation spectroscopy and normal 
fluorescence based assays can be named in this regard [4]. 
Fluorescence based assays are not necessarily only ligand binding 
assays. Cellular (e.g. functional) assays that are fluorescence based also 
exist and have great perspectives due to their usual robustness and 
ease of handling [5, 6]. 
A primary bottleneck in compound screening is the identification of 
the compound or compounds that are responsible for biological activities 
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in complex mixtures, such as combinatorial and natural compound 
libraries. This also holds true for the screening of metabolic mixtures [7]. 
The activities and/or affinities of metabolites, which usually closely 
resemble the structure of the mother compound, are extremely important 
determinants in the final actions of a drug. Cumbersome labour intensive 
and costly dereplication processes usually have to be performed in order 
to separate the compounds in the mixtures (usually in 96- to 1536-well 
plates) before the separated compounds can be resubmitted to the 
original assays [8, 9]. An example is shown in Figure 1.  
 
 
Figure 1: Active metabolite profiling using an HPLC based dereplication 
format with 96-well plates. Bioassay-guided detection of active 
metabolites with characterization by mass spectrometry allows 
identification of active metabolites in metabolic mixtures. Metabolite 
mixtures are collected into 96-well plates after separation by HPLC. The 
fractions are then screened for activity with relevant bioassays (e.g., 
receptor binding or enzyme inhibition assays). Adapted from Fura et al 
[7].  
 
 
Receptor screening technologies [10, 11] do allow affinity 
screening of individual components, but they are usually not capable of 
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detecting individual compounds in mixtures. Some receptor affinity 
screening strategies concern the binding of active metabolites to a 
receptor followed by off-line centrifugal ultrafiltration, thus resulting in the 
collection of bound ligands and allowing characterization by LC-MS. With 
this methodology, Lim et al [12] detected three ERα binding mono-
hydroxylated metabolites of tamoxifen and N-desmethyl-tamoxifen in rat 
liver microsomal incubations. Similar methodologies were reported by 
Sun et al [13]. These technologies, however, lack the ability of efficient 
trapping of low affinity ligands in the presence of high affinity ligands or in 
the presence of high concentrations of the parent compound.  
This major bottleneck could be circumvented by direct on-line post-
column connection of the desired bioassays to the separation technique 
used in the dereplication process (mostly HPLC) [14], now also known as 
High Resolution Screening (HRS). When performed in parallel with MS 
measurements, chemical information of the individual compounds could 
directly be linked to their biological activities [15, 16]. The aim of the 
present thesis is the evaluation of HRS for active metabolite screening 
and for screening of affinities towards drug metabolizing enzymes. 
Therefore, this chapter firstly reviews the evolvement and current state of 
HRS. Principles and applications are discussed and advantages and 
drawbacks are evaluated. Then, drug metabolizing enzymes and 
bioactivation are introduced as these topics are used throughout this 
thesis.  
 
 
High Resolution Screening 
 
The term High Resolution Screening (HRS) dates from the 1990’s 
and was introduced with the development of the first truly on-line post-
column bio-detection assay [14]. With the advent of HRS, novel 
approaches arose in screening methodologies thereby opening ways for 
the rapid and efficient screening of complex mixtures. In this respect, not 
only combinatorial chemistry libraries were opened for rapid screening, 
but emphasis was laid on natural compound libraries [15, 16]. Whereas 
active impurities in HTS may pose delays in the process, with HRS they 
are easily detected as separate active compounds. The ease of 
parallelisation allowed the simultaneous screening towards several 
targets [17]. This parallelisation actually involved the application of post-
column flow splitters and directing the splitted flows to the desired 
detection methods. A general scheme of a HRS setup which employs 
assay parallelisation is shown in Figure 2. The following paragraph gives 
a detailed description of the different bioassay formats. 
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Figure 2: General scheme of a HRS-setup with two parallelized 
bioassays. After gradient HPLC with post-column make-up gradient (A), 
the total flow is split (B) to the two parallelized bioassays. Via 
subsequent bioassay T-unions (C), the target proteins (T1 and T2) are 
added to the splitted parts of the HPLC effluent into reaction coils (D). 
Substrate or ligand (S1 and S2) is then added to the following reaction 
coils. After the on-line bioreactions, a fluorescence readout is commonly 
employed (FLD). Parallel Mass Spectrometry (MS) readout allows 
identification of active compounds. A parallel assay format provides 
selectivity data when two similar targets are used. A.S. = autosampler. 
 
 
General principles of High Resolution Screening 
 
The main characteristic of HRS based assays is the continuous 
mixing of target protein and tracer molecules, usually from different 
reservoirs, with a carrier flow. This carrier flow can directly transport 
injected samples into the system or the carrier flow can be replaced by 
the effluent of a separation technique, such as HPLC [18]. After mixing in 
a reaction chamber, which commonly exists of coiled or non-coiled 
tubing, the reaction products go directly to a detection unit 
(homogeneous format) or first pass some kind of separation step to 
separate bound or reacted tracer molecules from non-bound or non-
reacted tracer molecules (heterogeneous format). To maintain relatively 
stable target and tracer solutions over time, they are usually stored at 
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appropriate temperatures (0-4 °C) and introduced into the reaction unit 
by superloops [19], which are actually large volume syringes. When 
eluting compounds interact with the target screened for, temporary 
changes in detector signal are reported as they elute. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic view of the estrogen receptor assay in 
hererogeneous format. (1) Effluent from HPLC. (2) Flow split to MS and 
the bioassay. (3) Addition of estrogen receptor. (4) Reaction coil. (5) 
Addition of the fluorescent ligand coumestrol. (6) Reaction coil. (7) 
Restricted access column. (8) Fluorescence detector. Adapted from van 
Elswijk et al [15]. 
 
 
Basically, HRS assay formats can be divided into two major 
classes, namely heterogeneous and homogeneous assays. The main 
advantage of heterogeneous assay formats is their intrinsically high 
sensitivity due to low background fluorescence. An example is given by 
Oosterkamp et al, who simultaneously developed a heterogeneous and 
homogeneous assay format for the estrogen receptor [20]. These 
assays, which are based on the natively fluorescent ligand coumestrol, 
could be operated in a homogeneous way because of the fluorescence 
enhancement of coumestrol in the active site. Although the non-bound 
coumestrol interferes with the measured signal, this is compensated for 
by the intrinsic stability of homogeneous assay formats. Other assays 
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that mainly rely on homogeneous formats are enzymatic assays in which 
the inhibition of the conversion of a non-fluorescent substrate into a 
fluorescent product by test compounds is a measure of enzyme affinity 
[21]. While heterogeneous assays usually prove to be less stable due to 
clogging risks of the restricted access columns used, as in the case with 
the estrogen receptor α, the removal of the background fluorescence 
usually renders the assay more sensitive. A schematic view of a HRS 
based  receptor assay in heterogeneous format reported in literature is 
depicted in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: HRS screening of a pomegranate extract. (1) luteolin (2) 
quercetin (3) kaempferol. (A) TOC of a Pomegranate extract. (B) TOC 
identity confirmation with standards. (C) Corresponding receptor affinity 
trace. Adapted from van Elswijk et al [15]. 
 
 
The main causes of decreased stability in heterogeneous assays 
are the ease of clogging of column materials used (in the restricted 
access columns) for the unbound analyte removal at the end of the on-
line reaction coil(s) and the breakthrough times of these columns which 
are relatively short, especially when organic modifiers used in HPLC 
separations are employed. An increased column volume is not a viable 
option in this respect as this change also result in more band broadening 
of eluting compounds and hence compromise resolution. One other 
remarkable characteristic of heterogeneous assay columns is their ability 
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to not only trap the non-bound ligand, but also potentially interfering 
eluting compounds [15]. A typical example of this concerns the screening 
of plant extracts, which contain many flavones and isoflavones that may 
interfere with the fluorescent ligand used, e.g.  coumestrol used in the 
estrogen receptor assay. Figure 4 shows that plant extracts can be 
screened for estrogen receptor affinity in a heterogeneous assay format 
with coumestrol as tracer ligand. Due to trapping of non-bound flavones 
and isoflavones, which have similar fluorescent characteristics as the 
tracer ligand coumestrol, these compounds from the plant extracts do not 
interfere with the fluorescent affinity monitoring. While in homogeneous 
assay formats (unbound) eluting compounds may intrinsically alter the 
fluorescence, in heterogeneous assays they are thus usually trapped. 
With most HRS based assays currently developed, the coupling to 
separation technologies like HPLC leads to the introduction of organic 
solvents, such as methanol or acetonitrile. The well known incompatibility 
of most biochemical targets with such agents is slightly compensated by 
the relatively short post-column reaction times used in the on-line 
biochemical assays, effecting minimal destruction of biochemical target 
molecules before detection. Another important aspect in this regard is 
the increasing concentration of organic modifier when gradient HPLC 
separation is applied. While efficient and universal separations are 
mainly based on gradients of organic modifiers, thereby allowing most 
compounds in mixtures to be separated on the basis of their large 
differences in lipophilicity and/or polarities, these gradients do pose 
problems in post-column detection. This problem can efficiently be 
solved by the addition of a counteracting post-column gradient, allowing 
an effluent with a constant concentration of organic modifier to enter the 
bio-assays [15].  
 
Assays developed in High Resolution Screening format 
 
First High Resolution Screening assays 
 
The first post-column on-line biochemical detection system was 
developed by Przyjazny et al [22]. This proof of principle setup made use 
of the high affinity interactions of avidin with biotin and biocytin. Avidin 
occupied with an affinity dye was continuously mixed with the HPLC 
effluent. Upon biotin or biocytin elution, the dye was displaced from the 
active site of avidin resulting in optical changes, which were measured 
by UV. In this way, for the first time, two cross-reactive compounds 
present in one mixture could efficiently be separated and individually be 
detected as compounds with affinity for avidin in an on-line assay format. 
Although this on-line assay showed novel possibilities for rapid screening 
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of biochemical interactions in mixtures, the UV based detection 
methodology rendered the assay format less useful for the screening of 
unknown mixtures. Since the UV absorbance was measured at 345 nm, 
it can be expected that many compounds in mixtures also show 
absorbance at this wavelength. Subsequently, Przyjazny et al developed 
a post-column homogeneous fluorophore-linked assay [23]. Fluorescein 
labeled avidin, which was continuously pumped into a post-column 
reaction chamber together with the HPLC effluent, showed fluorescence 
enhancement when eluting biotin and derivatives interacted with avidin. 
While this setup largely overcame the UV associated problems, this 
assay format might pose problems if other biotin like compounds with 
affinity do not result in fluorescence enhancement when bound in the 
active site. This general problem was circumvented with the 
development of another fluorescence based post-column on-line 
biodetection system [14]. This system made use of immobilised digoxin 
and fluorescently labeled anti-digoxigenin FAB fragments for the 
detection of digoxin like molecules. Eluting digoxins can react with the 
fluorescent antibodies, thereby occupying their active sites and rendering 
them inactive for further binding to an upstream placed affinity column 
with immobilized digoxin. The non-retained fluorescent antibodies can 
subsequently be detected with a fluorescence detector. Although mainly 
developed for proof of principle reasons, the system might find its use in 
the analysis of digoxin like metabolites found in urine of patients with hart 
rhythm disorders using preventive digoxin like medicines [18]. 
Table 1 lists the currently developed HRS assay formats in 
chronological order and their assay characteristics. All these HRS 
assays are discussed in this chapter. From the HRS assays developed, 
most assays are based on fluorescence detection. The last few years, 
however, HRS assays are developed which use a mass spectrometer for 
biochemical detection. One of the few exceptions is an HRS assay 
developed by Neungchamnong et al. For the detection of anti-oxidants in 
mixtures, Neungchamnong et al developed a HRS strategy capable of 
on-line post-column detection of anti-oxidants in mixtures based on UV 
detection [24]. On-line post-column chemical oxidation of a model 
compound resulted in the continuous formation of a colored product, 
which can be monitored spectrophotometrically. Due to the high 
wavelength of the colored product, there are usually no compounds in 
the screened mixtures that interfere with the biochemical assay. Eluting 
antioxidants consequently temporarily reduce the formation of the 
oxidized product, thereby showing a decrease in the UV signal. This 
system could be very valuable in the food industry, where information 
about the presence of anti-oxidants in food is studied intensively. 
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Table 1: HRS assay formats developed in chronological order. 
Heterogeneous assay formats are indicated under “Assay Type”. 
 
Year Author Target Protein Assay Type Analytes Ref.
1990 Przyjazny Avidin Optical changes of ligand when bound to target. Biotin like [22] 
1993 Irth Fluorescein labeled antibodies Heterogeneous assay format based on 
immobilized antigen column. 
Digoxin like [14] 
1993 Przyjazny Avidin Fluorescence enhancement of ligand when 
bound to target. 
Biotin like [23] 
1994 Oosterkamp Fluorescein labeled antibodies Heterogenous assay format based on 
immobilized antigen column. 
Digoxin like [18] 
1996 Oosterkamp Estrogen Receptor Fluorescence enhancement of ligand when 
bound to target. Both demonstrated in 
homogeneous and heterogeneous assay formats. 
(Xeno)-Estrogens [20] 
1996 Miller Fluorescein labeled antibodies Heterogenous assay format based on 
immobilized antigen column. 
GCSF like [25] 
1996 Oosterkamp Antibodies Heterogenous assay format based on fluorescein 
labeled antigen (leukotriene) and immobilized 
antibodies. 
Leukotrienes [26] 
1996 Lutz Antibodies Heterogenous assay format based on hollow 
membrane filter and fluorescent or enzyme 
labeled antigens. 
Biotin like [27] 
1997 Oosterkamp Estrogen Receptor (with 
coumestrol as fluorescent ligand) 
Theoretical concepts of on-line screening. 
Detection based on labeled ligands. 
Estradiol [28] 
1997 Oosterkamp Fluorescein labeled streptavidin 
with biotin based affinity resin 
Theoretical concepts of on-line screening. 
Detection based on labeled affinity proteins. 
Heterogeneous assay format. 
Biotin [29] 
1998 Oosterkamp Fluorescein labeled urokinase 
receptor 
Heterogeneous assay format based on 
immobilized ligand column. 
Urokinase receptor 
ligands 
[30] 
1999 Van Bommel Enzyme labeled streptavidin Heterogeneous assay format based on 
fluorescent product generated via enzyme label. 
Only in FIA mode. 
Biotin like [31] 
1999 Van Bommel Enzyme labeled streptavidin Heterogeneous assay format based on 
fluorescent product generated via enzyme label. 
Biotin like [32] 
2000 Ingkaninan AChE Colorimetric product formation of enzymatic 
reaction. 
AChE inhibitors [33] 
2000 Ingkaninan AChE Colorimetric product formation of enzymatic 
reaction. 
AChE inhibitors [34] 
2000 Van Bommel Enzyme labeled streptavidin Heterogeneous assay format based on 
fluorescent product generated via enzyme label. 
Biotin like [35] 
2000 Haake Antibodies Antibody binding to trancducer of optical 
biosensor. 
Isoproturon pesticide like [36] 
2000 Mazereeuw Streptavidin Heterogeneous assay format based on free flow 
electrophoresis with detection of fluorescein 
labeled biotin as readout. 
Biotin like [37] 
2001 Hogenboom Antibodies Mass spectrometry based measurement of probe 
antigen binding to antibodies. Only in FIA mode. 
Biotin and digoxin [38] 
2001 Schobel Estrogen Receptor (ER) Fluorescence enhancement of ligand when 
bound to target. 
(Xeno)-Estrogens [17] 
2001 Schenk Fluorescein labeled antibodies Heterogenous assay format based on 
immobilized antigen column. 
Cytokines [39] 
2003 Schenk Fluorophore labeled phosphate 
binding protein 
Fluorescence enhancement of target protein 
upon binding of inorganic phosphate. 
Phosphate consuming or 
releasing enzymes 
[40] 
2003 Rhee Acetylcholine esterases (AChE)  Fluorescent product formation of enzymatic 
reaction. 
AChE inhibitors [21] 
2003 Derks Antibodies Mass spectrometry based measurement of probe 
antigen binding to antibodies. 
Biotin and digoxin like [41] 
2003 Schenk Phosphodiesterases (PDEs) Fluorescent product formation of enzymatic 
reaction. 
PDE inhibitors [16] 
2003 Schenk Fluorescein labeled antibodies Flow cytometry based assay with digoxin coated 
beads. 
Digoxin like [19] 
2003 Van Elswijk Angiotensin converting enzyme 
(ACE) 
Mass spectrometry based measurement of 
enzymatic product formation. 
ACE inhibitors [42] 
2003 Krabbe Iron(III)methyl calcein blue Mass spectrometry based measurement of 
methyl calcein blue. 
Analytes (phosphorylated 
peptides) with high affinity 
for metal ions. 
[43] 
2004 Van Elswijk Estrogen Receptor (ER) Fluorescence enhancement of ligand when 
bound to target. 
(Xeno)-Estrogens [15] 
2004 De Boer Cathepsin B Mass spectrometry based measurement of 
enzymatic product formation. 
Cathepsin B inhibitors [44] 
2004 Hirata Tyrosine kinase Time resolved FRET with labeled 
antiphosphotyrosine antibodies and labeled 
phosphorylated peptide. Only in FIA mode. 
Tyrosine kinase inhibitors [45] 
2005 Nuengchamnong Free radical (2,2’-diphenyl-1-
picrylhydrazyl; DPPH) 
Colorimetric measurement of non-reacted DPPH. Antioxidants [24] 
2005 Krabbe Iron(III)methyl calcein blue Mass spectrometry based measurement of 
methyl calcein blue. 
Analytes with high affinity 
for metal ions. 
[46]  
2005 De Boer Cathepsin B Mass spectrometry based measurement of 
enzymatic product formation. Microfluidic assay 
format. 
Cathepsin B inhibitors [47] 
2005 De Boer Cathepsin B Mass spectrometry based measurement of 
enzymatic product formation. High temperature 
LC separation based. 
Cathepsin B inhibitors [48] 
2006 De Jong AChE Mass spectrometry based measurement of 
enzymatic product formation. 
AChE inhibitors [49] 
 
 
 19
General Introduction                                                                                       Chapter 1 
When transferring batch-like assay formats into on-line systems, 
one of the important questions is whether the biochemical characteristics 
of the target protein in the batch format resemble the characteristics in 
the on-line format. Because multiple binding sites on the target molecule 
might complicate the interactions, Oosterkamp et al used theoretical 
models to show that biochemical interactions are preserved in on-line 
systems that employ labeled ligands [28] or when labeled proteins are 
used, also if multiple binding sites are present [29]. The theoretical 
models were ultimately validated with a (fluorescence enhancement 
based) receptor affinity detection assay [20] and fluorescein-labeled 
streptavidin and biotin, respectively.  
 
Antibody and biotin based High Resolution Screening 
 
HRS assay formats based on antibodies are usually very stable 
and sensitive due to the inherent stability and high affinity of the 
antibodies. Therefore, these assay formats are used frequently for proof 
of principle studies on new HRS methodologies. An on-line assay format, 
based on high affinity antibody interactions, was the on-line post-column 
methionyl granulocyte colony stimulating factor (GCSF) analysis [25]. 
This methodology, based on immunochemical detection, was applied to 
the detection of metabolites of GCSFs, which are important determinants 
in immune mediated responses. Cytokines are other mediators in 
immune responses. Also for this class of compounds, the ratio of 
different cytokines produced is much more important than the total 
amount of cytokine like compounds as different effectors might produce 
different ratios of cytokines. The development of an on-line post-column 
assay sensitive to cytokines and based on immunochemistry by Schenk 
et al therefore created the possibility of rapidly determining relative 
concentrations of cytokines, thereby allowing the measurement of 
important cytokine profiles in biological matrices [39]. Yet another on-line 
assay relied on the passage of fluorescence labeled leukotrienes through 
an immobilized antibody column when these fluorescent leukotrienes are 
bound to antibodies in solution. When leukotrienes elute from the on-line 
HPLC column, they compete with the fluorescence labeled leukotrienes 
for the limited amount of antibodies present in solution, thereby altering 
the amount of fluorescence labeled leukotrienes that will bind to the 
antibodies in solution [26]. This results in less fluorescence labeled 
leukotrienes that pass the immobilized antibody column to the 
fluorescence detector. 
Another strategy, namely enzymatic signal amplification, was 
examined by van Bommel et al [31, 32]. Compared to the strategy 
described by Oosterkamp et al [20], which employed fluorescein-labeled 
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streptavidin and biotin, here the fluorescein label on the streptavidin was 
replaced by a peroxidase. After the removal of unbound streptavidin 
labeled peroxidase, a non-fluorescent substrate was added to the ligand 
bound (streptavidin labeled) peroxidase. A short reaction chamber then 
afforded the enzyme amplification by substrate conversion to fluorescent 
product. This enzyme amplification did afford a more sensitive assay 
than the fluorescence based on-line assay. A similar system, which was 
developed for the determination of proteins, was also described by van 
Bommel et al [35]. 
With the development of a hollow fibre based on-line assay, new 
possibilities for separating free and bound tracer in continuous flow 
immunochemical detection arose [27]. This methodology was 
demonstrated in a proof of principle study with fluorescently labeled 
biotin and anti-biotin antibodies. Since separation occurred by 
discrimination in size due to the semi-permeable hollow fibre, small-
unbound fluorescently labeled biotin could pass, while this was 
prevented when bound to biotin antibodies. Eluting ligands (e.g. biotin) 
increased the amount of unbound fluorescently labeled biotin, thereby 
allowing a means of detection. Moreover, the use of this methodology 
was also demonstrated with small enzymatic labels. In this context, biotin 
labeled with the relatively small enzyme horse radish peroxidase was 
used as ligand in combination with biotin antibodies. This adaptation 
rendered the methodology useful for commercially available enzyme 
immunoassay kits. Another immunoaffinity based assay was the on-line 
coupled label-free optical biosensor based on highly cross-reactive 
antibodies against the pesticide isoproturon [36]. Antigen detection was 
accomplished by a reduction of the antibody binding to the transducer. 
The biosensor technology resulted in sensitivities comparable with 
fluorescence based biochemical detection. Yet another technology, in 
which free flow electrophoresis was used, employs an electric field to 
generate a laminar flow perpendicular to the on-line assay flow [37]. All 
biochemical reagents undergo this laminar flow with different mobilities 
because of their different electrophoretic characteristics. This allows 
bound and non-bound tracer to be separated after which optical 
detection took place through the transparent electrophoresis cell. This 
separation technology made use of different chemical characteristics 
(affinity or size) than normally employed, namely electrostatic 
interactions. This makes it a possible attractive alternative if other 
heterogeneous on-line assay formats fail to work properly. 
Other novel and recent HRS based approaches are the use of flow 
cytometry for on-line post-column detection [19]. With this technology, 
fluorescence interferences of eluting compounds and unbound 
fluorescent immunoreagents are not detected. The principle is based on 
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the cytometer’s sole measurement of fluorescent immunoreagents bound 
to antigen labeled beads. Eluting antigens competed with the beads for 
the fluorescent immunoreagents thereby changing the amount of 
fluorescence associated with the beads. In this respect, the assay 
principle is similar to the one described by Oosterkamp et al [18] and 
could also be designated as an heterogeneous assay in which the 
immobilised support is continuously pumped through. This results in an 
assay format having both the stability characteristics of a homogeneous 
assay and the advantages of a heterogeneous assay, such as 
fluorescent background elimination and enhanced sensitivity [20]. This 
proof of principle assay, which made use of the often employed digitoxin-
antidigitoxin interactions, showed new perspectives in the on-line 
coupling of cell based assays and provided an alternative for the 
heterogeneous assay formats. 
The antibody or avidin based assay formats, described in this 
paragraph, were used in most cases to demonstrate a new HRS 
methodology. Most of the mentioned methodologies, however, are 
restricted for use with high affinity interactions. As enzyme systems 
generally show much lower affinities compared to antibody or avidin 
based systems, they are usually not suited for these strategies. This also 
holds true for receptor systems, although receptor systems generally 
have higher affinities as compared to enzymes. For receptor systems, 
the generally lower receptor concentrations and complex biological 
behaviour makes them less suitable for these assay formats. Moreover, 
many enzymes and receptors are membrane bound and will therefore 
probably clog on-line heterogeneous assay formats, in which free and 
bound ligand are to be separated prior to detection. Antibody based 
assay formats, however are ultimately suited to screen for cross reactive 
antigens in biological matrixes. These assays might find their way in 
diagnostic screening for disease mediators (e.g. cytokines, interleukins 
and other biomarkers). 
 
Receptor based High Resolution Screening 
 
A post-column assay for the human estrogen receptor α was the 
first on-line receptor affinity assay [20]. The assay used the natively 
fluorescent estrogenic compound coumestrol as ligand. Upon binding to 
the receptor binding site, coumestrol shows strong fluorescence 
enhancement, rendering the assay applicable to be conducted in a 
homogeneous format. Moreover, a restricted-access column based 
heterogeneous assay format was also demonstrated. Because of the 
removal of unbound coumestrol prior to detection in the heterogeneous 
assay format, background levels significantly decreased resulting in less 
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interferences and higher sensitivities. The assay showed its value in the 
analysis of mixtures containing multiple estrogens, such as 
environmental mixtures with contaminating estrogens. Applications of 
this methodology were reported by Schobel et al [17] and van Elswijk et 
al [15]. They used the technology, in which estrogen receptor α and β 
were used in parallel with MS, to rapidly screen for ERα and/or ERβ 
selective compounds in natural extracts.  
The urokinase receptor plays an important role in cell adhesion, 
migration, proliferation and crucial matrix degradations and is involved in 
intracellular degradation mediated diseases and effects proteolitic 
cascade systems of plasminogen activations [50]. This receptor was 
labeled with fluorescein for an heterogeneous on-line assay format 
similar to most heterogeneous immunoaffinity assays [30]. In this assay, 
the labeled receptor, which was continuously added to the HPLC 
effluent, was efficiently trapped on an affinity column with an immobilized 
urokinase support. Eluting ligands interacted with the receptor, thereby 
allowing the receptor to pass the affinity column unretained, after which 
they could be detected. This methodology allowed for the rapid 
determination of the composition of individual active breakdown products 
of urokinase in biological samples.  
For receptor based HRS assays, receptor concentrations in the 
assay have to be high enough in order to obtain good signal to noise 
ratios in short reaction times. This is often not the case. Also, the readout 
of many receptor based batch assays is based on second messenger 
formation. As the formation of second messengers in these assays 
usually occurs in time spans unsuitable for the relatively short post-
column assay times in HRS assays, monitoring receptor interactions this 
way is not an option for many receptor systems. Moreover, often cell 
based assays are needed in order to screen these second messenger 
interactions. Cell based assays in which living cells are used are 
practically impossible to conduct stably and continuously in HRS format. 
Fluorescence enhancement based ligand binding assays might look 
promising for receptor based HRS assays, but in the first place it is very 
difficult to find suitable ligands that show fluorescence enhancement in 
the active site of the receptor. This is especially true with membrane 
bound receptors in which the (apolar) ligands might also show 
fluorescence enhancement in the membrane environment. Moreover, 
ligand binding assays for receptor systems will only show affinity for the 
receptor and cannot be used as a functional assay to distinguish 
between e.g. agonism, antagonism and inverse agonism. HRS assays, 
therefore can only be used for a limited number of receptor systems. 
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Enzyme based High Resolution Screening 
 
The first on-line post-column enzyme affinity assay was described 
by Ingkaninan et al [33]. This colorimetric assay for acetylcholine 
esterase (AChE) activity used the common strategy in which a substrate 
is converted into a colored product. Enzyme inhibition due to eluting 
ligands resulted in a change in the UV baseline due to temporarily 
decreased formation of product. Ingkaninan et al later used this 
methodology in combination with parallel MS to rapidly examine plant 
extracts for individual active compounds with simultaneous identification 
[34]. They found an active compound that was identified as ungiminorine. 
This alkaloid showed a mild inhibitory effect on AchE and was a new 
AChE inhibitor found in an alcoholic extract of Narcissus ‘Sir Winston 
Churchill’.  In 2003, Rhee et al improved the on-line AChE inhibitor assay 
with the replacement of the colorimetric probe with the substrate 7-
acetoxy-1-methyl quinolinium iodide. On AChE dependent hydrolysis, the 
highly fluorescent product rendered the new assay suitable for 
fluorescent screening [21].  
A generic phosphate consuming assay, developed for on-line post-
column purposes, allowed the screening of mixtures for phosphate 
consuming or releasing enzymes [40]. This assay made use of 
phosphate detection through a fluorescence labeled phosphate binding 
protein that showed fluorescence enhancement upon phosphate binding. 
The presence of phosphate consuming or producing enzymes, which are 
the actual targets in the assay, changed the phosphate concentrations 
thereby allowing a means of detection. The enzyme alkaline 
phosphatase was used as a model target. An inhibitor of this enzyme, 
namely tetramisole, was detected in a plant extract thereby proving the 
effectiveness of the method. Phosphodiesterases, which play important 
roles in cell signalling e.g. by hydrolyzing second messengers like cAMP 
and cGMP, were the targets in an on-line post-column detection method 
described by Schenk et al [16]. The conversion of the fluorescent 
substrate Mant-cGMP by phosphodiesterases into the highly fluorescent 
Mant-GMP was key to this on-line biochemical assay. Similar strategies 
were exploited in the use of an HRS based biochemical detection system 
for angiotensin converting enzymes (ACE) [42]. Bioactive peptides found 
in hydrolyzed milk samples were simultaneously identified with MS. 
Special emphasis was laid at the ability of rapidly identifying bioactive 
compounds when many inactive compounds co-elute with the active 
components. For this purpose, Single Ion Monitoring (SIM) was used to 
exactly match the peak shapes and retention times of eluting compounds 
on MS with the peaks in the enzyme affinity trace.  
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While most fluorescence based enzymatic assays rely on straight 
forward fluorescence changes upon product formation, a more delicate 
approach, namely Time Resolved Fluorescence Resonance Energy 
Transfer (TR-FRET), was used by Hirata et al [45]. This on-line flow 
injection analysis assay used TR-FRET dependent emission of light from 
a fluorescently labeled substrate bound to a fluorescently labeled 
antibody when phosphorylated. Thus, upon substrate phosphorylation by 
a tyrosine kinase, the fluorescent antibody could bind thereby allowing 
TR-FRET to occur. The assay was used to screen for inhibitors of the 
tyrosine kinase. A major advantage of this system involved the long-lived 
emission and the high TR-FRET based emission wavelength of 665 
resulting in very low background fluorescence. In a FRET based follow-
up study by Hirata et al, another separation strategy than the normally 
used HPLC separation, namely size-exclusion chromatography, was 
applied [51]. Here, Hirata et al described the separation of a mixture of 
compounds containing protease inhibitors, followed by on-line post-
column screening of inhibitors towards the protease Subtilisin Carlsberg. 
This assay is based on a substrate peptide which is labeled with two 
fluorescent compounds. After digestion by the protease, the substantial 
intramolecular FRET quenching is reduced leading to an increase in 
fluorescence. It was demonstrated that two inhibitors in a mixture of 
compounds could both be detected in the HRS setup. Moreover, IC50 
values were determined for the inhibitors in flow injection analysis mode. 
For screening of expensive targets, miniaturization is very 
desirable. In order to reduce target consumption, a continuous flow 
microfluidic system capable of performing on-line bioaffinity assays has 
been developed [47]. With a total flow rate of only 4 µl/min., considerable 
reductions in costs compared to traditional on-line bioassay formats were 
made. With the cysteine protease cathepsin B as model enzyme, 
however, lower sensitivities were obtained compared to conventional on-
line bioassays, but non-specific binding was minimized. 
As fluorescent product formation is the obvious choice for 
enzymatic assay formats in general and for HRS based assay formats 
specifically, HRS assay formats are hampered by the short post column 
reaction times. Many enzymatic assays that are conducted in batch 
assay format need long reaction times (up to hours) and can therefore 
not be transformed into HRS based assay formats, which are restricted 
to short reaction times (maximum of minutes). In these cases, the short 
reaction times will result in very low signal to noise ratios, while longer 
reaction times result in unacceptable losses in resolution due to severe 
band broadening in the long reaction coils. HRS based assay formats 
are therefore only applicable to enzymatic assays that use short reaction 
times in order to get good signal to noise ratios. 
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High Resolution Screening based on mass spectrometric detection 
 
Since the need for fluorescent targets or ligands may seriously 
complicate assay development if none are easily available, MS based 
on-line assays were developed to overcome this problem [38, 41, 44]. In 
these assays, the tracer was not monitored by its fluorescent 
characteristics, but by its characteristic molecular mass. A proof of 
principle study, in which the concentration of free tracer molecules in the 
presence of target bound tracer molecules was monitored by MS, 
showed the potential of the methodology [38]. One of the main 
advantages of MS, namely the ease of measuring different ligand-target 
interactions in one assay, was demonstrated by Derks et al [41]. In this 
report the high affinity biotin-streptavidin and digoxin-anti-digoxigenin 
interactions were simultaneously measured in a post-column on-line 
biochemical assay by monitoring both the streptavidin and digoxin MS-
traces. De Boer et al [44] used electrospray ionization MS as a detection 
method for the identification of cathepsin B inhibitors by measuring 
changes in the formation of enzymatic products (AMC and Z-FR) of 
particular cathepsin B substrates. Retention time matching and peak 
shape comparison was done by comparing bioaffinity traces of eluting 
enzyme inhibitors with reconstructed ion currents (RICs) of possible co-
eluting compounds. Figure 5 shows chromatograms of the analysis of a 
mixture of two sets of co-eluting compounds spiked with two inhibitors. 
The actual inhibitors could easily and accurately be detected in the 
presence of the co-elution compounds. Another use of MS for on-line 
post-column biochemical detection involved the detection of analytes 
with a high affinity for metal ions [43]. Selective ion monitoring of a tracer 
ligand (methylcalcein blue) that is released upon ligand-exchange of the 
metal-ligand complex (iron(III)methylcalcein blue) by eluting analytes 
was used as basis for this type of analysis. This system was able to 
detect phosphorylated peptides as competing affinity compounds. Non-
phosphorylated and phosphorylated peptides were separated by HPLC 
prior to the on-line biochemical detection. Only the phosphorylated 
peptides were detected as metal-protein interacting compounds. A 
modified format of this assay allowed the screening of ligands with 
affinity for certain metal ions after an on-line ligand exchange reaction 
[46]. This assay was also performed on-line after HPLC separation for 
screening of potential ligands in mixtures. In another study, an on-line 
bioaffinity assay in which enzymatic product formation was monitored 
with MS was used to screen for acetylcholine esterase (AChE) inhibitors 
[49].  This assay monitored the hydrolysis of acetylcholine with MS. 
Inhibitors eluting from HPLC temporarily inhibit AChE thereby altering the 
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acetylcholine hydrolysis, which is monitored by MS. The MS 
simultaneously measured the mass spectrum of the eluting inhibitor.  
Since the introduction of organic modifiers, necessary for the HPLC 
separation of mixtures, into on-line bioaffinity assay negatively influences 
the bioaffinity interactions and reduces the maximum allowable on-line 
reaction times, other separation strategies than HPLC were investigated. 
The use of high temperature liquid chromatography (HTLC) coupled to 
an on-line bioaffinity assay omitted the use of high concentrations of 
organic modifiers in the on-line bioaffinity assay that was used [48]. The 
on-line bioaffinity assay used to test the system was based on the 
enzyme cathepsin B. Mixtures were separated by HTLC and cathepsin B 
inhibitors were subsequently identified with an MS based on-line 
bioaffinity assay. 
HRS assays based on MS detection are a possible option for 
enzymatic assay systems if fluorescence based assay formats are not 
available. These assay formats, however, are seriously hampered by the 
fact that optimal assay conditions usually employ buffer and co-factor 
conditions that are not compatible with MS. For these assays, in which 
enzymatic product formation is followed, MS compatible assay conditions 
have to be chosen. This most probably results in assay conditions far 
from optimal or assay conditions that render the assay unsuitable for on-
line assay formats. When looking at MS based HRS assays in which 
binding interactions are monitored, high affinity interactions are needed 
to obtain good signal to noise ratios. Therefore, these assay formats can 
probably not be used for most receptor systems that generally have 
lower affinity ranges as compared to antibody and avidin based systems. 
Also, much lower receptor concentration ranges are generally used as 
compared to antibody and avidin based systems thus resulting in low 
signal to noise ratios. Moreover, MS compatible assay conditions are in 
most cases unsuitable for receptor assays and membrane bound 
receptor systems will most probably give MS related problems. The 
obvious choice for MS based HRS formats therefore are non-membrane 
bound  enzyme systems which rapidly convert a substrate to its product 
(which is measured by MS) and for which no fluorescent enzymatic 
assay is available.   
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Figure 5: On-line HPLC continuous-flow experiment of a mixture of 
compounds spiked with two cathepsin B inhibitors, E-64 and leupeptin. 
Shown from top to bottom: mass chromatogram of the enzyme product 
AMC (m/z 176); mass chromatogram of the enzyme product Z-FR (m/z 
456); mass spectrum recorded at tR = 3.4 min; mass spectrum recorded 
at tR = 7.5 min; RICs of the most abundant peaks shown in the mass 
spectrum recorded at tR = 3.4 min; RICs of the most abundant peaks 
shown in the mass spectrum recorded at tR = 7.5 min. Adapted from De 
Boer et al [44]. 
 
 
High Resolution Screening as methodology for screening inhibition 
of drug metabolizing enzymes and for active metabolite screening  
 
Many assay formats have been developed for HRS formats. These 
methodologies are of value in the rapid and sensitive screening of 
several target enzymes and receptors. These methodologies are capable 
of collecting information on the affinities of individual compounds in 
complex mixtures that are screened in the pharmaceutical industry. 
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However, once interesting compounds have been identified and 
characterized, information of the metabolic profiles, corresponding 
bioaffinities and potential drug-drug interactions (DDIs) of the formed 
metabolites is of utmost importance. More specifically, information of 
potential DDIs at the level of Cytochrome P450s (CYPs) of lead 
compounds and their metabolites is crucial for successful drug discovery 
and development programs. Therefore, this thesis focuses on developing 
relevant HRS based assay formats in order to screen for these 
biochemical interactions. Additionally, parallel screening of DDIs at the 
level of several relevant CYPs would be a way of rapidly, simultaneously 
and in early stages providing crucial information of the active metabolite 
profiles and DDIs characteristics of pharmaceutically important (lead) 
compounds and their metabolites. This thesis describes the development 
of novel CYP bio-affinity detection systems coupled on-line to gradient 
reversed-phase HPLC in order to demonstrate the possibilities of parallel 
CYP affinity screening in an HRS format. 
HRS methodologies capable of measuring affinities of individual 
metabolites in metabolic mixtures to desired target proteins would be of 
added value for drug discovery and development. As an example of 
metabolite affinity screening in HRS format, rapid on-line profiling of 
estrogen receptor binding metabolites of tamoxifen is described in this 
thesis. 
As Glutathione S-Transferases (GSTs) are important Phase II 
metabolism enzymes that neutralize reactive intermediates and other 
hazardous electrophilic compounds, novel HRS methodologies capable 
of monitoring the affinities of individual compounds in mixtures to GSTs 
would be desirable as well. These HRS methodologies are not only 
important for detection of hazardous reactive intermediates and other 
electrophilic compounds, but also to detect GST inhibitors that may result 
in the build up of hazardous compounds in the body when they are not 
scavenged anymore by the inhibited GSTs.  
On the other hand might specific inhibitors for some GSTs have a 
favourable function. Some GSTs (e.g. GST Pi) are upregulated in 
cancerous cells and neutralize administered cytostatics, as these drugs 
are usually based on their reactive properties towards proteins and DNA. 
Additional administration of specific GST inhibitors might therefore 
decrease the neutralisation of cytostatics by GSTs and consequently 
increase their efficiency. Therefore, this thesis shows the potential of 
HRS based GST inhibition screening with a novel on-line biochemical 
detection system for the screening of specific GST Pi inhibitors in 
complex mixtures. 
Not only information of reactive intermediates and other 
electrophilic compounds is essential in drug discovery and development, 
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but also the presence of hazardous pro-oxidants and more specifically, 
the formation of reactive oxygen species. To address this and to look at 
the possibility for screening these biochemical interactions in a HRS 
format, this thesis describes the development of a HRS methodology for 
the detection of reactive oxygen species producing compounds and 
antioxidants in mixtures. 
Also, the on-line generation of metabolic mixtures, ready for HRS 
based screening processes, would be ideal for rapid and automated 
screening of affinity profiles of biologically active compounds and 
metabolites. As yet, several bioreactors for the generation of metabolic 
mixtures have been developed which use membrane bound CYPs as 
catalyst [52, 53]. However, these bioreactors usually have large volumes 
(≥ 100 ml), which makes them less suitable for the biotransformation of 
small quantities of compounds. Another system, reported recently, 
makes use of chip technology to metabolize substrates and to trap CYP 
metabolites on a microliter scale [54]. A stirred cell bioreactor has also 
been described which makes use of ultra-filtration for sample clean up 
[55, 56]. However, all mentioned bioreactors lack on-line coupling 
between analyte trapping and HPLC separation, which excludes on-line 
metabolite generation and identification. For CYP based DDI screening, 
usually microplate reader assay formats are used [57]. These assay 
formats cannot screen individual inhibitory compounds in (metabolic) 
mixtures. One elegant technique based on pulsed ultrafiltration MS is 
capable of measuring the extent of metabolism of compounds by CYPs 
[56, 58]. In potential, this technique is also capable of measuring 
inhibitory properties of individual compounds towards a panel of CYPs 
simultaneously, by incubating these compounds with relevant CYPs and 
selective probe substrates. None of these techniques, however, can be 
used to measure inhibitory potencies of individual compounds in 
mixtures towards a panel of CYPs. Thus, for affinity screening of 
individual metabolites in metabolic mixtures, cumbersome dereplication 
processes are commonly employed [7]. Also these techniques are not 
based on rapid and on-line screening of metabolic mixtures for the 
detection of individual metabolites with affinity to target proteins. For 
these reasons, this thesis describes a microsomal on-line CYP 
bioreactor coupled to solid-phase extraction and gradient reversed-
phase HPLC for the on-line formation, separation and affinity screening 
of metabolic mixtures. 
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The next part of the introduction focuses on the relevance and 
functioning of drug metabolizing enzymes and the possible fates and 
activities of formed metabolites. This more detailed description of drug 
metabolizing enzymes and the fates of their resulting metabolites is 
given in order to connect the compound activity screening part in general 
and the use of HRS technologies more specifically, with the topics 
described in this thesis. The possible use of HRS technologies in the 
screening of DDIs and active metabolites is namely the main topic of this 
thesis.  
 
 
Drug metabolizing enzymes in drug discovery and 
development 
 
Metabolism is one of the primary routes of elimination of drugs and 
other xenobiotics from the body. Biotransformation reactions such as 
oxidation and conjugation, leading to inactivation and/or activation of 
xenobiotics from the body, play an important role in pharmacological and 
toxicological effects of compounds entering the body. While enzymes 
involved in metabolism are expressed in most tissues of the body, the 
liver is the primary site of metabolism. The primary function of 
biotransformation enzymes is the enhancement of excretion of 
compounds by making them more hydrophilic. The subsequent excretion 
by the kidneys in urine and by the liver in bile clears the body of 
potentially harmful compounds and plays a major part in the body’s 
homeostasis. However, metabolic conversion can also lead to 
bioactivation [59, 60] potentially causing harmful effects to the body. 
Pharmacologically active metabolites can also be formed. These 
metabolites can contribute significantly to the overall therapeutic or 
adverse effects of drugs and other xenobiotics. These pharmacologically 
active metabolites can even entirely be responsible for the therapeutic 
effect of a drug. In fact, of the top 50 drugs that are prescribed in the 
USA, an estimated 22% undergo bioactivation into pharmacologically 
active metabolites that play a significant role in the overall therapeutic 
effects [61]. 
Inhibition of drug metabolism enzymes by xenobiotics can seriously 
affect the pharmacokinetics of other administered drugs. If the 
elimination rate of these drugs is reduced due to inhibition of enzymes 
that are involved in the metabolism of these drugs, elevated drug 
concentrations might result possibly giving rise to adverse drug reactions 
(ADRs). Otherwise might pro-drugs have a reduced efficacy if the drug 
metabolism enzymes that bioactivate these pro-drugs are inhibited. 
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ADRs can vary from minor effects, such as nausea, to serious life 
threatening situations [62] and even death [63]. In fact, from the over 
2.000.000 estimated serious ADRs in hospitalized patients; 
approximately 100.000 had fatal ADRs in the USA. This makes these 
adverse reactions between the 4th and 6th leading cause of death in the 
USA [64]. The cytochrome P450s (CYPs) constitute the most important 
class of enzymes involved in enzyme based ADRs. Some ADRs and 
reduced efficacy of drugs resulting from CYP inhibition are listed in Table 
2. Lin et al and Tanaka et al describe these ADRs in more detail [65, 66].  
 
 
Table 2: Several ADRs or reduced efficacy of drugs due to inhibition of 
CYPs that metabolize these drugs. These ADRs are caused by 
additional medication of other drugs that are inhibitor for the CYP(s) 
involved. 
 
Drug Comments Clinical effect Ref. 
Terfenadine, an 
antihistamine agent 
The pro-drug Terfenadine is rapidly converted to the 
pharmacologically active Fexofenadine by CYP3A4. Co-
administration of drugs that inhibit CYP3A4 (e.g. ketoconazole) 
can result in increased systemic Terfenadine concentrations. 
Terfenadine is a blocker of the delayed rectifier potassium 
current, which can result in (fatal) ventricular arrhythmias. 
[67] 
Codeine, an analgesic pro-
drug  
The pro-drug Codeine requires metabolic activation (by e.g. 
CYP2D6) to Morphine. Co-administered drugs that inhibit 
CYP2D6 (e.g. Quinidine) reduce the bioactivation of Codeine. 
Reduced or no efficacy. [68] 
Proguanil, an antimalarial 
pro-drug  
The pro-drug Proguanil requires metabolic activation (by e.g. 
CYP2C19) to Cycloguanil. Co-administered drugs that inhibit 
CYP2C19 reduce the bioactivation of Proguanil. 
Alterations in the pharmacokinetics and therapeutic 
effects 
[69] 
Trazodone and 
Nefazodone used as 
antidepressants 
Trazodone and Nefazodone block serotonin reuptake at nerve 
synapses. These drugs are inactivated by CYP2D6 mediated 
metabolism. Co-administered drugs that inhibit CYP2D6 result in 
elevated systemic Trazodone or Nefazodone concentrations. 
Serotonin syndrome, a possibly life-threatening symptom. [70, 
71] 
Beta-blockers like Atenolol 
or Propanolol 
These beta-blockers are inactivated by CYP3A4 metabolism. 
Mibefradil (potent CYP3A4 inhibitor with a long half-life) requires 
long washout periods when changing this co-administered blood 
pressure medication. 
Cardiogenic shock due to build-up of beta-blockers 
(metabolized by CYP3A4) can result after (co-
administered) blood pressure medication change from 
Mibefradil to a dihydropyridine calcium channel blocker. 
[72] 
Simvastatin, a lipid 
lowering drug for e.g. 
coronary artery disease 
Simvastatin, used in the management of hypercholesterolemia, is 
metabolized by CYP3A4. Co-administration of Mebefradil results 
in systemic build-up of Simvastatin.  
Rhabdomyolysis (the breakdown of muscle fibres 
resulting in their release into circulation) can occur and 
frequently results in kidney damage. 
[73-
75] 
 
 
Induction of drug metabolizing enzymes (by e.g. food components 
or environmental chemicals), such as different CYP isoenzymes, can 
result in increased rates of xenobiotic transformations [76, 77]. While this 
induction is the bodies defence against potentially harmful compounds 
by increasing their metabolism based elimination, its clinical importance 
lies in increased biotransformation and hence strongly enhanced 
elimination of certain drugs like omeprazole [78], cyclosporin [79] and 
some contraceptives [80], thereby lowering their therapeutic effects or 
resulting in non-responding patients to drug therapies. Other effects of 
CYP induction are the enhanced activation of compounds to yield toxic 
metabolites or reactive intermediates [81, 82]. One well known example 
is the increased bioactivation of acetaminophen to the hepatotoxic N-
acetylbenzoquinoneimine [83]. This metabolic conversion by CYP2E1 is 
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enhanced by the CYP2E1 inducers isoniazid, ethanol [84, 85] and 
benzene [86].  
Knowledge on the DDI potential, the metabolism and subsequent 
metabolite based effects of xenobiotics therefore is of major importance 
in drug discovery and development as well as in environmental sciences. 
 
Classification of biotransformation enzymes 
 
The biotransformation process is generally divided into three 
phases, namely phase I, phase II and phase III reactions. Oxidations, 
reductions and hydrolysis reactions, which introduce or modify functional 
groups into molecules, are usually phase I reactions. Subsequent phase 
II conjugation to thiols (glutathione), carboxylic acids (glucuronides), 
amines, epoxides and sulphate groups is meant to enhance excretion. 
This enhanced excretion is not only due to increased transportability as a 
result of the higher hydrophilicity, but also because the formation of the 
conjugates often renders them good substrates for plasma membrane 
transporter pumps. Such transporters are classified under the phase III 
reactions. 
 
Phase I metabolism 
 
The Phase I oxidation pathway is usually catalysed by the 
cytochrome P450 enzymes. Other microsomal phase I metabolism 
enzymes are the azoreductases, nitroreductases, peroxidases, 
monoamine oxidases, microsomal epoxide hydrolases and flavin-
monooxygenases. Among the non-microsomal Phase I metabolism 
enzymes are alcohol dehydrogenases and aldehyde dehydrogenases 
(involved in the detoxification of ethanol), xantine oxidases and 
dehydrogenases. Some classes of phase I metabolism enzymes, such 
as carboxylesterases, are located in both the endoplasmic reticulum 
(microsomes) and the cytosol. Figure 6A shows a pie diagram 
representing the major human enzymes responsible for Phase I 
metabolism. 
 
Cytochrome P450s 
 
Mammalian CYPs constitute a large superfamily of proteins, 
located through their N-terminal membrane-anchoring domain in the 
endoplasmic reticulum, with a molecular weight of approximately 55 kDa. 
Individual members of the CYP superfamily are expressed in almost 
every cell type in the body, but are located predominantly in the liver. 
The diversity of reactions catalyzed by CYPs, their extensive substrate 
 33
General Introduction                                                                                       Chapter 1 
specificity and the number of xenobiotics that are substrates for the 
enzyme system rank CYPs first in terms of the most versatile known 
detoxification system [87, 88].   
The wide variety of CYPs are divided into different families and 
subfamilies. When the amino acid sequence is less than 40 percent 
identical, CYP enzymes belong to different gene families. Between 40 
and 55 percent of amino acid identity puts them within the same families. 
When CYPs are more than 55 percent identical, they are classified as 
members of the same subfamily in which usually different isoenzymes 
are known [89]. 
The human genome encodes for 57 CYPs. Family 1 to 3 are 
relatively aselective enzymes which play a role in metabolism of drugs. 
The other CYPs play a role in metabolism of endogenous compounds 
like steroids and prostaglandins. For xenobiotic metabolism, the most 
important isoenzymes are CYP1A1/1A2, 2C8/9/19, 2D6, 2E1 and 3A4 
[90, 91]. In Figure 6A, human CYPs relevant for drug metabolism are 
shown. CYP1A1/1A2 are CYPs that are induced amongst others by 
cigarette smoke, charcoal-broiled meat (containing polycyclic aromatic 
hydrocarbons) and cruciferous vegetables [92, 93]. In general, CYP1A is 
responsible for the conversion of planar aromatic molecules, sometimes 
leading to reactive metabolites, which can ultimately lead to cancer [94, 
95]. The CYP2B subfamily is another subfamily of the CYPs [96, 97]. 
Despite its low basal hepatic abundance, the CYP2B subfamily is highly 
inducible by various chemicals [98]. CYP3A4 is the most abundant CYP 
in the human liver. Because CYP3A4 accepts substrates that are 
structurally very diverse [99], CYP3A4 is an important metabolising 
enzyme and therefore also important in DDIs [100]. DDIs at the level of 
CYPs [101] are of major concern in drug discovery and development 
programs as they may also cause unexpected, and in some cases life 
threatening, in-vivo performances. Table 2 gives a few examples of DDIs 
resulting ADRs.  
Otherwise, since CYP3A4 is involved in the clearance of many 
(expensive) drugs [102], this isoenzyme is an interesting candidate for 
inhibition during drug therapy. Upon inhibition, it allows for the elongated 
systematic circulation of administered drugs and/or major reduction of 
possible first-pass effects [103]. 
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Figure 6: Phase I (A) and Phase II (B) metabolism of currently marketed 
drugs. Adapted from Evans et al [104].  
 
 
Most drug metabolising isoenzymes of CYPs appear to be 
genetically polymorphic. A well known example is CYP2D6, which is 
inactive or deficient in 5-10 percent in the Caucasian population [105]. 
Besides this, the interindividual CYP2D6 concentration differs highly [97]. 
For CYP2D6, more than 80 different allelic variants are known. The 
consequences of the polymorphism at normal drug doses can be either 
adverse drug reactions or no drug response [106]. 
Screening of individual inhibitory compounds in (metabolic) 
mixtures towards a set of relevant CYPs is very important in the drug 
discovery and development process in order to identify potential DDIs at 
the level of CYP inhibition. To rapidly and sensitively screen these 
interactions, novel technologies are needed as the nowadays commonly 
used dereplication processes are very elaborate. In this thesis, novel 
HRS based methodologies are described for the identification of possible 
DDI compounds in mixtures at the level of individual CYPs. These 
methodologies are capable of rapidly, reproducibly and sensitively 
determining the affinities of CYP inhibitors in mixtures towards a panel of 
relevant CYPs. 
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Phase II metabolism 
 
Xenobiotics that have undergone a Phase I reaction may now 
undergo subsequent phase II metabolism through the newly introduced 
functional group, e.g. hydroxyl, amino, or carboxyl group. The Phase II 
metabolic biotransformations are usually needed to further enhance the 
hydrophilicity of the compounds, thereby facilitating their excretion. This 
is because many of these intermediate metabolites do not possess 
sufficient hydrophilicity to permit elimination from the body. Phase II 
biotransformation reactions include glucuronidation, sulfation, glutathione 
conjugation, amino acid conjugation, acetylation and methylation. Figure 
6B shows a pie diagram of the major Phase II metabolic enzymes 
involved in drug metabolism. Glucuronidation is the major Phase II 
reaction [107, 108]. In this conjugation reaction, the glucuronic acid is 
conjugated to an electron-rich nucleophilic heteroatom of the substrate, 
such as oxygen, nitrogen or sulphur using the cofactor UDPGA. The 
glucuronidation pathway is a high-capacity conjugation pathway, which 
usually decreases toxicity. The glucuronide conjugates are generally 
very hydrophilic and are excreted by the kidney or bile. Sulphate 
conjugation is another Phase II reaction which many xenobiotics undergo 
[109]. The highly polar sulphate conjugates are also readily secreted in 
the urine. Since sulfation is a low-capacity pathway for xenobiotic 
conjugation, it can be predominant when low concentrations of toxicant 
are present, while the glucuronidation process takes over if the toxicant 
concentrations increase. Not all Phase II metabolic reactions increase 
the hydrophilicity. Just like methylation, acetylation results in less 
hydrophilic metabolites [110, 111]. 
Glutathione (GSH) conjugation by Glutathione S-Transferases 
(GSTs) is an important pathway for reactive electrophilic compounds 
[112].  GSTs act by increasing the deprotonation rate of GSH thereby 
facilitating the reaction of GSH with electrophiles. Conjugation to GSH 
occurs in most cells in the cytoplasm [113], although microsomal GSTs 
are also known [1]. The liver and kidney, with GSH concentrations 
ranging from 5 to 10 mM, are the primary sites of GSH conjugation. As 
GSTs are important Phase II metabolism enzymes that neutralize 
reactive intermediates and other hazardous electrophilic compounds, 
novel HRS methodologies capable of monitoring the effects of individual 
compounds in mixtures for their interactions with GSTs are desirable. 
This thesis shows the potential of HRS based GST inhibition screening 
methodologies. Therefore, the GSTs are discussed in more detail in the 
next paragraph. 
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Glutathione S-Transferases 
 
Reduced GSH, usually known as GSH, is a water-soluble linear 
tripeptide synthesized in the body from L-glutamine, L-cysteine, and 
glycine [114]. The high electron donating capacity combined with high 
intracellular concentrations (up to millimolar levels) underlies its strong 
reducing and antioxidant action. GSH is used in the body as a co-factor 
for several peroxidase enzymes, transhydrogenases and most 
importantly the GSTs [115] for the GSH conjugation to a whole variety of 
endogenous and exogenous electrophilic compounds.  
GSTs play a critical role in cellular defence [116]. They are 
important as they provide protection against electrophilic compounds 
[113]. They are mainly found in the cytosol, although a microsomal form 
is also known [117]. Due to the high GSH concentration in most organs, 
the non-enzymatic conjugation of reactive electrophiles can also play a 
significant role [118]. Most of the GST substrates are xenobiotics among 
which many are drugs and other environmental chemicals, some of 
which some are mutagenic or carcinogenic. GSTs can also play 
important roles in cell protection against lipid peroxidation [119]. GST 
inhibition (by drugs), therefore is an unwanted process as it might result 
in reaction of reactive intermediates and other electrophilic compounds 
with cellular macromolecules. 
On the other hand might specific inhibitors for GSTs have a 
favourable function as some GSTs are upregulated in cancerous cells 
resulting in neutralization of administered cytostatics, GST inhibition can 
counteract this effect thereby increasing the efficiency of these 
cytostatics.  
Most GSTs are dimers composed out of two identical subunits, but 
heterodimers also exist. Soluble GSTs are divided into four classes, 
namely alpha(α), mu(μ), pi(π) and theta(θ) [120]. The subunits of the 
homodimers are designated with a two-digit number. This classification is 
based on homology. Subunits in the same class, which are able to form 
heterodimers, share at least 70 percent identity, while the subunits of 
different classes are less then 30 percent identical [121]. The expression 
levels of the different classes of GSTs differ highly in different cell types 
and organs. Certain chemicals can induce the expression of certain 
classes of GSTs [122, 123]. These responses are meant to facilitate the 
excretion of toxicants through GSH conjugation. A well known example is 
the over-expression of GST Pi in multi drug resistant tumour cells [55]. 
These observations indicate that GST Pi inhibitors might be potential co-
assisting drugs together with cytostatics [124-130]. Therefore, novel 
methodologies for the measurement of human GST Pi and mammalian 
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GST inhibition of individual compounds in complex mixtures is one of the 
topics described in this thesis. 
 
Bio-Activation 
 
Biotransformation does not necessarily lead to the clearance of a 
xenobiotic. Several xenobiotics undergo bioactivation yielding 
metabolites that possess activity or affinity for enzymes or receptors or 
for another biological system [7, 131, 132]. Adverse drug reactions can 
thus be caused by the parent xenobiotic but also by metabolites of that 
compound [133, 134]. Metabolites may be stable or chemically reactive 
leading to covalent binding to DNA, adduct formation to proteins or the 
formation of reactive oxygen species (ROS) leading to oxidative stress. 
In this regard, bioactivation may be explained either as enhanced activity 
or affinity of a metabolite towards an enzyme or receptor compared to 
the parent compounds, or it may be seen as a process in which the 
metabolite becomes more toxic e.g. due to its chemical reactivity. 
 
Pharmacologically active metabolites 
 
As stated before, phase I metabolism usually inactivates a 
xenobiotic, but in some cases a retained or even enhanced activity or 
affinity is observed for the metabolites formed [132]. In fact, some drugs 
are known as pro-drugs. Drugs that are activated by phase I metabolism 
include morphine [135], codeine [136], diazepam [137] and tamoxifen 
[132]. An extensive review by Rooseboom et al [138] describes the use 
of enzyme catalyzed bio-activation of amongst others anti-cancer pro-
drugs. Scheme 2 depicts several examples of metabolism based 
activation or inactivation of some drugs. 
Since metabolites may also exert their effect in a totally different 
pharmacological and/or toxicological way as the parent compound, these 
effects have to be examined [139]. This is one of the reasons why the 
development of safe drugs is very elaborate. Possible formation of active 
metabolites forces the drug discovery and development process to not 
only to carefully study the sorted effects of tested drugs, but also the 
effects of their metabolites. Therefore, and because pharmacological and 
toxicological knowledge of drug metabolites is obligated amongst other 
information in order to obtain FDA approval of new drugs, activities of 
metabolites towards enzymes and receptors that are expected to have 
relevant interactions with the metabolites have to be examined. To 
address the need for rapid and sensitive screenings methodologies 
capable of screening affinities of individual metabolites in such mixtures, 
HRS strategies might be ideal. As an example of this metabolite affinity 
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screening in HRS format, rapid on-line profiling of estrogen receptor 
binding metabolites of tamoxifen is described in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Examples of pharmacologically active or inactive metabolites 
formed after metabolism. Adapted from Fura et al [7]. 
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Toxicologically relevant metabolites 
 
The biotransformation of drugs into reactive metabolites can be 
performed by drug metabolism enzymes. There are many ways in which 
reactive metabolites can exert their effect. Several well known adverse 
effects are the result of adduct formation with DNA or proteins [140] or 
the formation of reactive oxygen species (ROS) leading to oxidative 
stress and/or idiosyncratic toxicity [59]. While DNA adduct formation may 
ultimately result in cancer, reactions with proteins can have a wide 
variety of effects ranging from malfunctioning of cells to organ 
destruction, often due to immune mediated idiosyncratic responses. 
Reactive metabolites can lead to GSH depletion [141], reversible protein 
modifications, protein adduct formation and subsequent irreversible 
protein damage [142]. Moreover, oxidative stress can seriously disturb 
the bodies homeostasis resulting in effects ranging from lipid 
peroxidation and apoptosis to teratogenesis and cancer [143].  
CYPs are responsible for the bioactivation of many xenobiotics 
[87]. CYP1A1 and 1A2 for example activate polycyclic aromatic 
hydrocarbons (PAHs) [144] and aromatic amines [145]. Induction of 
some CYPs may lead to increased carcinogenic potencies of pro-
carcinogenic compounds [146]. The importance of reactive metabolites 
in drug-induced pathogenesis therefore is a main factor in the safety 
assessment of not only drugs, but for practically all compounds that can 
come in contact with humans. Dietary and/or synthetic antioxidants may 
therefore provide protection against ROS. Many strategies in which 
antioxidants are used to counteract the destructive effects of oxidants 
are known [147-149] 
One of the chapters in this thesis deals with the post-column on-
line biodetection of ROS and antioxidants in mixtures. Moreover, the 
insertion of a CYP biotransformation system allows the screening of 
compounds that need to be bioactivated to exert their ROS producing 
properties. Such novel screening methodologies offer new perspectives 
for rapid screening of individual compounds in mixtures for their ROS 
producing or antioxidative properties. 
 
Receptor and enzyme targets in drug discovery and development 
 
The development of novel therapeutic agents or drugs with 
superior properties is the ultimate goal of the pharmaceutical industry. 
Efficacy, toxicity, side effects and interindividual responses to a drug 
need to be intensively studied before a drug can be marketed. The 
majority of drug actions are based on an interaction with a receptor, 
enzyme or transport pump. Many different receptor based cellular effects 
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are known. While some responses can be very rapid, others are slow. 
While receptors involved in nerve actions are extremely rapid, hormonal 
receptors exert their effect in a very slow manner. At least five different 
classes of receptor superfamilies can be distinguished, namely the ligand 
gated or ion-channel receptors, the G-protein coupled receptors 
(GPCRs), the tyrosine kinase receptors, the growth factor receptors and 
finally the nuclear or hormone receptors (NRs). GPCRs are the today’s 
most common druggable targets for a wide variety of diseases [150, 
151]. The NRs are mainly targeted against hormonal disorders and as 
contraceptives, while their use as a drug against NR mediated tumours 
[152] is unsurpassed.  
 
Nuclear receptors 
 
The superfamily of nuclear receptors (NRs) is the third major class 
of drug targets after the GPCRs and the kinases. They are a large family 
of transcription activators induced by ligands, thereby regulating a whole 
range of processes like embryonic development, physiology of organs, 
cell differentiations and hormone-regulated homeostasis [153]. Amongst 
the nuclear receptors are the estrogen, androgen, progesterone, 
glucocorticiod, thyroid hormone, retinoic acid, vitamin D and peroxysome 
proliferating activating receptor. Nuclear receptor based therapeutic 
interventions (in the form of agonists or antagonists) can extend to 
oncology, contraception, obesitas and dermatology. The estrogen 
receptor (ER) is a steroid receptor belonging to the superfamily of NRs. 
Regulation of ER signalling is not only an important target for 
contraceptive purposes, but also for ER dependent cancers [154, 155], 
like breast cancer which is a leading cause of death for women. 
In this thesis, metabolite affinity screening in HRS format with the 
ER as model target was conducted as an example of the applicability 
and value of HRS technologies for receptor affinity screening of 
individual metabolites in metabolic mixtures. The ER was also used as a 
model target receptor to screen metabolic mixtures for affinity of 
individual metabolites after fully automated metabolite formation. The 
drugs tamoxifen, which is used in breast cancer treatment, and raloxifen 
(used to prevent osteoporosis in post-menopausal woman) were used for 
the analysis of their CYP generated metabolite profiles with 
corresponding contributing affinities to the ER. These results can aid in 
the explanation of the complex pharmacology of these drugs, which is 
not only determined by the parent compounds but also at least to a 
significant extent by their metabolites. 
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Aims and scope of the Thesis  
 
Analysis of drug metabolism plays a very important role in the drug 
discovery and development process and also in the study of other 
xenobiotics, which may come in contact with humans. Rapid 
methodologies for the structural elucidation and biological activity profiles 
of complex metabolic mixtures, environmental samples and foods pose 
major problems, as usually complicated separation procedures have to 
be conducted prior to the subsequent characterisation of the individual 
components in mixtures. Drug-drug interactions (DDIs) at the level of 
metabolic enzymes are also crucial in this regard. Since these 
interactions may restrict the use of drug candidates and drugs, in clinical 
practice efficient strategies have to be employed for their assessment. 
Moreover, other negative effects, which can occur as a result of drug 
metabolism or drug-induced toxicity (e.g. due to the formation of reactive 
metabolites), may pose serious restrictions to the drug candidates and 
drugs. Therefore, structural identification and biological profiling is 
obligatory for all metabolites that are formed from existing drugs and new 
drug candidates. Besides the biological effects that lead compounds can 
exert via their target, also its metabolites have to be examined for 
biological effects. 
The general aim of the studies described in this thesis, was the 
development of novel on-line post-column bio-affinity detection strategies 
for the screening of individual compounds or metabolites in complex 
mixtures in an effort to facilitate the rapid screening of affinities and other 
biological activities of individual compounds in mixtures. As the first 
specific aim, these on-line post-column bio-detection strategies, also 
known as High Resolution Screening (HRS), were to be employed for 
metabolically and toxicologically important class of phase I enzymes, the 
Cytochrome P450s (CYPs). The CYP HRS systems were aiming at 
screening of CYP inhibition. Looking at the important roles of CYPs in 
possible adverse drug reactions due to xenobiotics in general and drugs 
specifically, these novel inhibition screening methodologies would allow 
major progress in drug discovery and development by providing the 
possibility for rapid screening of individual compounds in mixtures for 
binding and turnover by CYPs as well as potential DDIs. The second aim 
was the application of HRS in the screening of active metabolites in 
metabolic mixtures together with prior generation of the metabolic 
mixtures. For this, an HRS based on-line post-column profiling 
methodology for metabolites with affinity for the Estrogen Receptor α 
(ERα) was demonstrated. Subsequent on-line coupling of a bio-reaction 
unit to the HRS ERα methodology was employed to look at the possibility 
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of fully automated metabolic profiling for ERα affinities with MS 
identification. The third aim of this thesis was the development of a HRS 
technology which couples two parallel enzyme affinity detection systems 
for Glutathione S-Transferases (GSTs) to gradient reversed-phase 
HPLC. GSTs are important phase II enzymes that play a role in the 
protection against electrophilic compounds and reactive intermediates. 
Finally, the development of a HRS methodology for screening 
compounds that induce the formation of reactive oxygen species (ROS) 
and antioxidants in mixtures was demonstrated. This latter HRS 
methodology may be of added value in drug discovery and toxicology 
and in the food industry. 
 
Outline of this thesis 
 
In Chapter 1, a description of the literature of HRS and its 
applications is given. Then, the importance of metabolic enzymes such 
as CYPs and GSTs and their pharmacological and toxicological 
relevance to xenobiotics in general and drugs more specifically is 
discussed. The formation of active metabolites and their potential 
consequences are also discussed.  
In Chapter 2, the development of a HRS-system including a novel 
CYP bio-affinity detection system coupled on-line to gradient reversed-
phase HPLC is described. This chapter shows the successful use of 
membrane bound mammalian CYPs in HRS based systems. The 
subsequent parallelization of three different mammalian CYP bio-affinity 
detection systems coupled on-line to gradient reversed-phase HPLC 
(Chapter 3) emphasises the concept of simultaneous metabolic 
screening towards different important CYP families. Finally, Chapter 4 
describes the use of human CYPs in HRS based screening. Since 
human CYPs most closely mimic possible DDIs at the level of CYPs in 
humans, they constitute the ultimate assay formats to be used in DDI 
screening. 
In Chapter 5, the rapid on-line profiling of ERα binding metabolites 
of tamoxifen is described. In addition, the HRS methodology developed 
for screening active metabolites in metabolic mixtures is subsequently 
used for the fully automated generation and subsequent active 
metabolite profiling of metabolic libraries for the ERα. This study is 
described in Chapter 6. 
The successful development of an on-line post-column biochemical 
detection methodology for GSTs and GST Pi inhibitors in mixtures is 
presented in Chapter 7. It describes the use of the important Phase II 
metabolism enzymes, the GSTs, in on-line post-column screening 
technologies. High Resolution Screening of mixtures for the rapid 
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detection of reactive oxygen species producing compounds and 
antioxidants is demonstrated in Chapter 8.  
 Chapter 9 first summarizes the work described in this thesis. Then 
it gives specific conclusions per chapter followed by general conclusions 
regarding the use of HRS for DDI screening at the level of enzyme 
inhibition and for screening of biologically active compounds and 
metabolites. Finally, Chapter 9 gives future prospects. 
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Commandeur and Nico P. E. Vermeulen  
 
Adapted from: Journal of Biomolecular Screening, 2005, 10(5), p. 427-36 
 
Abstract 
 
A High Resolution Screening (HRS) platform, coupling on-line affinity 
detection for mammalian Cytochrome P450’s (CYPs) to gradient 
reversed-phase high performance liquid chromatography (HPLC), is 
described. To this end, the on-line CYP enzyme affinity detection 
(EAD) system was optimized for enzyme (β-NF induced rat liver 
microsomes), probe-substrate (ethoxyresorufine) and organic 
modifier (methanol or acetonitrile). The optimized CYP EAD system 
has firstly been evaluated in flow-injection analysis (FIA) mode with 7 
known ligands of CYP1A (α-naphthoflavone, β-naphthoflavone, 
ellipticine, 9-hydroxy-ellipticine, fluvoxamine, caffein and phenacetin). 
Subsequently, IC50-values were on-line in FIA-mode determined and 
compared with those obtained with standard microsomal assay 
conditions. The IC50-values obtained with the on-line CYP EAD 
system agreed well with the IC50-values obtained in the standard 
assays. For high affinity ligands of CYP1A, detection limits of 1 pmol 
to 3 pmol injected (n = 3; S/N = 3) were obtained. The individual 
inhibitory properties of ligands in mixtures of the ligands were 
subsequently investigated using an optimized CYP EAD system on-
line coupled to gradient HPLC. Using the integrated on-line gradient 
HPLC CYP EAD platform, detection limits of 10 pmol to 25 pmol 
injected (n = 1; S/N = 3) were obtained for high affinity ligands. It is 
concluded that this novel screening technology offers new 
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perspectives for rapid and sensitive screening of individual 
compounds in mixtures exhibiting affinity for liver microsomal CYPs.  
 
 
Introduction 
 
Cytochromes P450 (CYPs) constitute the most important group 
of hepatic biotransformation enzymes involved in the metabolism of 
drugs and other xenobiotics [1-3]. CYPs are membrane-bound heme-
containing proteins that are expressed in the endoplasmatic reticulum 
of cells and on the inner membranes of mitochondria[4]. The major 
CYPs involved in drug metabolism are located in the liver, although 
they also occur in other organs and tissues [5]. For the catalytic 
cycling, CYPs depend on the electron-donating capacity of NADPH 
CYP reductases [6]. 
Metabolism of chemical entities by CYPs may have important 
biological consequences. Bio-activation, resulting in metabolites with 
enhanced pharmacological or toxicological activities can occur, while 
the biological activity of parent compounds may also be antagonized 
by one or more of its active metabolites. Inhibition of CYPs by parent 
compounds and/or their metabolites may also result in drug-drug 
interactions[7]. Knowledge of the affinity of new chemical entities and 
drug candidate compounds to CYPs is therefore generally seen as 
crucial in drug discovery and development and safety assessment [7, 
8].  
When many compounds need to be evaluated for CYP binding, 
for CYP-mediated turnover and for drug-drug interactions at the level 
of CYPs [9, 10], often in-vitro High Throughput Screening (HTS) 
methodologies are used. The method of choice for this type of 
screening is currently the inhibition of fluorescent metabolite 
formation from probe substrates in microplate reader screening 
assays [11-14]. This approach, however, cannot be applied for the 
identification of CYP ligands in mixtures of compounds, as is the case 
with natural compound extracts, combinatorial chemistry mixtures 
and drug metabolite mixtures. In such cases, separation of the 
mixtures followed by CYP affinity testing of the individual compounds 
is needed. Several years ago, a new on-line High Resolution 
Screening (HRS) concept for the screening of ligands to the estrogen 
receptor (ERα) was reported [15]. This HRS concept was based on a 
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continuous flow bio-assay, coupled on-line to HPLC. It circumvented 
several of the above-mentioned problems by combining the resolving 
power of HPLC with efficient screening properties of a bio-assay. 
Meanwhile, such HRS assays have been based on soluble receptors 
[15, 16], enzymes [17] and antibodies [18, 19]. Systems based on 
mass spectrometry in which compounds are screened for affinity 
towards several receptors and enzymes in one bio-assay also exist 
[20, 21]. However, no bio-affinity detection systems are yet available 
for the screening of individual compounds in mixtures for CYP affinity.  
In this article, we describe the design, optimization and validation of a 
novel HRS system based on CYP enzyme affinity detection (CYP 
EAD). The novel CYP EAD system is based on the inhibition of 
fluorescent product formation by CYPs [22, 23]. The CYP EAD 
system is operated by mixing CYP enzyme, substrate and co-factor 
continuously with the eluent of a carrier solution. In a hand made 
knitted [19, 24] reaction coil, the substrate is converted into a highly 
fluorescent product. Eluting ligands compete with the substrate for 
the active site of the CYP concerned and cause a temporary 
decrease in fluorescent product formation monitored by fluorescence 
detection. The CYP EAD system was first evaluated for individual 
components in flow-injection analysis (FIA) mode and subsequently 
coupled on-line to gradient HPLC for on-line detection of affinities of 
individual compounds in mixtures to CYPs. When operated in 
gradient HPLC CYP EAD mode, the carrier solution of the FIA system 
is replaced by the eluent of a gradient HPLC system, allowing 
mixtures of compounds to be separated by HPLC and subsequently 
detected on-line with the new CYP EAD system. The CYP EAD 
system in HPLC mode is useful in rapid determinations of possible 
CYP1A based drug-drug interacting metabolites in metabolic mixtures 
resulting from lead compounds or even hits. Moreover, it can be 
utilized in parallel with a hit finding HRS assay for simultaneous quick 
determination of unwanted drug-drug interacting hits in mixtures. 
 
 
Experimental Section 
 
Materials  
 
Ethoxyresorufin, Tween 20 and 80, L-α-phosphatidylcholine-
dilauroyl, saponin (from Quillaja Bark), glycerol, casein hydrolysate, 
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polyethyleneglycol 6000 (PEG 6000), polyethyleneglycol 3350 (PEG 
3350), polyethylenimine (50% aq. solution) and α-naphthoflavone (α-
NF) were purchased from Sigma (Zwijndrecht, NL). Dextran (MW 60-
90kD) was from Duchefa (Haarlem, NL), caffein and sodium cholate 
from Aldrich (Zwijndrecht, NL) and β-naphthoflavone (β-NF) from 
Acros (Den Bosch, NL). β-Nicotinamide adenine dinucleotide 
phosphate (NADPH) tetra sodium salt was obtained from Applichem 
(Lokeren, B), ELISA blocking reagent from Hoffmann-La Roche 
(Mannheim, D), bovine serum albumin (BSA) from Life Technologies 
(Paisley, GB) and methanol (MeOH) and acetonitrile (MeCN) were 
purchased from Baker (Deventer, NL) and were of HPLC reagent 
grade. All other chemicals were of the highest purity grade 
commercially available. 
Rat liver microsomes (β-NF induced) were prepared as 
described elsewere [25]. In short: livers from β-NF induced rats were 
homogenized at 4 °C in 2 volumes of 50 mM potassium phosphate 
buffer (pH 7.4) with 0.9% sodium chloride using a Potter-Elvehjem 
homogenizer. The homogenate was centrifuged for 20 min at 
12000g, and the supernatant obtained was further centrifuged for 60 
min at 100000g. The resulting pellet was washed twice and 
subsequently resuspended in 50 mM potassium phosphate buffer (pH 
7.4), 0.9% sodium chloride, and 25% glycerol and stored at -80 °C. 
Protein concentration in the microsomes was determined to be 13.1 
mg/ml. 
 
Instrumentation 
 
Two Knauer K-500 HPLC pumps (Berlin, Germany) were used 
to control the Pharmacia 50 ml superloops (Uppsala, Sweden) 
containing enzyme (rat liver Cytochrome P450’s) and co-
factor/substrate (NADPH/ethoxyresorufine), respectively and one 
Knauer K-500 HPLC pump for delivery of the injected samples. Both 
superloops were kept on ice. For proper operation of the pumps at 
low flow rates (100 μl/min), and for pulse dampening, flow restrictors 
were inserted directly after the pumps and before the superloops. The 
flow restrictors, comprising 10 cm length, 25 μm i.d., 375 μm o.d. 
fused silica connected to a 2 μm frit filter produced back-pressures of 
approximately 100 bar. The pressure limits of the pumps were set 20 
bar higher than the working pressure to prevent damage to the 
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superloops due to possible clogging of the system. Sample injections 
were performed with a Gilson 234 autoinjector (Villiers-le-Bel, France) 
equipped with a Rheodyne (Bensheim, Germany) six-port injection 
valve (injection loop, 50 μl). An Agilent 1100 (Waldbronn, Germany) 
series fluorescence detector (λex 530 nm; λem 586 nm) was used for 
monitoring fluorescence. The temperature of the reaction coil was 
controlled by a Shimadzu CTO-10AC column oven (Duisburg, 
Germany). During optimization, the carrier solution was water (100 
μl/min). Samples were flow-injected in the carrier solution prior to 
mixing with buffer solution containing the enzyme (100 μl/min) and 
the co-factor/substrate solution (100 μl/min). Knitted PTFE reaction 
coils (0.25 mm i.d.; 0.8 mm o.d.; internal volumes of 25, 50, 75, 100 
and 150 μl) were tested for the on-line enzymatic reaction prior to 
detection. All hardware was integrated in one system by Kiadis B.V. 
(Groningen, NL) and was controlled by software developed by Kiadis 
B.V. 
  
CYP enzyme affinity detection in flow-injection analysis mode 
 
A scheme of the CYP enzyme affinity detection (EAD) system 
in flow-injection analysis (FIA) mode is shown in Figure 1A. The CYP 
EAD system is operated by mixing CYP enzymes (liver microsomes 
from β-NF-induced rats), substrate (ethoxyresorufine) and co-factor 
(NADPH) continuously with a carrier solution. After mixing in a knitted 
reaction coil, the substrate ethoxyresorufine is converted in the 
reaction coil into the highly fluorescent product resorufine [26]. The 
high expression level of CYP1A in β-NF induced rat liver microsomes 
and the selective O-dealkylation of ethoxyresorufine by CYP1A 
provides an excellent means of selective monitoring of the carrier 
solution for the presence of compounds posessing affinity for CYP1A. 
Eluting ligands (i.e. both inhibitors and substrates) competing with 
ethoxyresorufine for the active site of the CYPs concerned cause a 
(temporarily) decreased production of resorufine that is monitored by 
fluorescence detection. 
 
CYP enzyme affinity detection on-line coupled to HPLC 
 
For operation of the CYP EAD system in HPLC mode (Figure 
1B), two pumps were used to control the HPLC-gradient and, directly 
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after the HPLC-column, two pumps to compensate for increasing 
organic modifier concentrations before delivery of the eluent to the 
CYP EAD system. An Agilent 1100 series UV detector monitored the 
HPLC eluent at 220 nm, parallel to the fluorescent CYP EAD signal. 
HPLC separations were performed using a Phenomenex (Torrance, 
USA) 30 mm length × 2 mm i.d. stainless-steel column (Luna 3μ 
C18(2)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: (A) Schematic view of the CYP EAD system in FIA mode. 
Superloop-A (SL-A) and superloop-B (SL-B) are used to deliver 
enzyme and substrate to the reaction coil, respectively. Ligands are 
introduced into the system by injection on the carrier solution with the 
autosampler (AS). Ligands temporarily inhibit fluorescent product 
formation, which is monitored with a fluorescence (FLD) detector. (B) 
The carrier flow from the FIA system is replaced by a gradient 
reversed phase HPLC system. After HPLC, the make-up pumps 
produce a counteracting gradient, resulting in a CYP EAD compatible 
constant organic modifier concentration. The eluent is then split 1:9 
(90% to UV detection and 10% to CYP EAD). 
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The eluent from the HPLC was directed to a T-piece and splitted 1:9 
with a flowsplitter (5 cm length, 50 μm i.d., 375 μm o.d. and 5 cm 
length, 25 μm i.d., 375 μm o.d. fused silica connected to the T-piece) 
to the CYP EAD system and the UV detector, respectively. For HPLC 
analysis, test compounds were dissolved in 30% MeOH in water. The 
HPLC column was eluted as follows: an initial flow rate of 1000 μl/min 
H2O : MeCN (95:5) for 2 min; then, a ‘decreasing flow rate’ gradient 
of 12 min to 190 μl/min H2O : MeCN (5 : 95) was performed, followed 
by 10 min at H2O : MeCN (5 : 95) with a flow rate of 190 μl/min. 
Finally, the column was equilibrated to the starting conditions in 0.5 
min. To maintain a constant concentration of organic modifier in the 
CYP EAD system, another ‘increasing flow rate’gradient was mixed 
with the eluent from the column prior to the flowsplitter. This 
compensatory gradient was as follows: an initial flowrate of 500 
μl/min for 2 min at H2O : MeCN (3 : 1); an increasing flow rate 
gradient of 12 min to 1300 μl/min H2O : MeCN (100 : 0); 10 min at 
H2O : MeCN (1300 : 0) with a flow rate of 1300 μl/min. The H2O and 
the MeCN both contained 6% Tween 20. Re-equilibration was 
performed in 0.5 min. The concentration of MeCN in the eluent after 
addition of the make-up gradient was 12% with a constant flow rate of 
1500 μl/min. The initial high flow rate through the column, afforded by 
the decreasing flow rate gradient, ensures good resolution, combined 
with a constant CYP EAD compatible organic modifier concentration 
of 12% after mixing of the decreasing flow rate gradient. 
 
Microplate reader assay of CYP1A affinity 
 
The microplate reader assay is based on O-dealkylation of 
ethoxyresorufine to the highly fluorescent resorufine by microsomal 
CYP1A [26]. The fluorescence of resorufine was measured at λex 530 
nm (bandwidth 8 nm) and λem 580 nm (bandwidth 30 nm) on a Victor2 
1420 multilabel counter (Wallac, Turku, Finland). 
Microplate reader assays were performed under two different 
conditions, namely normal conditions (1) and conditions used in the 
CYP EAD system (2), in order to determine possible differences in 
IC50’s obtained. Concentration ranges of test compounds were 
prepared by serial dilution of compounds dissolved in DMSO (50 μl) 
with DMSO (150 μl). A mixture (150 μl) of rat liver microsomes (39.3 
μg protein/ml) and ethoxyresorufine (150 nM) in 50 mM potassium 
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phosphate buffer (pH 7.4), containing 2.5 mM MgCl2, was incubated 
for 15 min at 37ºC. Then, one of the following solutions (75 μl) was 
added to start the reaction: 1) (normal conditions): a freshly prepared 
mixture of test compound in DMSO (20 μl) and 80 μl of a solution 
containing 50 μM NADPH in 12 % MeCN or 2) (CYP EAD 
conditions): a freshly prepared mixture of test compound in DMSO 
(20 μl) and 80 μl of a solution containing 50 μM NADPH, 1 mg/ml 
PEG 6000 and 2 mg/ml Tween 20 in 12 % MeCN. The increase in 
resorufin fluorescence was measured each minute over 6 minutes 
with the Victor2. The initial linear increase in resorufin fluorescence 
was a measure of the enzymatic activity. Inhibition curves based on 
11 concentrations and a blank were measured in quadruplicate for 
each test compound. IC50-values for each compound were 
determined with Prism3 software for both assay formats.  
 
 
Results and Discussion 
 
Development and optimization of the CYP EAD system in flow-
injection analysis mode 
  
Continuous mixing of enzyme (CYP), a substrate 
(ethoxyresorufine) and the eluent from a carrier flow into a reaction 
coil is the basic concept of the new CYP EAD system, presented 
here. In the reaction coil, a continuous formation of fluorescent 
product takes place and is measured by a fluorescence detector at 
the end of the reaction coil. Eluting ligands temporarily inhibit 
fluorescent product formation thus allowing detection of enzyme 
inhibition potential. The CYP EAD system developed was first tested 
by cooling the reaction coil to 0°C. This temperature decrease 
resulted in a reduced enzymatic activity, in decreased product 
formation and hence, in a lower baseline (Figure 2). After 
equilibration of the reaction coil to 37°C, resulting in a baseline rise to 
the original level, injections of the inhibitor α-naphthoflavone (α-NF; 
100.0 pmol) resulted in signals of 95% of the maximum signal, while 
blank injections showed no peaks at all. Injections of α-NF (100.0 
pmol) in the system with the reaction coil cooled to 0°C gave no 
peaks (data not shown), indicating that the signals were due to α-NF 
and not caused by fluorescence quenching. The CYP EAD system 
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was developed for the detection of CYP1A inhibitors in mixtures. 
Hence, the system was optimized both for assay sensitivity (signal to 
noise ratio) and for assay resolution (band broadening).  
The influence of additives, substrate and enzyme 
concentration, reaction time and temperature were first investigated 
in flow-injection analysis (FIA) CYP EAD mode in order to optimize 
the performance of the CYP EAD system. The influence of 
acetonitrile and methanol, to be used in HPLC mode, on the CYP 
EAD system performance was also tested in the FIA mode. All 
measurements were done in triplicate. Membrane-bound CYPs and 
lipophilic compounds may adsorb to the wall of reaction coils, 
sometimes resulting in severe peak broadening. Several strategies 
were tested to reduce this phenomenon.  
Additives: Different additives were tested to optimize resolution. 
Initially, the first superloop (SL-1, Figure 1) contained β-NF induced 
rat liver microsomes (39.3 μg protein/ml) in potassium phosphate 
buffer (50 mM, pH 7.4), containing 2.5 mM MgCl2). The second 
superloop (SL-2, Figure 1) contained a solution of 40 μM NADPH, 
300 nM ethoxyresorufine and additive in potassium phosphate buffer 
(50 mM, pH 7.4), containing 2.5 mM MgCl2. Water was used as 
carrier solution. BSA, casein hydrolysate , glycine, glycerol, L-α-
phosphatidylcholine dilauryl and ELISA blocking reagent were tested 
as additives at different concentrations, but none improved the 
resolution when the inhibitor α-NF was injected at concentrations of 
0.4 or 2 μM (data not shown). Similar experiments with additives 
were previously conducted by Oosterkamp et. al. [15], who in contrast 
found that casein hydrolysate substantially reduced non-specific 
binding of the estrogen receptor to the reaction coils and band 
broadening resulting in higher resolution. Since this was not the case 
in the present experiments it is suggested that the observed band 
broadening is mainly caused by the ligands and not the enzyme. 
Several polymers were subsequently tested for their ability to 
improve resolution at concentrations of 0.4, 1 and 2 mg/ml in SL-2. 
Dextran resulted in significantly narrowed, but also smaller peaks. 
Slightly smaller, but significantly narrower peaks were obtained in the 
case of polyethylenimine at a concentration of 1 mg/ml in SL-2. 
Equally good results in terms of resolution were obtained using PEG 
6000 or PEG 3325. A concentration of 1 mg/ml PEG 6000 in SL-2 
was found to be optimal and was therefore used further. 
 65
On-line CYP1A Enzyme Affinity Detection                                               Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The reaction coil of the CYP EAD system was first placed at 
37°C, then at 0°C resulting in no enzymatic activity. After re-
equilibration to 37°C, the inhibitor αNF was injected in duplicate. 
 
 
Various detergents (Tween 20 and Tween 80, sodium cholate 
and saponin) added to the carrier solution were tested to increase 
resolution (final concentrations of 0.17, 0.33, 0.67 and 1.33 mg/ml in 
the reaction coil for each detergent tested). All detergents tested 
significantly improved the resolution (data not shown). At detergent 
concentrations higher then 1.33 mg/ml, however, significant 
reductions in enzyme activity were seen. This is due to solubilization 
of microsomes. Saponin gave very irregular pump pressures. Sodium 
cholate resulted in increased baseline noise. Tween 20 and Tween 
80 gave equally good results in terms of increased resolution. The 
resolution in terms of peak width (2 μM α-NF injections) decreased 
from 5.2 min when no detergents were used to 3.3 min when an 
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optimal Tween 20 or Tween 80 concentration of 0.67 mg/ml was 
used. 
Temperature: To evaluate temperature effects, 
ethoxyresorufine was not added to SL-2, but injected directly into the 
CYP EAD system. Water was used as carrier solution. Reaction coil 
temperatures of 15 to 60ºC in steps of 5 ºC and 37 ºC were 
examined. The optimum temperature (yielding the highest resorufine 
signal upon 300 nM ethoxyresorufine injections) was found to be 37 
°C. This reaction coil temperature was subsequently used for further 
optimization.  
Substrate, enzyme, coil volume and organic modifiers:  To test 
the performance of the CYP EAD system with different 
concentrations of substrate, microsomes, reaction coil volume, MeOH 
and MeCN, the inhibitor α-NF was injected in different amounts (i.e. 
0, 18, 32 and 56 pmol). The results are shown in Figure 3A-E.  The 
signal to noise (S/N) ratios were examined for each type optimization. 
Since the CYP EAD system does not give a linear, but a sigmoidal 
response (in accordance with the enzymatic kinetics of CYP), S/N 
ratios were chosen for optimization rather than peak areas. Similar 
strategies were previously followed in other on-line affinity detection 
methodologies [16, 24]. All concentrations used in the optimization 
process represent concentrations of the constituents in the reaction 
coil and not in the superloops (Figure 1A). 
Substrate concentration: When varying the ethoxyresorufine 
concentration, optimal S/N ratios were obtained at a concentration of 
150 nM. This ethoxyresorufine concentration was therefore used for 
further optimization. 
Enzyme concentration: In the optimization of the microsomal 
protein concentration in the reaction coil (Figure 3B), an optimum was 
found at a microsomal protein concentration of 19.7 μg protein/ml. 
Protein concentrations higher than 40 μg/ml were not tested because 
of the inherently increasing risk of clogging the CYP EAD system. 
Optimal S/N ratios were observed at a microsomal protein 
concentration of 19.7 μg protein/ml. This concentration was used for 
further optimization.  
Coil volume: The S/N ratios obtained with different reaction coil 
volumes are shown in Figure 3C. While larger coil volumes (i.e. 
longer reaction times) increased sensitivity in terms of S/N ratios, 
resolution was degraded. Similar effects have been seen with on-line 
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estrogen receptor affinity detection screening by Oosterkamp et al 
[15]. With the present CYP EAD system, these effects are probably 
due to a combination of more product formation and more peak 
broadening (lower resolution) due to larger reaction coil volumes. 
Therefore, the smallest reaction coil volume (25 μl) was selected for 
further optimization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A-E: Assay optimization results. Different α-napthoflavone 
(aNF) concentrations were used for optimization of different 
parameters (A = substrate concentration, B = protein concentration, C 
= coil volume, D = MeOH concentration and E = MeCN 
concentration).   
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Organic modifier concentration: Increasing the concentration of 
MeOH initially decreased the S/N ratios, probably due to enzyme 
destruction (Figure 3D). When the concentration of MeOH was further 
increased, however, an increase in S/N ratio was seen. This 
observation was primarily due to increased resolution resulting in 
higher and sharper peaks. This effect was also described in 
Oosterkamp et. al. [15] and is probably caused by reduced non-
specific binding of enzyme, ligands and substrate. At even higher 
concentrations of organic modifier, this effect was less pronounced 
and S/N ratios decreased again, most likely due to enzyme 
denaturation. With MeCN, a similar effect was seen, except for the 
initial S/N ratios (Figure 3E). 
Although higher organic modifier concentrations will decrease 
enzymatic activity, a higher organic modifier concentration does allow 
more eluent from the HPLC column to flow into the CYP EAD system, 
resulting in higher sensitivity due to higher compound concentrations 
in the reaction coil. Finally, organic modifiers may increase resolution 
due to the creation of a more lipophilic environment, thus preventing 
lipophilic compounds and enzymes from adsorbing to the walls of the 
reaction coil. Reaction coil organic modifier concentrations of 3 to 6 % 
MeOH and 1 to 3 % MeCN were found to be optimal. 
 
Variability 
 
Inter-day and intra-day variability were determined as follows: 
Intra-day variability was determinated by injecting α-NF (25.0 pmol, 
eliciting 67 % inhibition of the enzyme activity in the CYP EAD 
system) under optimized conditions, in triplicate, at 3.5 hour time 
intervals. The intra-day variability was examined without changing the 
content of the superloops. For inter-day variability, α-NF (25.0 pmol) 
was injected daily in triplicate for three days with fresh solutions in the 
superloops each day. The optimized conditions consisted of β-NF 
induced rat liver microsomes (59.1 μg protein/ml in SL-1, resulting in 
19.7 μg protein/ml in the reaction coil), potassium phosphate buffer 
(50 mM, pH 7.4 containing 2.5 mM MgCl2) in SL-1 (100 μl/min) and 
NADPH (40 μM), ethoxyresorufine (450 nM in SL-2, resulting in 150 
nM in the reaction coil) and 1 mg/ml PEG 6000 in the same buffer in 
SL-2 (100 μl/min). The carrier solution (100 μl/min) contained 12% 
MeCN with 2 mg/ml Tween 20. Intra-day and inter-day variability 
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were both less than 3%, which is well within the range of bio-
analytical screening methods [16, 27]. 
 
Assay validation (FIA mode) 
 
Microplate reader assay for CYP1A inhibition: For validation of 
the CYP EAD system, microplate reader-based assays were 
performed for comparison of the IC50-values with those obtained with 
the CYP EAD system. All tested compounds showed sigmoidal 
concentration-response curves. The compounds were tested under 
two microplate reader conditions (setup 1 and 2), namely standard 
conditions (setup 1) and optimized conditions used in the CYP EAD 
system (setup 2) to determine possible differences in affinities. The 
IC50-values obtained with the two different experimental conditions 
are presented in Table I and were found to be similar. Since similar 
results were obtained in setup 1 and setup 2, the conditions used in 
the CYP EAD system, which resemble the conditions of setup 2, are 
expected to give the same results in terms of affinities as conditions 
normally used in CYP affinity screening (setup 1). 
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Figure 4: Injections (triplicates) of the  inhibitor α-napthaflavone in the 
CYP EAD system. Total amounts of 200.0 pmol, 100.0 pmol 50.0 
pmol, 25.0 pmol, 12.5 pmol, 6.3 pmol and 3.1 pmol were injected. 
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CYP EAD system in FIA mode: The noise of the CYP EAD 
system was usually less than 3 % of the maximal inhibition signal 
(Figure 4). The performance of the optimized CYP EAD system was 
ultimately evaluated with seven known CYP1A ligands and the data 
obtained was compared with the data from the microplate reader 
assay. In order to measure possible quenching of resorufine 
fluorescence by the ligands used, all ligands were also tested in the 
CYP EAD system in which the substrate ethoxyresorufine was 
replaced by the product resorufine, at concentrations similar to as 
that formed during reaction in the optimized CYP EAD system. Blank 
carrier solution injections did not give a negative signal in the CYP 
EAD system. Injections of the inhibitory test compounds at high 
concentrations resulted in quenching of the fluorescence of resorufine 
in a number of cases, e.g. caffein, phenacetin, fluvoxamine and β-NF 
injected at amounts of 4.0, 0.6, 0.5 and 0.2 μmol, respectively. The 
IC50-curves for these compounds were therefore only determined at 
concentrations less than the lowest respective concentration at which 
quenching was observed. 
 
 
Figure 5: IC50 curves (n=3) obtained for 7 different CYP1A ligands in 
the CYP EAD system in FIA mode. 
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For the CYP EAD assay, the total amount of inhibitory test 
compound injected was used to calculate the maximum concentration 
in the reaction coil. The dilution factor of the injected test compound 
to the final concentration in the reaction coil was determined first, in 
the following way: Known concentrations of resorufine (10 μM and 
100 μM) were injected into the CYP EAD system and the fluorescent 
peak heights were recorded. Next, the same concentrations of 
resorufine were infused via the carrier solution into the CYP EAD 
system. The increases in fluorescence after equilibration were 
compared to the peak heights of the injected resorufine samples. This 
was performed in triplicate. The peak heights obtained were 40 % of 
the baselines obtained in the infusion experiments at both resorufine 
concentrations tested, indicating that the concentration of resorufine 
in the reaction coil  was 13.3 % of the injected concentration (40/3 = 
13.3 % due to the extra dilution factor of 3 in the reaction coil).  
Each ligand tested was injected at different concentrations 
(prepared by serial dilution of 400 μl solutions in DMSO with 400 μl 
carrier solution) starting at a concentration eliciting 100% inhibition of 
the CYP EAD signal in FIA mode and ending at a concentration 
giving a S/N ratio of 3. A typical result for the inhibitor α-NF is shown 
in Figure 4. The cumulative results for all seven inhibitory test 
compounds are shown in Figure 5. The correspondingly calculated 
IC50-values are presented in Table I. The detection limit for each 
tested compound (S/N = 3) is also shown in Table I. For caffein and 
phenacetin quenching of fluorescence at high concentrations 
prevented construction of complete IC50-curves. For high affinity 
inhibitors, such as α-NF, ellipticine and 9-hydroxyellipticine, IC50-
values obtained with the CYP EAD system were well in accordance 
with those of the microplate reader assays. For low affinity inhibitors 
(i.e. caffein and phenacetin) the inhibition curves could not be 
measured accurately with the CYP EAD system up to 100% 
inhibition, therefore the comparison of the microplate reader assays 
and the CYP EAD system in those cases were less concordant, but 
estimates of the affinities could still be made. 
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Table 1: IC50-values of 7 CYP1A inhibitors measured with the CYP 
EAD system in FIA mode with measured σ’s for every compound, 6 
CYP1A inhibitors measured with the CYP EAD system in HPLC 
mode and 7 CYP1A inhibitors measured in two different batch assay 
formats. Setup 1 = ACN and Setup 2 = ACN, PEG 6000 and Tween 
20. Det. lim. = Detection limit (S/N ratio = 3). 
 
 
 FIA CYP EAD system HPLC CYP EAD 
system 
Microplate Reader Assays 
Inhibitor IC50-values 
(μM ± SEM; 
n=3) 
Det. lim. 
in pmol 
 
σCOM IC50-
values 
(μM; n=1) 
Det. 
lim. in 
pmol  
 
Setup 1: 
IC50 (μM  ± 
SEM; n=4) 
Setup 2: 
IC50 (μM  ± 
SEM; n=4) 
Ellipticine 0.015±0.003 1.32 1.21 0.022 10 0.017±0.002 0.020±0.004 
9OH-ellipticine 0.023±0.009 1.32 1.14 0.030 10 0.017±0.004 0.015±0.004 
α-naphthoflavone 0.015±0.003 3.13 1.37 0.023 25 0.026±0.008 0.043±0.006 
β-naphthoflavone 0.051±0.005 53.7 1.10 0.156 200 0.067±0.016 0.102±0.033 
Fluvoxamine 1.88±0.70 170 0.58 N.D. N.D. 1.24±0.21 2.07±0.27 
Phenacetin 305 3890 0.33 128 10000 101±17 197±48 
Caffein 1327 25120 0.31 301 40000 2924±784 2760±216 
 
 
 
On-line coupling of the CYP EAD system to gradient HPLC 
 
For on-line CYP based biochemical detection after HPLC 
separation, the CYP EAD system in FIA mode (Figure 1A) was 
replaced by the CYP EAD system in HPLC mode (Figure 1B). Six 
inhibitory compounds were injected at 5 different concentrations and, 
after HPLC separation, detected with the CYP EAD system. IC50-
values were calculated in the same way as for the CYP EAD system 
in FIA mode. The IC50-values of the test compounds of the CYP EAD 
system in HPLC mode are presented in Table I. The latter IC50-
values were well in agreement with those obtained with the CYP EAD 
system in FIA mode and the microplate reader assay results (setup 2) 
in the case of the high affinity inhibitors. For the low affinity inhibitors 
phenacetin and caffein, fluorescence quenching when injected in the 
CYP EAD system in high concentrations was observed. This 
preventing IC50-curves from being constructed. 
Representative superimposed chromatograms of different 
concentrations of the strong inhibitor α-NF and the weak inhibitor 
phenacetin are shown in Figure 6A and 6B, respectively. A 
representative chromatogram of a mixture of six test compounds is 
given in Figure 6C. Due to the sensitivity of the CYP EAD system, 
some baseline drift is observed during the gradient HPLC 
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separations. The make-up HPLC gradient does not totally supress 
the baseline drifting. When less HPLC eluent is flowing into the CYP 
EAD system, the baseline drift is significantly decreased, but so is 
also the sensitivity. 
 
σ Determinations 
 
A major focus during the optimization of the CYP EAD system 
in FIA mode has been the elimination of tailing problems caused by 
lipophilic ligands and membrane-bound CYPs, while at the same time 
attention was paid to the prevention of enzyme destruction. The 
determination of σ‘s was used to describe peak broadening (or 
resolution) of compounds in the optimized CYP EAD system. Due to 
the nature of the CYP EAD system, in which compounds are 
subjected to an environment with a relatively low organic modifier 
concentration, it may be expected that compounds with a lipophilic 
character will have lower resolution, due to adsorption in the reaction 
coil, than hydrophilic compounds. To test this hypothesis, the σ’s for 
the injection port connected directly to the fluorescence detector 
(σFLD) and for the CYP EAD system eluting only with buffer (σBUF) 
were determined with resorufine injections (100 nM, triplicate 
injections). Finally, the σ’s of the CYP EAD system (σTOT) at test 
compound concentrations eliciting approximately 50% inhibition in the 
CYP EAD system, were determined to calculate the σ’s of the 
respective test compounds (σCOM). For calculation of the σ’s of the 
test compounds, the following formula was used: 
 
σCOM = √ ( (σTOT)2 - (σBUF) 2 - (σFLD) 2) 
 
The σBUF was 0.12 and σFLD was 0.08. The calculated σCOM’s are 
presented in Table I. Compounds with more lipophylic character, as 
deduced from longer retention times on gradient HPLC (Figure 6C) 
and lower solubility in aqueous environments, indeed had larger σ’s 
than the hydrophilic compounds.  
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Figure 6: A) Superimposed CYP EAD traces of α-napthoflavone (α-
NF)  injected in different concentrations in the on-line CYP EAD 
HPLC system. B) Superimposed CYP EAD traces of phenacetin  
injected in different concentrations in the CYP EAD HPLC system. C) 
CYP EAD trace of a mixture of 6 compounds  injected in  the CYP 
EAD HPLC system (injected compounds are subsequently: caffein (4 
μmol; 5.5 min), phenacetin, (400 nmol; 9.0 min), 9-hydroxyellipticine 
(0.1 nmol; 13.0 min), ellipticine (0.04 nmol; 14.5 min), α-
napthoflavone(0.1 nmol; 17.5 min) and β-napthoflavone (0.4 nmol; 
18.5 min) .).  
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Conclusions 
 
The on-line coupling of a novel CYP enzyme affinity detection 
(EAD) system to HPLC, as described in this study, enables for the 
first time CYP affinity screening of individual compounds in mixtures. 
Laborious preparative HPLC separation of compounds from mixtures, 
followed by microplate reader based assays of the individual 
compounds can be replaced by a single HPLC run coupled to on-line 
CYP EAD. The CYP EAD system in HPLC mode was able to 
separate a mixture of six ligands and subsequently detect them 
individually on-line as CYP1A inhibitors. Moreover, with the new CYP 
EAD system, both in FIA mode and in HPLC mode, IC50-values of 
seven known ligands were determined and were in accordance with 
traditional microplate reader assays. For high affinity ligands of 
CYP1A, detection limits of 1 to 3 pmol (n = 3; S/N = 3) were obtained. 
Different analytical parameters, such as substrate and enzyme 
concentration, reaction time, temperature, additives and organic 
modifier concentration, were optimized for the CYP EAD system. The 
intra-day and inter-day variability (with an amount of α-NF eliciting 
67% of maximal inhibition) were both less then 3 % of the maximal 
inhibition signal. In contrast to previous on-line biochemical-based 
assays, in which soluble receptor (estrogen receptor [15]), enzymes 
(phosphodiesterases [17]) or antibodies (against cytokines or 
leukotrienes [18, 19]) were used, measures were employed to 
prevent band broadening and to obtain stable baselines for longer 
time periods. The present HPLC based post column on-line CYP 
EAD system gave σ’s ranging between 0.31 min and 1.37 min for 
compounds eliciting 50% of the maximum inhibition measured with 
the CYP EAD system, which were about as good as σ’s seen in 
similar systems [15-17]. The σ’s of the compounds tested (at IC50 
concentration) indicate that more lipophilic compounds have larger 
σ’s. This may be due to adsorption of more lipophilic compounds in 
the reaction coil. More lipophilic compounds are also usually higher 
affinity inhibitors, which can also account for the larger σ’s found. In 
conclusion, the HPLC based post column on-line CYP EAD system is 
a valuable new tool to screen affinities of individual compounds in 
mixtures selectively and sensitively. This may be of great added 
value in drug discovery & toxicology. 
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coupled on-line to gradient reversed-phase 
HPLC 
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Vermeulen 
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Abstract 
 
A High Resolution Screening (HRS) technology is described, in which 
gradient HPLC is connected on-line to three parallel placed bio-
affinity detection systems containing mammalian Cytochrome P450’s 
(CYP’s). The three so-called Enzyme Affinity Detection (EAD) 
systems contained respectively liver microsomes from rats induced 
by β-naphthoflavone (CYP1A-activity), phenobarbital (CYP2B-
activity) and dexamethasone (CYP3A-activity). Each CYP EAD 
system was optimized for enzyme, substrate and organic modifier 
(isopropylalcohol, methanol and acetonitrile) in flow injection analysis 
(FIA) mode. Characteristic CYP ligands were used to validate the 
CYP EAD systems. IC50-values of the ligands were measured and 
found to be similar to those obtained with conventional microtiter-
plate reader assays. Detection limits (n = 3; S/N = 3) of potent 
inhibitors ranged from 1 - 3 pmol for CYP1A activity, 4 - 17 pmol for 
CYP2B activity and 4 - 15 pmol for CYP3A activity. The three 
optimized CYP EAD systems were subsequently coupled to gradient 
HPLC and used to screen compound mixtures for individual ligands. 
In order to increase analysis efficiency, finally a HRS system was 
constructed in which all three CYP EAD systems were coupled on-
line and in parallel to gradient HPLC. The triple parallelized CYP EAD 
system was shown to enable rapid profiling of individual components 
in complex mixtures for inhibitory activity to three different CYP’s. 
 81
On-line CYP1A, 2B and 3A Enzyme Affinity Detection                            Chapter 3 
Introduction 
 
Cytochromes P450 (CYP’s) are of major importance for the 
disposition and metabolism of drugs and other xenobiotics [1, 2]. The 
enzymes are membrane-bound heme-containing proteins that are 
expressed in the endoplasmatic reticulum of cells and on the inner 
membranes of mitochondria. The major CYP’s involved in drug 
metabolism are located in the liver, although they also occur in other 
organs and tissues. For catalysis, CYP’s depend on the electron-
donating capacity of NADPH CYP-reductases. Because CYP’s play a 
crucial role in the disposition and metabolism of drugs, it is of 
profound importance to determine the affinity of CYP’s for drugs as 
well as for their metabolites. Especially in drug discovery and 
development, new chemical entities (NCE’s) and lead compounds as 
well as their metabolites must be evaluated for their affinities towards 
relevant CYP isoenzymes [3-5].  
When many compounds are to be screened for their affinity to 
CYP’s [6, 7], often in vitro High Throughput Screening (HTS) 
methodologies are used [8, 9]. Usually, the inhibition of fluorescent 
metabolite formation from probe substrates is employed for this 
purpose [10-12]. These HTS-based methodologies, however, cannot 
be used for the identification of individual ligands in compound 
mixtures. In these cases, mixtures have to be separated 
chromatographically before affinity screening of individual compounds 
can occur [13, 14]. Natural compound extracts, combinatorial 
chemistry libraries and drug metabolite mixtures are representative 
for these types of mixtures [15]. Other methodologies, in which 
ligands are first captured by (immobilized) target biomolecules 
followed by their release and subsequent separation and detection 
[16], lack the possibility of identification of low affinity compounds in 
the presence of high affinity compounds.  
Several years ago, a new on-line High Resolution Screening 
(HRS) concept based on a continuous-flow biochemical assay 
coupled on-line to HPLC and circumventing several of these 
disadvantages was described [17]. Subsequently, HRS-based bio-
affinity detection methods for ligands of e.g. the estrogen receptor 
[18], phosphodiesterases [19], acetylcholine esterases [20], 
angiotensin converting enzymes [21] and antibodies [22] have been 
described. We recently developed a novel HRS based bio-affinity 
detection system to screen on-line for compounds with affinity for rat 
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liver microsomal CYP1A activity [23]. In the latter HRS-system, 
CYP1A induced rat liver microsomes and the substrate 
ethoxyresorufine were added post-column to the HPLC eluate to 
allow a metabolic reaction for a period of time. The CYP1A mediated 
conversion of ethoxyresorufine to the highly fluorescent product 
resorufine was monitored continuously by fluorescence detection, 
thus allowing the on-line screening of individual inhibitors of CYP1A 
in mixtures. For CYP substrate and inhibitor binding and drug-drug 
interaction screening, however, it is desirable to determine the 
inhibitory potential of compounds towards multiple relevant CYP’s, 
ideally simultaneously. 
In the present study, a HRS triple CYP Enzyme Affinity 
Detection (CYP EAD) system was developed for this purpose. The 
system consists of three parallel configured CYP EAD systems, with 
rat liver microsomes as principal source of CYP’s. For proof of 
principle, CYP1A, 2B and 3A activities, respectively using β-
naphthoflavone (βNF), phenobarbital (PB) and dexamethasone 
(DEX)-induced rat liver microsomes were used. First, the CYP2B and 
CYP3A EAD systems were developed and optimized in flow injection 
analysis (FIA) mode and thereafter they were coupled individually on-
line to HPLC. The CYP1A EAD system used was similar to the 
CYP1A EAD system recently described [23]. Finally, the three CYP 
EAD systems were incorporated on-line and in parallel in a gradient 
HPLC apparatus. The entire HRS triple CYP EAD system was then 
used for the simultaneous screening of inhibitors for each of the three 
CYP’s. The methodology could ideally be employed in the late 
discovery and early development stage in the overall drug discovery 
and development process for screening lead compounds or metabolic 
mixtures from these lead compounds. 
 
 
Experimental Section 
 
Materials 
 
Ethoxyresorufin, Tween 20, polyethyleneglycol 6000 (PEG6000), 
aminopyrine, α-naphthoflavone (α-NF), miconazole and nifedipine 
were purchased from Sigma (Zwijndrecht, The Netherlands). Caffeine 
and metyrapone were obtained from Aldrich (Zwijndrecht, The 
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Netherlands). β-Naphthoflavone (β-NF) was supplied by Acros (Den 
Bosch, The Netherlands). β-Nicotinamide adenine dinucleotide 
phosphate (NADPH) tetra sodium salt was purchased from 
Applichem (Lokeren, Belgium). Trifluoroacetic acid (TFA) was bought 
from Merck (Schuchardt, Germany). Methanol (MeOH), acetonitrile 
(MeCN) and 2-propanol (iPA) came from Baker (Deventer, The 
Netherlands) and were of HPLC reagent grade. All other chemicals 
were of the highest purity grade commercially available. 
β-Naphthoflavone (βNF) and phenobarbital (PB) induced rat 
liver microsomes were prepared as described previously [24]. Protein 
concentrations in the β-NF and PB induced rat liver microsomes were 
13.1 mg/ml and 9.9 mg/ml, respectively. Dexamethasone (DEX)-
induced rat liver microsomes were also prepared as described 
previously [24] except that 60 mg DEX/kg rat was used for induction. 
Protein concentration in the DEX microsomes was 12.9 mg/ml.  
 
Apparatus 
 
 The configuration of the CYP EAD systems in flow injection 
analysis (FIA) and HPLC mode was similar to the EAD system 
described recently for CYP1A activity [23]. A general scheme of the 
current triple parallelized CYP EAD system coupled on-line to 
gradient reversed-phase HPLC is shown in Figure 1. The CYP EAD 
systems are operated by mixing CYP enzymes (rat liver microsomes 
from induced rats), substrate and co-factor (NADPH) continuously 
with a carrier solution (FIA mode) or with an HPLC effluent (HPLC 
mode). Superloop A, C and E contain CYP enzymes (from DEX, PB 
and βNF induced microsomes, respectively) for the three respective 
EAD systems (CYP3A, CYP 2B and CYP1A based). For mixing of the 
substrates and co-factor with their “corresponding” CYP in every 
reaction coil, the substrates (BTFC, pentoxyresorufin and 
ethoxyresorufin, respectively) were continuously pumped through 
superloop B, D and F for the CYP3A, CYP2B and CYP1A EAD 
systems, respectively. Co-factor, which is obviously needed for every 
CYP EAD system, was present in all three substrate containing 
superloops (B, D and F). As enzyme, substrate and co-factor are 
continuously added to the reaction coils, the substrates are converted 
in the reaction coils into highly fluorescent products. Eluting ligands 
(i.e. both inhibitors and substrates) competing with the substrates for 
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the active sites of the CYP’s concerned cause a (temporarily) 
decreased production of fluorescent product that is monitored by 
fluorescence detection. 
 
 
Figure 1: Schematic view of the triple and parallelized CYP1A, 2B 
and 3A EAD system in gradient HPLC mode. After HPLC, the make-
up pumps produce a counteracting gradient, resulting in a constant 
CYP EAD compatible organic modifier concentration. The eluent is 
then split 1:1:2:6 to the CYP2B, 3A and 1A EAD systems and the UV 
detector, respectively. Eluting ligands cause a temporary inhibition of 
fluorescent product formation in the reaction coils, which is monitored 
with fluorescence (FLD) detectors. When operated in FIA mode (not 
shown in Figure), the HPLC system including the flow split is replaced 
by a carrier solution line. Ligands are then injected with an 
autosampler (A.S.) in the carrier solution and transported directly to a 
single P450 EAD system. SL = Superloop (all operated at a flow rate 
of 100 μl/min). Org = Organic modifier. SL A, C and E contain the 
enzymatic sources for CYP3A, 2B and 1A, respectively. SL B, D and 
F contain the substrates BTFC, pentoxyresorufin and ethoxyresorufin, 
respectively. SL B, D and F also contain the co-factor NADPH. 
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For optimization processes and for screening pure compounds, 
only one CYP EAD system was used at the time and was operated in 
FIA mode. This implicates that compounds injected via an 
autosampler are directly introduced into one of the three CYP EAD 
systems. When operated in HPLC mode (Figure 1), the autosampler 
is replaced by a total HPLC system with two additional post-gradient 
pumps in order to compensate for the increasing concentration of 
organic modifier during the HPLC gradients. 
Knauer K-500 HPLC pumps (Berlin, Germany) were used to 
control the Pharmacia 150 ml superloops (Uppsala, Sweden) and to 
conduct the HPLC gradients. The superloops were kept on ice during 
operation. Agilent 1100 (Waldbronn, Germany) series fluorescence 
detectors were used for monitoring the fluorescent CYP EAD signals. 
An excitation wavelength (λex) of 530 nm and an emission wavelength 
(λem) of 586 nm were used for measuring the fluorescence of the 
enzymatic product resorufin in case of the CYP1A EAD and the 
CYP2B EAD. For the CYP3A EAD, an excitation wavelength (λex) of 
409 nm and an emission wavelength (λem) of 530 nm were used for 
measuring the enzymatic product 7-HFC. Knitted PEEK reaction coils 
(to obtain optimal mixing) were used during the optimization process 
of the CYP EAD systems (0.50 mm i.d., 1.59 mm o.d.; internal 
volumes of 75, 100, 150, 200, 400 and 500 μl; representing different 
reaction times) prior to fluorescence detection. The temperature of 
the reaction coils (37°C) was controlled by a Shimadzu CTO-10AC 
column oven (Duisburg, Germany). When the three CYP EAD 
systems were coupled simultaneously in parallel to a single HPLC 
setup, the effluent from the HPLC was directed through a 5-piece and 
splitted 1:1:2:6 by means of a flowsplitter. The two 10 % (v/v) 
fractions were directed to the CYP2B EAD and the CYP3A EAD 
systems, while the 20 % (v/v) fraction was introduced into the CYP1A 
EAD system. The remaining 60 % (v/v) fraction was directed to the 
UV detector. All hardware was integrated in one system by Kiadis 
B.V. (Groningen, NL) and was controlled by software developed by 
Kiadis B.V. 
 
CYP Enzyme Affinity Detection in Flow-Injection Analysis mode 
 
The three CYP EAD systems are operated by continuous 
mixing of rat liver microsomes, substrate and co-factor (NADPH) with 
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a carrier solution when operated in FIA mode and the effluent from an 
HPLC separation when operated in HPLC mode (Figure 1). After 
mixing of the substrate with CYP’s in a knitted reaction coil, it is 
enzymatically converted into a highly fluorescent product. Eluting 
ligands (i.e. both inhibitors and substrates), which compete with the 
substrate for the active site of the respective CYP’s, will cause a 
(temporary) decrease in formation of fluorescent product. The CYP1A 
EAD system used was similar to a previously described system [23]. 
The CYP2B EAD system is based on the ability of CYP2B to 
metabolize pentoxyresorufin into highly fluorescent resorufin. 
Similarly for the CYP3A EAD system, 7-benzyloxy-4-
trifluoromethylcoumarin (BTFC) [10] is used, yielding highly 
fluorescent 7-hydroxy-4-trifluoromethylcoumarine (7-HFC) after 
debenzylation by CYP3A. The carrier solution initially used in the 
optimization process for the CYP2B and 3A EAD systems was water. 
The enzyme solutions (PB-induced rat liver microsomes in case of 
CYP2B and DEX-induced rat liver microsomes in case of CYP3A) 
and substrate solutions (pentoxyresorufin for CYP2B and BTFC for 
CYP3A, with NADPH as co-factor in both solutions) were kept on ice 
in superloops and were added to the carrier flow at a flow rate of 100 
μl/min each. 
During the optimization processes of the CYP EAD systems, 
the carrier solution was pumped at a flow rate of 100 μl/min. Flow 
injections (40 μl) were made into the carrier solution prior to mixing of 
the carrier solution with the enzyme and co-factor/substrate solution. 
Substrate and enzyme concentrations, detergents, blocking agents 
and concentrations of organic modifier (IPA, MeCN and MeOH) were 
optimized in FIA mode as well. 
As starting conditions for the CYP2B EAD system, superloop 1 
contained PB-induced rat liver microsomes (20 μg protein/ml) and 
superloop 2 substrate pentoxyresorufin (0.70 μM) and co-factor 
(NADPH; 40 μM). The inhibitor proadifen (injected in different 
amounts: 0, 6.8, 13.6, 27.3, 54.5, 109, 218, 436, 872 pmol) was used 
during the optimization process. The buffer used in the superloops 
consisted of 50 mM potassium phosphate buffer (pH 7.4 containing 
2.5 mM MgCl2). The volume of the knitted reaction coil was 75 μl. For 
the CYP3A EAD system, superloop 1 contained DEX-induced rat liver 
microsomes (20 μg protein/ml) and superloop 2 substrate BTFC (4.5 
μM) and NADPH (40 μM). The enzymatic reaction took in this case 
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place in a 200 μl knitted PEEK tubing. The inhibitor ketoconazole 
(injected in different amounts: 0, 12.5, 25, 50, 100, 200, 400, 800, 
1600, 3200) was used as a reference compound during the 
optimization. For the optimization process, the substrate 
pentoxyresorufin for CYP 2B EAD was tested at concentrations 
ranging from 100 nM to 1800 nM (Figure 2a), while for the CYP3A 
EAD system, substrate (BTFC) concentrations from 1 μM up to 30 
μM were tested (Figure 2b). The microsomal concentrations for both 
the CYP 2B and 3A EAD systems were tested in the range of 10 to 
100 μg protein/ml, in steps of 10 μg protein/ml. Coil volumes were 
tested for both CYP EAD systems from 100 to 500 μl, with steps of 
100 μl. PEG6000 was tested for both systems in the range from 0.5 
mg/ml up to 5mg/ml in steps of 0.5 mg/ml, while Tween 20 was tested 
in the concentration range of 50 to 500 mg/L (in steps of 50 mg/L). 
The tested organic modifiers (MeOH, MeCN and ACN) were tested 
for both systems in the range of 1% to 10 %, in all cases in steps of 
1%. 
 
CYP Enzyme Affinity Detection coupled to HPLC 
 
After optimization and validation of the CYP EAD systems in 
FIA mode, the CYP EAD systems were individually evaluated and 
validated in HPLC mode before integrating them into a triple 
parallelized HPLC format. This optimization and validation of every 
individual CYP EAD system was done in a similar way as described 
previously for the CYP1A system [23]. When all CYP EAD systems 
were evaluated and validated individually, all three CYP EAD 
systems were connected and integrated into the total triple CYP EAD 
system in HPLC mode as described in Figure 1. 
HPLC separations were performed using a Phenomenex 
(Torrance, USA) stainless-steel column, 30 mm × 2 mm i.d., Luna 
3μm particles, C18(2). An injection volume of 40 μl was used. The 
starting flow rate over the analytical column was 700 μl/min, H2O:IPA 
(95:5), and was maintained for 4 min. The water and organic phase 
both contained 0.1 % (v/v) acetic acid. Next a 5 – 99 % (v/v) IPA 
gradient was applied in 15 min, followed by a post-gradient time of 22 
min. During this gradient the flow rate gradually decreased to 70 
μl/min. Subsequently re-equilibration of the column to the starting 
conditions was performed in 5 min. To maintain a constant 
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concentration of IPA after the HPLC column, a second gradient with 
an increasing flow rate was configured after HPLC separation. The 
initial flow rate equaled 400 μl/min, H2O:IPA (9:1) and was  kept 
constant for 4.7 min. Next, a gradient with increasing flow rate profile 
was applied for 15 min. The final flow rate of the second make-up 
HPLC system was set at 1030 μl/min. H2O:IPA (99:1) and was 
maintained during the 22 min post gradient. Finally, re-equilibration to 
starting conditions was performed in 0.5 min. The aqueous and 
organic modifier solution of the make-up HPLC system contained 100 
mg/L Tween 20. The total flow rate of the entire HPLC system was 
kept constant at 1100 μl/min and contained a constant IPA 
concentration of 7 % (v/v). During the evaluation and validation 
process of every individual CYP EAD system in HPLC mode, the 
HPLC effluent was splitted in a 1:9 ratio. The 10 % (v/v) fraction of 
the flow being directed to the CYP EAD system and the 90 % (v/v) 
fraction to the UV detector. A mixture of different CYP2B ligands, i.e. 
70 μM metyrapon, 6000 μM aminopyrine, 7000 μM chloramphenicol 
and 50 μM proadifen, was used for validation of the CYP2B EAD 
system in HPLC mode. For the CYP3A EAD system, a mixture of 
three CYP3A ligands was used, i.e. 28 μM ketoconazole, 52 μM 
miconazole and 430 μM nifedipine.  
After the evaluation and validation process of every individual 
CYP EAD system in HPLC mode, the final triple HPLC CYP EAD 
system was constructed (Figure 1). For the final triple HPLC CYP 
EAD system, a less steep gradient was chosen to obtain a higher 
separation efficiency. A gradient time of 30 instead of 15 min was 
used. After adding make-up solutions, the HPLC effluent was split 
into the three CYP biochemical assays and a UV detector. Prior to 
mixing with the biochemical reagents, a T-piece was inserted to add 
an aqueous Tween 20 (12 g/L) solution at 50 μl/min to the CYP1A 
EAD system. In this way peak broadening was substantially reduced 
in the CYP1A EAD system. To increase the specificities of the 
respective CYP’s in every system, inhibitors of other CYP’s present in 
the microsomal preparations were included in every CYP EAD 
system. In this way activities of interfering CYP’s could be inhibited. 
[10]. To achieve this goal, the following inhibitors were added to 
superloop 1: ketoconazole (10 μM) and metyrapon (1.5 μM) for 
CYP1A EAD, ketoconazole (10 μM) and α-NF (400 nM) for CYP2B 
EAD and metyrapon (1.5 μM) and α-NF (400 nM) for CYP3A EAD. 
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First, the triple HPLC CYP EAD system was tested for 
robustness and stability of the enzymatic assays over time. It was 
found that the triple HPLC CYP EAD system could be run in a stable 
and continuous fashion if the reaction coils and the detector cells 
were washed once a week with a 20 % Tween 20 solution. The 
enzyme and substrate solutions in the superloops could be operated 
for at least eight hours before they had to be refreshed. After eight 
ours, the enzymatic activity of the CYP2B and 3A assays declined 
approximately 20 %, while for the CYP1A assay this decline was only 
10 %. A mixture of different CYP ligands was used for validation of 
the triple parallelized CYP EAD system in HPLC mode. The mixture 
contained the CYP1A inhibitors ellipticine (200 μM), 9-
hydroxyellipticine (200 μM), α-naphthoflavone (50 μM) and β-
naphthoflavone (600 μM) and the substrates phenacetin (15 mM) and 
caffein (25 mM). For CYP2B, the inhibitors metyrapon (300 μM) and 
proadifen (500 μM) and  the substrate chloramphenicol (8 mM) were 
used. For CYP3A, the inhibitors ketoconazole (250 μM) and 
miconazole (8 μM) with the substrate nifedipine (400 μM) were used. 
Of this total mixture, a concentration range was prepared by serial 
dilution of the mixture dissolved in ethanol (50 μl) with 50 % (v/v) 
aqueous ethanol (300 μl). The mixture and the serial dilutions were 
then injected in the triple parallelized CYP1A, 2B and 3A EAD system 
in gradient HPLC mode. 
 
Microplate Reader Assays for CYP Inhibition 
 
Microplate reader assay for CYP2B: The microplate reader assay for 
CYP2B activity was done in a similar way as done for CYP1A activity 
[23]. In short, a mixture of 150 μl PB-induced rat liver microsomes (40 
μg protein/ml) and pentoxyresorufin (300 nM) in potassium 
phosphate buffer (50 mM; pH 7.4) containing MgCl2 (2.5 mM) was 
incubated for 15 min at 37 °C. Subsequently, 75 μl of one of the 
following solutions was added to start the reaction: (setup 1) a freshly 
prepared mixture of 20 μl solution of test compound in H2O and 80 μl 
of a solution containing NADPH (50 μM) in 3 % (v/v) IPA or (setup 2) 
a freshly prepared mixture of 20 μl solution of test compound in H2O 
and 80 μl of a solution containing NADPH (50 μM), PEG6000 (0.5 
mg/ml) and Tween 20 (100 mg/L) in 3 % (v/v) IPA. The fluorescence 
of resorufin was measured at λex 530 nm (bandwidth 8 nm) and λem 
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580 nm (bandwidth 30 nm) on a Victor2 1420 multilabel counter 
(Wallac, Turku, Finland).  
Microplate reader assay for CYP3A: The microplate reader assays for 
CYP3A activity were performed in a similar way as for CYP1A and 
CYP2B activity, with minor modifications. A mixture of 150 μl DEX-
induced rat liver microsomes (40 μg protein/ml) and BTFC (4.5 μM) in 
potassium phosphate buffer (50 mM; pH 7.4) containing MgCl2 (2.5 
mM) was used as enzyme and substrate mix, respectively. The 
fluorescence was measured at λex 405 nm (bandwidth 8 nm) and λem 
530 nm (bandwidth 30 nm). 
 
 
Results 
 
In order to optimize, evaluate and validate the CYP EAD 
systems, FIA mode was used for the CYP EAD systems as the FIA 
mode allowed a much more rapid evaluation and validation process 
than when HPLC mode was used. The FIA mode might also be used 
to screen pure compounds for CYP inhibition.  
 
Optimization of the CYP EAD systems in FIA mode 
 
Additives, substrate and enzyme concentration and reaction 
time are important parameters influencing the robustness and 
sensitivity of on-line biochemical assays in general [19] and also of 
CYP EAD’s specifically [23]. Hence similar strategies were used to 
optimize the present CYP2B and 3A EAD systems, at first in Flow 
Injection Analysis (FIA) mode. During every optimization step, the 
resolution and sensitivity obtained with known inhibitors (metyrapone 
for CYP2B and ketoconazole for CYP3A) were determined. The 
effects of IPA, MeCN and MeOH, later to be used in HPLC mode, 
were also tested on the performance of the CYP EAD systems in FIA 
mode.  
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Figure 2: Substrate optimization results of the CYP EAD systems in 
FIA mode. (A): Optimization of the substrate pentoxyresorufin for the 
CYP2B EAD system and (B) for the CYP3A EAD system with the 
substrate BTFC. For CYP2B, metyrapone was used as inhibitor; for 
CYP3A, ketoconazole was used. 
 
 
Substrate optimization: The substrate optimization was 
conducted by injecting an appropriate test compound in different 
concentrations (as depicted in Figure 2) for every substrate 
concentration that was tested. For the CYP2B EAD system, a 
concentration of 600 nM substrate (pentoxyresorufin) resulted in the 
highest S/N-ratios (Figure 2a) and also in the highest resolution. In 
case of the CYP3A EAD system, the S/N-ratios increased 
significantly with concentrations of the substrate BTFC increasing 
from 1 μM up to 9 μM (Figure 2b). Higher concentrations of BTFC 
only gave minor improvements in S/N-ratios, while the resolution 
decreased significantly. This decreased resolution was observed in 
the form of band broadening of signals from injected inhibitors. A 9 
μM concentration is lower then the apparent Km of BTFC, which is 
above the limit of aqueous solubility as described for similar systems 
[12]. For CYP2B, 600 nM pentoxyresorufin and for CYP3A, 9 μM 
BTFC were used further.   
Enzyme optimization: When varying the microsomal protein 
concentrations in the respective CYP EAD systems, protein 
concentrations higher then 70 μg/ml were found to result in lower 
resolutions for both the CYP2B as the 3A EAD systems, while the 
S/N-ratios did not increase. Therefore, a microsomal protein 
concentration of 70 μg/ml was used in both CYP EAD systems.  
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Optimization of reaction time: For both the CYP2B and 3A EAD 
system, a reaction coil volume of 200 μl gave good S/N-ratios and 
was therefore used. Larger reaction coil volumes, i.e. up to 500 μl, 
increased the S/N-ratios slightly. This was probably due to longer 
reaction times. The resolutions obtained in these cases, however, 
were reduced significantly. 
Additives: PEG6000 and Tween 20 were found to prevent peak 
broadening in both the CYP2B and 3A EAD system: 0.5 mg/ml 
PEG6000 (in superloop 2) and 100 mg/L Tween 20 (in the carrier 
solution) gave optimal resolution both for the CYP2B and the 3A EAD 
system while maintaining enzymatic activity.  
Optimization of organic modifier: The effect of organic modifiers 
(IPA, MeCN and MeOH) on the performance of the CYP EAD 
systems was also investigated in FIA mode. For the CYP2B and 3A 
EAD systems, similar effects were seen as described previously for 
CYP1A activity [23]: optimal concentrations of organic modifier were 
found to be 4.0 % (v/v) IPA, 2.0 % (v/v) MeCN and 3.5 % (v/v) MeOH 
for both the CYP2B as the 3A EAD system.  
 
Variability 
 
Inter-day and intra-day variability for the CYP EAD systems 
were determined in FIA mode under optimized conditions. Intra-day 
variability, determined by injecting 300 pmol metyrapone (causing 67 
% inhibition of the enzyme activity in the CYP2B EAD system) in 
triplicate, at 2.5 hour time intervals was found to be 6.4 %. For inter-
day variability, metyrapone (300 pmol) was injected in triplicate for 
three sequential days and found to be 7.3 %. The inter- and intra-day 
measurements for the CYP3A EAD system were conducted in a 
similar way, with 150 pmol ketoconazole (causing 67 % inhibition of 
the enzyme activity in the CYP3A EAD system) In this case, intra-day 
variability was 6.9 % while inter-day variability 8.2 %. With both CYP 
EAD systems these variabilities were within the normal range of bio-
analytical screening methods [18, 25]. For CYP1A, these inter-day 
and intra-day variabilities were already described in literature [23] and 
were both less than 3 %. 
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Validation of the CYP EAD systems in FIA mode 
  
 For validation purposes, the CYP2B and 3A EAD systems in 
FIA mode were evaluated as to sensitivity and robustness of the 
respective bio-affinity assays. In order to investigate possible effects 
in the on-line CYP EAD systems due to the addition of reagents 
necessary to reduce peak broadening, microplate reader assays 
were performed with and without the addition of these reagents and 
the results were subsequently compared. Moreover, since induced rat 
liver microsomal systems were used for this proof of principle study 
and most inhibition parameters described for CYP inhibition in 
literature are based on human (single) CYP systems, we used the 
well known and accepted microplate reader format in order to obtain 
reliable IC50 values of the test compounds for the microsomal CYP’s 
used.  
For the determination of IC50 values obtained with the on-line 
CYP EAD systems, the dilution factors of reference inhibitors were 
first determined. This was done in a similar way as described recently 
for the CYP1A EAD system [23]. Briefly, resorufin concentrations of 
10 μM and 100 μM were injected in the CYP EAD systems to 
measure peak heights of the resorufin standards. Next, the same 
resorufin concentrations were added to the carrier solution. The 
increase in fluorescence was subsequently compared with the peak 
heights of the injected resorufin samples. Peak heights thus obtained 
were 34 and 30 % (n=3) of the baselines of the resorufin 
concentrations injected with the CYP2B and 3A EAD systems, 
respectively. This implies resorufin concentrations of 11.3 and 10.0 % 
of the injected concentrations in the reaction coil of the CYP2B and 
3A EAD systems, respectively. Each inhibitory test compound was 
then injected in different concentrations (prepared by serial dilution of 
400 μl solutions with 400 μl carrier solution), starting at a 
concentration causing 100 % enzyme inhibition in the CYP EAD 
system and ending at a concentration giving S/N ratios of 3. The 
cumulative results for all inhibitory test compounds are shown in 
Figure 3 as typical IC50 curves. 
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Figure 3: (A): IC50 curves (SD; n=3) for 5 different CYP2B ligands 
with the CYP2B EAD system in FIA mode. (B): IC50 curves (SD; n=3) 
for 3 different CYP3A ligands with the CYP3A EAD system in FIA 
mode. 
 
 
The IC50 curves for the CYP2B EAD system are shown in 
Figure 3a, while the IC50 curves obtained with the CYP3A system are 
shown in Figure 3b. The test compounds used for both CYP EAD 
systems are shown in the legends corresponding to Figure 3a and 
3b. The IC50 values obtained from these IC50 curves are shown in 
Table I, for both the CYP2B as the 3A EAD system. For evaluation 
and validation purposes of the EAD systems in HPLC mode, the IC50 
values obtained with the EAD systems in HPLC mode (described in 
the following section) are also shown in the Table. Moreover, Table I 
provides the lowest detectable inhibitor concentration for all tested 
compounds (i.e. detection limit at S/N = 3). Inhibitor concentrations 
that led to significant quenching of the fluorescent signal in the CYP 
EAD systems were not used for calculating the IC50 values [23]. 
Aminopyrine and chloramphenicol showed quenching at 
concentrations higher than 15 and 10 mM, respectively. The IC50 
values obtained with both microplate reader setups are also shown in 
Table I and were used to evaluate and validate the results from the 
CYP EAD assays. 
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On-line coupling of the CYP Enzyme Affinity Detection systems 
to HPLC 
 
Figure 1 shows the final configuration of the triple CYP EAD 
system coupled on-line to gradient HPLC. The optimized conditions 
of the CYP1A EAD system, which were recently described [23], were 
taken as CYP1A EAD system conditions in the present study. The 
CYP2B and 3A EAD systems were first optimized in the “Optimization 
of the CYP EAD systems in FIA mode” section, followed by coupling 
each individual CYP EAD system to gradient HPLC. These individual 
CYP EAD systems in HPLC mode were then validated by testing both 
systems with individual inhibitors injected in different concentrations 
and by injecting mixtures of inhibitors. Finally, all three CYP EAD 
systems were coupled in parallel to gradient HPLC. 
Figure 4: CYP2B EAD trace of a mixture of 4 compounds  injected in 
the CYP2B EAD system in HPLC mode (eluting compounds are: 
metyrapon (70 μM; 8.5 min), aminopyrine, (6000 μM; 9.5 min), 
chloramphenicol (7000 μM; 27.0 min) and proadifen (50 μM; 29.0 
min)). 
 
 
Typical bio-affinity (EAD) chromatograms resulting from 
injections of mixtures of inhibitory ligands of CYP2B and of 3A, in the 
respective individual EAD systems in HPLC mode, are shown in 
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Figure 4 and 5b, respectively. For CYP2B EAD in HPLC mode, only 
the chromatogram of the EAD trace was shown. For the CYP3A EAD 
system in HPLC mode, a mixture of three CYP3A ligands was 
injected. In this case, both the chromatogram of the EAD trace 
(Figure 5b) and the UV trace (Figure 5a) were shown, because the 
injected mixture of seemingly three inhibitors showed actually four UV 
and EAD peaks. LC-MS/MS confirmed that nifedipine ( [M + H+] = 
347) was the third peak in the chromatogram, while the second peak 
was an unknown product with [M + H+] = 329. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: (A) UV trace of a mixture of 3 compounds (and a 
breakdown product) injected in  the CYP3A EAD system in HPLC 
mode (eluting compounds are: ketaconazol (28 μM; 14.5 min), 
breakdown product (19.0 min), nifidipine (430 μM; 21.5 min) and 
miconazole (52 μM; 25.0 min)). (B) Corresponding CYP3A EAD trace 
of the mixture depicted in B.  
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All reference compounds used in the CYP2B and 3A EAD 
systems in FIA mode were also used to validate the CYP EAD 
systems in HPLC mode. The corresponding IC50 values (constructed 
from 5 different injected concentrations), calculated in the same way 
as described in the “Validation of the CYP EAD systems in FIA mode” 
section, are presented in Table I. 
Finally, the CYP1A, 2B and 3A EAD systems were 
simultaneously coupled to a single gradient HPLC (Figure 1) in order 
to examine a triple CYP EAD system for on-line screening of potential 
drug-drug interactions of individual compounds in mixtures in a panel 
of three CYPs. For this purpose, a mixture of 12 different CYP ligands 
was prepared. The ligands used are all known ligands for at least one 
of the CYP’s. A concentration range of the mixture was prepared and 
the serial dilutions were subsequently injected in the triple parallelized 
CYP1A, 2B and 3A EAD system in gradient HPLC mode. Figure 6 
shows an overlay of the bio-affinity signals for the CYP1A (Figure 6a), 
CYP2B (Figure 6b) and CYP3A EAD systems (Figure 6c) and the 
corresponding UV trace (Figure 6d). The lowest EAD trace in every 
EAD chromatogram shows the highest inected mixture concentration. 
The subsequent other two EAD traces in every EAD chromatogram 
resulted from 16 times diluted mixture and 256 times diluted mixture, 
respectively. 
 
 
Discussion 
 
The development of a HRS-platform with three CYP-containing 
Enzyme Affinity Detection (EAD) systems configured in parallel and 
on-line with gradient HPLC was the primary goal of this study. For 
this purpose, β-naphthoflavone (β-NF), phenobarbital (PB) and 
dexamethasone (DEX) induced rat liver microsomes were used for 
induction of CYP1A, 2B and 3A, respectively. Additives, substrate 
and enzyme concentration and reaction time are important 
parameters influencing the robustness and sensitivity of on-line 
biochemical assays in general [19] and of CYP EAD’s specifically 
[23]. Hence similar strategies were used to optimize the present 
CYP2B and 3A EAD systems. 
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The CYP EAD systems were first evaluated and optimized in 
FIA mode as the FIA mode allowed a much more rapid evaluation 
and optimization process than when HPLC mode was used. The FIA 
mode might also be used to screen pure compounds for CYP 
inhibition. It has to be stated, however, that this on-line methodology 
is merely developed and ultimately suitable to screen inhibition of 
individual compounds in mixtures towards a panel of CYP’s. Current 
HTS based 384-well and higher plate assay based methodologies 
namely have uncontested throughput rates compared to the CYP 
EAD systems in FIA mode, in which throughput rates of 20 to 60 
samples can be obtained at the maximum. After the evaluation and 
validation process, microplate reader based assay formats were used 
to compare and validate the results obtained for the on-line CYP EAD 
systems. This was done, since induced rat liver microsomal systems 
were used for this proof of principle study and most inhibition 
parameters described for CYP inhibition in literature are based on 
human (single) CYP systems. Well known and accepted microplate 
reader formats are therefore able to obtain reliable IC50 values of the 
test compounds for the microsomal CYP’s used. Only these 
microplate reader data could confidently be used to correctly validate 
IC50 values obtained in the on-line CYP EAD systems. Moreover, 
because induced rat liver microsomal preparations are not a validated 
matrix and are subject to variations in CYP contents and activity, CYP 
reductase activity and many other factors, these microplate reader 
assays had to be conducted for comparison reasons. 
In the optimization process, the additives PEG6000 and Tween 
20 were found to prevent peak broadening in both the CYP2B and 3A 
EAD system and were thus used in the CYP 2B and 3A EAD 
systems. Compared to CYP1A [23], however, CYP2B and 3A were 
much less tolerant towards Tween 20 as CYP1A still functioned 
properly with Tween 20 concentrations up to 670 mg/L in the carrier 
solution [23]. The lower concentrations of Tween 20 did result in 
higher resolutions for CYP 2B and 3A EAD when compared to 
omitting this detergent, but the highest resolution and consequently 
the least amount of tailing was obtained in the CYP1A EAD system, 
which used the highest concentration of Tween 20 (Figure 6). 
Previously reported on-line biochemical assays usually did not use 
detergents to prevent band broadening [17, 21, 25], mainly because 
these assays are based on soluble protein targets (i.e. antibodies and 
the angiotensin-converting enzyme). Membrane-bound CYP’s 
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apparently cause severe band broadening by sticking to walls of the 
reaction coils due to the lipophilic membranes [23]. Eluting lipophilic 
compounds may in turn show additional retention by adhering to the 
microsomes and the walls of the reaction coils. Similar non-specific 
drug binding to microsomes was described recently [26]. Although the 
EAD systems use fairly low concentrations of microsomes, adhesion 
to reaction coils is still a major problem. This apparently results from 
the on-line character in which microsomes, although at low 
concentrations, are continuously pumped through. When no 
measures are taken to prevent adhesion of microsomes, the amount 
of adhered microsomes builds up in time. This in contrary to batch 
based off-line systems, in which microsomal adhesion only becomes 
a problem at much higher concentrations. PB- and DEX-induced rat 
liver microsomes were used in the present study for CYP2B and 3A 
affinity screening, although it has to be noted that these enzyme 
sources are not fully selective for these two isoforms. Moreover, the 
selectivity of pentoxyresorufin (for CYP2B) and BTFC (for CYP3A) is 
not 100 % [10, 27, 28]. Nevertheless, these microsomes were chosen 
for a proof of principle demonstration of parallel CYP affinity 
screening, because we reasoned that absolute selectivities were not 
essential for this purpose. The up-regulated CYP2B [29] and 3A [30] 
levels resulting from induction of rats with PB and DEX give 
significantly higher turnover rates of the respective substrates 
pentoxyresorufin and BTFC and therefore ensure higher selectivities 
and sensitivities. When varying the microsomal protein 
concentrations in the CYP 2B and 3A EAD systems, much higher 
protein concentrations (70 μg/ml) were found to be necessarily in 
order to obtain sufficient S/N ratios for on-line CYP EAD. Additionally, 
longer reaction coils were needed in order to produce enough 
fluorescent product in these on-line assays. For the CYP1A EAD 
system described previously [23], the microsomal protein 
concentration was found to be optimal at a much lower concentration 
(20 μg/ml). For this CYP EAD system, also smaller reaction coil 
volumes were sufficient for obtaining good S/N ratios. This difference 
in optimal protein concentration and the use of small reaction coil 
volumes can be explained by the relatively high turnover rate of 
ethoxyresorufin by CYP1A and high concentrations of CYP1A 
isoenzymes in α-NF-induced rat liver microsomes compared to the 
CYP2B and 3A concentrations in the PB and DEX induced rat liver 
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microsomes [31]. Large reaction coil volumes, i.e. up to 500 μl 
(resulting in longer reaction times), decreased the S/N-ratios slightly, 
but the resolution significantly. This phenomenon is most likely 
caused by increased dispersion of the injected sample when 
employing larger reaction coils. With CYP1A, a smaller reaction coil 
volume of 25 μl was used because ethoxyresorufin O-dealkylation, 
the biochemical basis of the CYP1A EAD system, involves a high 
affinity and high turnover substrate [32]. With the CYP2B and 3A EAD 
system, increasing IPA, MeCN or MeOH concentrations led to 
decreasing S/N ratios with a concomitant increase in the resolution. 
Higher concentrations of organic modifier in principle allow more 
effluent to be introduced into the CYP EAD system when coupled on-
line to HPLC. Therefore, compromises have to be made between 
resolution, S/N ratios and amount of HPLC effluent, and thus sample, 
introduced into the CYP EAD systems. As observed previously [23], 
CYP1A was more stable towards the organic modifiers tested then 
CYP2B and 3A. When MeOH is used as organic modifier, problems 
with affinity determinations of amine containing ligands may arise due 
to possible condensation reactions with formaldehyde formed by CYP 
[33]. This effect can be prevented by the use of reduced glutathione. 
  
Table I: CYP2B: IC50-values of 5 CYP2B inhibitors measured with 
the P450 2B EAD system in FIA mode, HPLC mode and in two 
different microplate reader formats. CYP3A: IC50-values of 3 CYP3A 
inhibitors measured with the P450 3A EAD system in FIA mode, 
HPLC mode and in two different microplate reader formats (Setup 1: 
ACN; Setup 2: ACN, PEG and T20). Det. lim. = Detection limit (S/N 
ratio = 3). 
 
CYP2B 
 FIA EAD HPLC EAD Microplate Reader Assays 
Inhibitor IC50’s (μM ± 
SEM; n=3) 
Det. Lim. 
in pmol 
IC50’s: 
(μM; n=1) 
Det. Lim. 
in pmol 
Setup 1: IC50’s 
(μM  ± SEM; n=4) 
Setup 2: IC50’s 
(μM  ± SEM; n=4) 
Metyrapon     0.30±0.02 4 0.60 60    0.28±0.09   0.22±0.07 
Proadifen     0.24±0.10 17 0.40 240   0.41±0.21   0.21±0.05 
Chloramphenicol     75±13 877 93 7760 80±9 61±4 
Phenobarbital 1062±66 9933 N.D N.D 608±43 402±53 
Aminopyrine     617±390 4750 826 76000 455±38 321±71 
CYP3A 
Ketaconazole   0.33±0.04 15   0.28±0.17 120   0.28±0.01 0.24±0.01 
Miconazole   0.11±0.01 4   0.13±0.19 32     0.10±0,005 0.094±0,004 
Nifedipine   6.3±4.5 200 3.89±4.2 1600   9.0±1.3 9.7±2.2 
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For validation purposes, first the CYP2B and 3A EAD systems 
in FIA mode were evaluated as to sensitivity and robustness of the 
respective bio-affinity assays. The cumulative results for all inhibitory 
test compounds are shown in Figure 3 and the resulting IC50 values in 
Table I. The differences between IC50 values obtained with the 
microplate reader assays in setup 1 and setup 2 were only significant 
in a few cases. However, such differences are not un-common for 
microsomal CYP inhibition assays when measured with different 
methodologies [12].  Taking this into consideration, the IC50 values 
obtained with the CYP EAD systems in FIA mode were rather well 
comparable with those of the microplate reader assays (Table I) and 
can thus even be used as initial IC50 value estimates. 
When placing the optimized and validated CYP2B and 3A EAD 
systems on-line after HPLC, typical EAD bio-affinity chromatograms 
resulting from injections of mixtures of inhibitory ligands of CYP2B 
and of 3A (Figure 4 and 5b, respectively) show the applicability of the 
CYP EAD systems in HPLC mode to separate and subsequently 
identify the individual inhibitors. For CYP 2B, all injected compounds 
were separated and could individually be judged for their inhibitory 
potential. For the CYP3A EAD system in HPLC mode, a mixture of 
three CYP3A ligands was injected. As the UV chromatogram 
obtained for the analysis of this injected mixture (Figure 5a), actually 
showed four peaks, LC-MS/MS was used to identify the unknown 
compound. It was found that the unknown product was actually a 
breakdown product of nifedipine, which is probably a nitroso-
dehydronifedipine and known to result from photo degradation of 
nifedipine due to sunlight [34]. The corresponding CYP3A EAD trace 
(Figure 5b) accurately identified all three reference ligands as well as 
the nifedipine breakdown product as inhibitors of CYP3A. These 
results clearly show the potential of the CYP EAD systems in HPLC 
mode to measure individual inhibitors in mixtures, which is not 
possible using other rapid CYP based bio-affinity screening 
methodologies [35, 36]. When reference compounds were injected in 
a concentration response sequence, IC50 values could be constructed 
for individual inhibitors for both the 2B as the 3A EAD system (see 
Figure 3 and Table I). The IC50 values obtained with the CYP2B and 
3A EAD systems in HPLC mode were well comparable to those 
obtained with the microplate reader assays and with the CYP2B and 
3A EAD systems in FIA mode. The CYP EAD systems could thus be 
used to screen individual compounds in mixtures for their inhibitory 
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potencies and moreover, reliable IC50 values could be determined if 
the concentrations of the screened compounds are known. When 
using unknown compound mixtures, an evaporative light scattering 
detector might be used for estimating compound concentrations in 
order to determine IC50 values of CYP inhibitors in these unknown 
compound mixtures. 
Then, the triple parallelized CYP1A, 2B and 3A EAD system in 
gradient HPLC mode was constructed. It proved to be very robust as 
it could run continuously without failure. The long operating time with 
one batch of enzymes and substrates in the superloops (eight hours) 
afforded a system that could efficiently be used for continuous 
measurements. It was demonstrated that even in a mixture of 12 CYP 
inhibitors, the triple parallelized CYP1A, 2B and 3A EAD system in 
gradient HPLC mode was able to individually identify the ligands and 
their relative inhibitory potency towards each of the three CYP 
systems (Figure 6). In contrast to HTS strategies [8] or MS-based 
screening methodologies [37, 38], our methodology does not only 
allow the simultaneous screening of the inhibition potential of 
compound mixtures towards three CYP’s, but also the identification of 
the individual compounds in these mixtures by splitting the HPLC 
effluent to a mass spectrometer (MS). The HRS-technology 
developed combines the resolving power of HPLC with the sensitivity 
and selectivity of a bio-affinity assay. The ability to detect and identify 
CYP ligands on-line after HPLC separation eliminates much of the 
time and labour required for a fraction collection strategy. Instead of 
the rat liver microsomes combined with selective substrates as used 
in this study, human CYP based EAD systems could be used as well. 
The present triple configured HRS-platform may rapidly provide 
relevant data during the drug discovery and development process, 
mainly in the late discovery to early development stage, by profiling 
lead and drug candidate molecules as well as CYP based drug-drug 
interactions of metabolic mixtures. 
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Figure 6: A mixture of 12 compounds at 3 different concentrations 
injected in the triple parallalyzed CYP1A, 2B and 3A EAD system in 
HPLC mode. The lowest EAD trace in every EAD chromatogram 
shows the highest inected mixture concentration. The subsequent 
other two EAD traces in every EAD chromatogram resulted from 16 
times diluted mixture and 256 times diluted mixture, respectively. 
Injected compounds are: 1) methyrapon (300 μM; 7.5 min), 2) caffein 
(25 mM; 10.0 min), 3) 9-hydroxyellipticine (200 μM; 15.5 min), 4) 
ellipticine (200 μM; 19.5 min), 5) ketaconacole (250 μM; 20.0 min), 6) 
phenacetin (15 mM; 20.5 min), 7) chloramphenicol (8 mM; 23.0 min), 
8) nifidipine (400 μM; 26.0 min), 9) proadifen (500 μM; 27.0 min), 10) 
miconazole (8 μM; 30.0 min), 11) α-napthoflavone(50 μM; 40.0 min) 
and 12) β-napthoflavone (600 μM; 41.0 min) . (A) P450 1A EAD trace 
(B) P450 2B EAD trace (C) P450 3A EAD trace (D) UV trace.
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Abstract 
 
Here we describe two on-line human Cytochrome P450 (CYP) 
Enzyme Affinity Detection (EAD) systems coupled on-line to gradient 
HPLC. The EAD systems contain either human CYP1A2 or 2D6, both 
obtained from an E-coli expression system. Conditions for both EAD 
systems were first optimized in a microplate reader format and 
subsequently in a Flow Injection Analysis (FIA) mode. Under 
optimized conditions, both CYP EAD systems were validated with 
known ligands. IC50 values obtained with the CYP EAD systems in 
FIA mode were well comparable with those measured in the 
microplate reader format. Detection limits of 0.4 and 1.0 pmol (n = 3; 
S/N = 3) were obtained for the CYP1A2 inhibitors ellipticine and α-
naphthoflavone, respectively. In the case of CYP2D6, detection limits 
of 0.8 and 6.0 pmol (n = 3; S/N = 3) were obtained for the inhibitors 
quinidine and quinine, respectively. Both EAD systems were finally 
connected to gradient HPLC and used to screen known compound 
mixtures for the presence of CYP1A2 and 2D6 inhibitors. IC50 values 
obtained for ligands in HPLC mode were in accordance with those 
obtained with the CYP EAD systems in FIA mode and with the 
microplate reader format. Finally, the on-line CYP2D6 EAD system 
was used to screen the stereoisomers of a mixture of 
methylenedioxy-alkylamphetamines (XTC analogs) on a chiral 
analytical column for the presence of inhibitory activity. In total 10 
stereoisomers, corresponding to 5 XTC analogs were 
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chromatographically separated and screened for their CYP2D6 
affinity. It is concluded that this so-called High Resolution Screening 
(HRS) technology offers great perspectives for rapid and sensitive 
screening of individual compounds in mixtures exhibiting affinity for 
single human CYP isoforms.  
 
 
Introduction 
 
Cytochromes P450 (CYP’s) constitute the most important 
enzymes involved in the biotransformation of drugs and other 
xenobiotics. Amongst these, is a vast array of clinically, toxicologically 
and physiologically important compounds [1-3]. In humans, hepatic 
CYP1A2, 2C9, 2C19, 2D6 and 3A4 are the most important isoforms 
in xenobiotic metabolism [4-6]. Of those isoforms, CYP2D6 is 
considered one of the most important enzymes, because of its 
polymorphic nature [7-9]. Genetic polymorphisms may result in 
differences in substrate specificity, loss of protein function, increased 
enzymatic activity or even different (adverse) effects of drugs [7, 10]. 
Despite the fact that CYP2D6 represents only approximately 2-4% of 
total human hepatic CYP’s, it plays an important role in the oxidation 
of drugs and xenobiotics, metabolizing about 30% of the drugs that 
are currently on the market [11, 12]. Although not as pronounced as 
in the case of CYP2D6, interindividual differences in CYP1A2 may 
also result in different enzymatic activities towards drugs and 
xenobiotics [13]. These interindividual differences are extensively 
studied and associated with differences in cancer susceptibility 
towards environmental and food-derived carcinogenic compounds 
[14]. The enzyme is for example induced by cigarette smoking or by 
charcoal-broiled meat ingestion [15, 16].  
CYP inhibition studies are often performed on new chemical 
entities (NCEs) during the drug discovery and development process. 
Rapid high-throughput screening approaches are frequently utilized in 
order to keep pace with the increasing numbers of NCEs, generated 
by combinatorial chemistry and natural compound libraries [17, 18]. 
The current CYP inhibition screens are usually based on a single 
enzyme paradigm for compound-compound interactions [19]. This 
actually means that NCEs inhibiting the metabolism of a probe 
substrate for a specific CYP also will inhibit other substrates for that 
enzyme. Thus, also potential drug-drug interactions can be evaluated 
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for each enzyme of interest. One of the drawbacks in this strategy is 
that in case of mixtures of compounds (e.g. combinatorial libraries, 
natural compounds or metabolic mixtures), no conclusion can be 
drawn about the individual compound(s) in the mixtures that are 
responsible for the inhibitory potential towards the CYP screened for. 
To evaluate the active compounds in mixtures, usually HPLC 
separation followed by affinity screening of all separate fractions is 
performed [20]. One strategy to overcome this cumbersome process 
is the use of High-Resolution Screening (HRS), which stands for the 
on-line affinity detection after HPLC separation [21, 22]. HRS 
systems in which compounds can be screened for affinity towards 
soluble receptors (e.g. the estrogen receptor) and enzymes (e.g. 
phosphodiesterases) in one bio-assay already exist [22, 23]. 
Recently, a new HRS methodology for the screening of compounds 
with affinity for CYP1A enzymes in rat liver microsomes was 
developed [24]. Although being very sensitive and capable of rapidly 
identifying the CYP inhibitors in mixtures, this methodology still lack 
the added specificity that could be obtained when using 
heterologously expressed human CYP’s. 
This article describes the development of two CYP EAD 
systems coupled on-line to HPLC. One EAD system utilizes 
heterologously expressed human CYP2D6 as enzyme source and 
the second heterologously expressed human CYP1A2, thus giving 
rise to two truly specific human CYP EAD systems. Continuous 
mixing of enzyme, a non-fluorescent substrate and the eluent from a 
HPLC system in a reaction coil is the basis of this HRS methodology. 
In the reaction coil a continuous formation of a fluorescent product 
takes place, which is measured at the end of the reaction coil. Eluting 
CYP ligands temporarily inhibit the enzymatic formation of the 
fluorescent product, thereby allowing for detection of the inhibition 
potential of the ligands. Both the CYP1A2 and 2D6 EAD systems 
were firstly optimized and validated in flow injection analysis (FIA) 
mode and subsequently coupled to gradient HPLC for on-line 
screening of individual CYP inhibitors in mixtures. Finally, the 
CYP2D6 EAD system was coupled on-line to isocratic chiral HPLC 
for stereoselective screening of CYP2D6 inhibitors in mixtures. 
 
 113
On-line CYP1A2 and 2D6 Enzyme Affinity Detection                              Chapter 4 
  
 
Experimental Section 
 
Materials 
 
7-Methoxy-4-(aminomethyl)-coumarin (MAMC) was synthesized 
by Onderwater et al. [25]. Methoxyresorufin, Tween 20 and Tween 
80, saponin (from Quillaja Bark), glycerol, polyethyleneglycol 6000 
(PEG6000), polyethyleneglycol 3350 (PEG3350), quinidine, 
sparteine, tripolidine, dextromethorphan and α-naphthoflavone (αNF) 
were purchased from Sigma (Zwijndrecht, The Netherlands). 
Proadifen was purchased from SmithKline&French laboratories 
(Herts, United kingdom), quinine from Fluka (Zwijndrecht, The 
Netherlands) and caffeine and sodium cholate from Aldrich 
(Zwijndrecht, The Netherlands). Codeine and phenacetin were 
purchased from Brocades (Maarssen, The Netherlands). β-
Naphthoflavone (βNF) was supplied by Acros (Den Bosch, The 
Netherlands). β-Nicotinamide adenine dinucleotide phosphate tetra 
sodium salt (NADPH) and TRIS (hydroxymethyl) aminomethane were 
obtained from Applichem (Lokeren, Belgium). Methanol (MeOH) and 
acetonitrile (ACN) were purchased from Baker (Deventer, The 
Netherlands) and were of HPLC reagent grade. All other chemicals 
were of the highest purity grade commercially available. 
 
Microsomal protein 
 
CYP1A2: The plasmid pCWori+ containing the modified 
CYP1A2 sequence fused to the rat cytochrome P450 NADPH-
reductase [26], was transformed in E. coli strain DH5α by heat shock. 
Expression and membrane isolation was performed as follows: A 
single ampicillin-resistant colony of E-coli (DH5α) transformed with 
the fusion plasmid expression construct [26, 27] was grown o/n at 37 
ºC in 20 ml Luria-Bertani (LB) medium containing 100 µg/ml 
ampicillin. This pre-culture was used to inoculate 1 liter of Terrific 
Broth (TB) medium, supplemented with 100 µg/ml ampicillin, 1.0 mM 
thiamine, 0.5 mM δ-ALA, 0.10 µg/ml riboflavin and 3 ml of a trace 
elements solution [10 mM FeCl3, 1 mM ZnCl2 , 1.2 mM CoCl2, 0.9 
mM NaMoO4, 0.7 mM CaCl2, 0.6 mM CuCl2, 0.8 mM H3BO3 in 10 M 
HCl]. Protein expression was induced directly and after 24h with 1.0 
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mM IPTG. Cultures were grown at 28 ºC with shaking at 125 rpm for 
48 h. Cells were harvested by centrifugation at 4000 rpm for 30 min 
at 4 ºC. All subsequent steps were carried out at 4 ºC. The pelleted 
cells were resuspended in 50 ml PBS buffer (10 mM potassium 
phosphate buffer, pH 7.4, containing 0.15 M NaCl) followed by 
centrifugation at 4000 rpm for 20 min. The supernatant was removed 
and the pelleted cells were resuspended in approximately 40 ml TSE 
buffer (75 mM Tris-HCl buffer, pH 7.5, containing 250 mM sucrose 
and 0.25 mM EDTA). Cells were subjected to three cycles of 
disruption with a cooled French pressure cell (1000 psi). The 
disrupted cells were centrifugated at 4000 rpm for 10 min to remove 
intact cells. The supernatant was further centrifugated at 100000 g for 
one hour. The resulting pellet was resuspended in 2 ml PBS buffer 
and frozen at –80 ºC. 
 
 
 
 
Figure 1: Schematic view of a CYP EAD system in HPLC mode. 
Superloop-A (SL-A) and superloop-B (SL-B) are used to deliver 
enzyme and substrate to the reaction coil, respectively. Ligands are 
introduced into the system by a gradient reversed phase HPLC 
system. Ligands temporarily inhibit fluorescent product formation, 
which is monitored with a fluorescence (FLD) detector. After HPLC, 
the make-up pumps produce a counteracting gradient, resulting in a 
CYP EAD compatible constant organic modifier concentration. The 
eluent is then split 1:9 (90% to UV detection and 10% to CYP EAD). 
AS = autosampler. 
 
 115
On-line CYP1A2 and 2D6 Enzyme Affinity Detection                              Chapter 4 
  
CYP2D6: E. coli membranes containing CYP2D6 and the human 
CYP NADPH-reductase were produced according to Keizers et al 
[28]. 
 
Instrumentation 
 
The configuration of the individual CYP EAD systems in flow 
injection analysis (FIA) and HPLC mode was similar to that described 
recently for the on-line CYP1A EAD system by J Kool et al [24]. A 
general scheme of a CYP EAD system coupled on-line to gradient 
reversed-phase HPLC is shown in Figure 1. All experiments were 
performed with a Gilson 234 autosampler (Villiers-le-Bel, France) 
equipped with a Rheodyne (Bensheim, Germany) six-port injection 
valve (injection loop, 40 μl). An Agilent 1100 (Waldbronn, Germany) 
series fluorescence detector (λex 530 nm; λem 586 nm for P450 1A2 
EAD and λex 370 nm; λem 470 nm for P450 2D6 EAD) was used for 
detection, while Knauer K-500 HPLC pumps (Berlin, Germany) were 
used to deliver the carrier solution in flow injection analysis mode and 
to control the reagent (enzyme and substrate) containing Pharmacia 
50 ml superloops (Uppsala, Sweden). A Shimadzu CTO-10AC 
column oven (Duisburg, Germany) controlled the temperature of the 
enzymatic reaction. Knitted PEEK reaction coils (0.5 mm i.d.; 1.59 
mm o.d.; internal volumes of 25, 75, 150, 300, 500 and 800 μl) were 
tested for the on-line enzymatic reactions prior to detection. When the 
enzyme affinity detection assays were coupled to chromatographic 
systems, Knauer K-500 HPLC pumps, a 1/9 flowsplitter (5 cm length, 
50 μm i.d., 375 μm o.d. and 5 cm length, 25 μm i.d., 375 μm o.d. 
fused silica connected to a T-piece) and an Agilent 1100 series UV 
detector (220 nm) were additionally used in the system. All hardware 
was integrated in one HRS-system by Kiadis B.V. (Groningen, NL) 
and was controlled by software developed by Kiadis B.V. 
 
On-line CYP1A2 and 2D6 EAD systems in FIA mode 
 
A schematic representation of an on-line CYP enzyme affinity 
detection (EAD) system in FIA mode is shown and described by Kool 
et al [24]. During the optimization process in FIA mode, the carrier 
solution consisted of water and was pumped at a flow rate of 100 
μl/min. Flow injections were made on the carrier solution prior to 
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mixing with enzyme (100 μl/min) and substrate (100 μl/min). Enzyme 
(CYP1A2 or CYP2D6) and substrate (methoxyresorufin) for CYP1A2 
EAD or MAMC for CYP2D6 EAD) were housed at 0°C in superloops. 
The CYP1A2 concentration was 0.35 nM, whereas the CYP2D6 
concentration was 60 nM. The buffer that was used for the enzyme 
and substrate solutions consisted of potassium phosphate (50 mM, 
pH 7.4 for CYP1A2 and pH 7.8 for CYP2D6), containing 2.5 mM 
MgCl2.  
 
On-line CYP1A2 and 2D6 EAD systems in HPLC mode 
 
Gradient HPLC separations were performed using a 30 mm 
length × 2 mm i.d. stainless-steel column (Phenomenex Luna 3μ 
C18(2)). The chromatographic separations were performed using a 
decreasing flow rate gradient. The initial flow rate was set at 700  
μl/min. A pregradient of 2 min was applied using water and acetonitril  
in a95:5 ratio. Subsequently the percentage ACN was increased to 
95% within 12 min. During this time period the flow rate dropped 
gradually to 100 μl/min. A postcolumn gradient of 10 min,  H2O:ACN 
(5:95), with a flow rate of 100 μl/min was applied. After 
chromatographic separation the column was equilibrated to the 
starting conditions in 0.5 min. In order to obtain a constant and 
bioassay compatible concentration of organic modifier in the P450 
EAD system, an additional makeup gradient with an initial flow rate of 
300 μl/min was added to the HPLC effluent. Throughout the 
chromatographic separation the total flow rate after dilution of the 
HPLC effluent was 1 ml/min. By using this approach the 
concentration acetonitrile introduced in the biochemical assay was 
10%. During the chromatographic separation the flow rate of the 
makeup gradient was increased to 900 ul/min in 12 min and was 
maintained atthis level during the postgradient. During a 0.5 min 
equilibration period the flow rate was decreased to starting 
conditions. The aqueous and organic modifier solvents of the makeup 
gradient both contained 4 g/L Tween 20 in the case of CYP1A2 and 
100 mg/L Tween 20 in the case of CYP2D6. The advantage of a 
decreasing flow rate gradient compared to a normal gradient when 
coupled on-line to a biochemical assay is that the dilution factor of the 
HPLC effluent increases with increasing organic modifier percentage. 
When applying a standard gradient however the dilution factor is 
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constant. During a decreasing flow rate gradient polar compounds 
are diluted less then more apolar compounds. Consequently the 
sensivity of the method is enhanced for these types of compounds.   
 
Chiral chromatography coupled to CYP2D6 EAD 
 
For the stereoisomer separation of a series of XTC-analogs, 
isocratic separations were performed on a 250 mm length × 4.6 mm 
chiral Cyclobond I 2000 RSP column (Astec). The separated 
compounds were simultaneously detected with UV detection and the 
CYP2D6 EAD. The chiral column was eluted with a 100 mM 
potassium phosphate buffer containing 0.1 % triethylamine and 5% 
MeCN (pH adjusted to 4.0 with acetic acid) at a flow rate of 500 
μl/min. To obtain a CYP2D6 EAD compatible pH, a make-up flow 
consisting of 300 mM TRIS (pH 10.5; 500 μl/min.), which was mixed 
with the HPLC effluent, ensured a final pH of 7.4 after equilibration in 
a 50 μl reaction coil. The diluted effluent was directed through to a T-
piece and splitted in a 1:9 ratio using a flowsplitter. 10% of the flow 
was directed to the CYP2D6 EAD system and 90% was splitted to the 
UV detector.  
  
Microplate reader assays for CYP inhibition 
 
For CYP1A2, the fluorescence of the metabolic product 
resorufin was measured at excitation and emission wavelengths of 
530 nm (bandwidth 8 nm) and 580 nm (bandwidth 30 nm), 
respectively, on a Victor2 1420 multilabel counter (Wallac, Turku, 
Finland). Tests were performed under (1) normal conditions and (2) 
conditions used in the P450 1A2 EAD system. In this way possible 
differences between the obtained IC50’s were determined. 
Concentration ranges of test compounds were prepared by serial 
dilution of compounds dissolved in 50 μl DMSO with 150 μl DMSO. A 
mixture (150 μl) of CYP1A2 (0.2 nM) and methoxyresorufin (1.2 μM) 
in 50 mM potassium phosphate buffer (pH 7.4), containing 2.5 mM 
MgCl2, was incubated for 15 min at 37ºC. Then, 75 μl of one of the 
following solutions was added to start the reaction: 1) (normal 
conditions): a freshly prepared mixture of 20 μl test compound in 
DMSO and 80 μl of a solution containing 50 μM NADPH in 10 % ACN 
or 2) (CYP1A2 EAD conditions): a freshly prepared mixture of 20 μl 
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test compound in DMSO and 80 μl of a solution containing 50 μM 
NADPH, 1 g/L PEG6000 and 4 g/L tween 20 in 10 % ACN. The initial 
linear increase in resorufin fluorescence was a marker of the 
enzymatic activity. Inhibition curves based on 11 compound 
concentrations and a blank were measured in quadruplicate for each 
test compound. IC50 values for each compound were determined 
with Prism3 software for both assay formats. 
 
 
 
 
 
 
 
 
 
Figure 2: Microplate reader 
assay based optimization 
results of (A) detergents for 
CYP2D6 and (B) organic 
modifiers for CYP1A2. Initial 
increases in fluorescence in 
the presence of the tested 
additives were measured. 
 
 
 
Results and Discussion 
 
This study describes the development of two on-line Enzyme 
Affinity Detection (EAD) systems for the screening of affinities of 
individual compounds in mixtures for human CYP1A2 and 2D6 
isoenzymes. Subsequent on-line coupling of the EAD systems to 
gradient HPLC allowed isoenzyme selective screening of affinities of 
individual compounds in mixtures as they eluted from the HPLC 
column. Both EAD systems presented in this study relied on E-coli 
expression systems for the supply of the CYP isoenzymes. 
Combination with relatively selective probe substrates, ensured 
sensitivity and total selectivity for both CYP’s, this in contrast to the 
previously used CYP EAD systems containing microsomal CYP’s 
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[24]. The relatively specific substrates methoxyresorufin and MAMC 
were used as probe for monitoring the formation of fluorescent 
product (respectively resorufin by CYP1A2 and 7-hydroxy-4-
(aminomethyl)-coumarin (HAMC) by CYP2D6). The post-column EAD 
systems are operated by simultaneous mixing of CYP, cofactor and 
substrate with the mobile phase in a reaction coil. The substrate 
reacts with the enzyme to form a fluorescent product. Inhibitors of this 
enzymatic reaction will temporarily inhibit the formation of fluorescent 
product, which is detected as a negative peak in the fluorescence 
readout. A scheme of a CYP EAD system in HPLC mode is shown in 
Figure 1. For CYP2D6 EAD, quinidine was used as model inhibitor 
whereas α-naphthoflavone (αNF) served as model inhibitor for 
CYP1A2 EAD. The on-line EAD systems were first developed and 
optimized in Flow Injection Analysis (FIA) mode, before coupling to 
 
gradient HPLC. 
igure 3: Injections (triplicates) of fluvoxamine  in the CYP1A2 EAD 
YP EAD in FIA mode 
Optimization of the CYP EAD systems: The optimization of the 
CYP 
F
system in FIA mode. Total amounts of 18.4, 9.2, 4.6, 2.3, 1.2, 576, 
288, 144, 72, 36 and 18 pmol were injected. 
 
 
C
 
EAD systems was done in a similar way as recently described 
for the optimization of the on-line rat liver microsomal CYP1A system 
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[24]. As expected for the CYP1A2 and 2D6 EAD systems, the 
maximum formation of fluorescent product was observed at 37°C. 
Also, several additives were tested for their ability to increase 
resolution in both CYP EAD systems. The polymers PEG 3325 and 
6000 as well as the detergents Tween 20 and 80 and saponin were 
examined for their ability to reduce enzymatic activity using a 
microplate reader format. Up to 3 g/L PEG 3325 and 6000 did not 
alter enzymatic activity of both CYP’s. In the case of CYP1A2, Tween 
20 and 80, could be used for up to 6 g/L with retention of 50% of the 
original enzymatic activity. For CYP2D6 however, only amounts up to 
150 mg/L Tween 20 or 80 could be used (Figure 2A). A combination 
of Tween and PEG proved optimal for improving resolution in both 
CYP EAD systems, a result consistent with literature [24]. The 
optimal conditions were 4 g/L Tween 20 with 1 g/L PEG 6000 in the 
carrier solution for CYP1A2 EAD and 100 mg/L Tween 20 with 1 g/L 
PEG 6000 for CYP2D6. Km concentrations of the substrates 
methoxyresorufin and MAMC, determined in a microplate reader 
assay, were used as substrate concentrations in the respective 
reaction coils. The Km value of methoxyresorufin for CYP1A2 was 
0.40 μM ± 0.06 μM, and corresponded well with literature [29]. The 
presence of PEG 6000 (1 g/L) and Tween 20 (4 g/L) did not change 
the Km value significantly. For CYP2D6, the Km value was also 
determined with and without using PEG 6000 and Tween 20, and 
was found to be 50 μM ± 6 μM which corresponded well with 
literature [28]. The effect of reaction time on the on-line enzymatic 
reactions was investigated by using reaction coils of different volumes 
fluvoxamine as probe inhibitor for CYP1A2 and quinidine for 
CYP2D6. For CYP1A2, S/N ratios leveled off at reaction coil volumes 
higher than 150 μl, while the resolution decreased with increasing 
volumes of reaction coil. In the case of CYP2D6, similar effects were 
seen, but the S/N ratios leveled off at a reaction coil volume of 400 μl. 
This effect is probably a result of two factors: 1) increased formation 
of fluorescent product from the respective substrates due to longer 
reaction times and 2) a greater dispersion of injected ligands. These 
effects were also seen in similar HRS systems [24, 30]. 
When coupling the CYP EAD systems to gradient HPLC, 
organic modifiers necessary for the separation are also introduced 
into the system. The influence of organic modifiers was therefore first 
evaluated in a microplate reader format. MeOH was found to 
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decrease the enzymatic reaction of CYP1A2 by 50 % at a 
concentration of 7 % of MeOH, while in the case of IPA and MeCN 
these percentages were 3 and 6 %, respectively (Figure 2B). For 
CYP2D6, concentrations of 2, 3 and 3.5 % for MeOH, IPA and MeCN 
were found, respectively. The enzymatic activity of CYP1A2 was 
markedly more stable compared to CYP2D6. The fact that the 
CYP1A2 used is a fusion protein with NADPH CYP reductase means 
that no separation from the CYP and the reductase after solubilisation 
can occur [31]. This could attribute to the inherent stability of the 
present CYP1A2 fusion protein to detergents and organic modifiers. 
The present microplate reader assays were performed over a 6 min 
time period, while the biochemical reactions in the optimized on-line 
CYP EAD systems last for time periods of only 20 sec. for CYP1A2 
and 80 sec. for CYP2D6. It was therefore expected that higher 
organic modifier concentrations could be used in the on-line 
biochemical assay formats. This was indeed observed in both the 
CYP EAD systems, where organic modifier concentrations twice as 
high as those in the microplate reader assay were found before a 
50% decrease in enzymatic activity was found. 
 
 
Table I: IC50 values of 6 CYP1A2 inhibitors measured with the 
A2 in HPLC mode Microplate reader 
CYP1A2 EAD system in FIA mode, 4 CYP1A2 inhibitors measured 
with the CYP1A2 EAD system in HPLC mode and 6 CYP1A2 
inhibitors measured in two different batch assay formats. Detection 
limits for both on-line modes are also given. N.D. = Not Determined. 
Setup 1: IPA, PEG and Tween 20. Setup 2: IPA. Det. Lim. = 
Detection Limit (S/N ratio = 3). 
 
CYP1A2 in FIA mode CYP1Inhibitor 
IC50’s 
(µM ± SEM; 
Det. Lim. 
in pmo
n=3) 
l 
IC50’s (µM; 
n=4) 
Det. Lim. 
in pmol 
Setup 1 (μM ± 
SEM; n=4) 
Setup 2 (μM ± 
SEM; n=4) 
Ellipticine ±0.005 .004 001    0.007±0.005 0.4 0.011 32   0.026±0     0.008±0.
9OH-Ellipticine    0.011±0.006 0.4 0.004±0.002 30   0.033±0.004     0.010±0.006 
α-Naphtoflavone    0.06±0.02 1.0 0.031±0.020 50   0.06±0.01     0.08±0.02 
Fluvoxamine    0.63±0.10 18 0.15±0.01 350   0.28±0.03     0.46±0.03 
Phenacetin  87±6 82 N.D. N.D. 123±15 154±4 
Caffein  8025    5338±78 N.D. N.D. 5262±595   2619±554 
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The final optimized conditions of the CYP1A2 EAD were as 
follow
Figure 4: (A) IC50 curves (n=3) obtained for 6 different CYP1A2 
or CYP2D6 EAD, the optimized conditions were as follows: 
The f
s: The first superloop (SL-1) contained CYP1A2 (0.35 nM) in 
potassium phosphate buffer (50 mM, pH 7.4, 2.5 mM MgCl2). The 
second superloop (SL-2) contained a solution of 40 μM NADPH, 1.2 
μM methoxyresorufin and 1 g/L PEG 6000 in potassium phosphate 
buffer (50 mM, pH 7.4, 2.5 mM MgCl2). The carrier solution or the 
decreasing flow rate gradient contained 4 g/L Tween 20, while a 100 
μl reaction coil was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ligands in the CYP1A2 EAD system in FIA mode. (B) IC50 curves 
(n=4) obtained for 4 different CYP1A2 ligands in the CYP1A2 EAD 
system in HPLC mode. (C) IC50 curves (n=3) obtained for 6 different 
CYP2D6 ligands in the CYP2D6 EAD system in FIA mode. (D) IC50 
curves (n=1) obtained for 4 different CYP2D6 ligands in the CYP2D6 
EAD system in HPLC mode. 
 
 
F
irst superloop (SL-1) contained CYP2D6 (60 nM) in potassium 
phosphate buffer (50 mM, pH 7.8, 2.5 mM MgCl2). The second 
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superloop (SL-2) contained a solution of 40 μM NADPH, 150 μM 
MAMC and 1 g/L PEG 6000 in potassium phosphate buffer (50 mM, 
pH 7.8, 2.5 mM MgCl2). The carrier solution or the decreasing flow 
rate gradient contained 100 mg/L tween 20, while a 400 μl reaction 
coil was used. 
Validation of the CYP EAD systems: Several inhibitory ligands 
of both CYP EAD systems were injected (in triplicate) in 
concentrations yielding 0 to 100 % enzyme inhibition. A typical result 
obtained with fluvoxamine in the CYP1A2 EAD system is shown in 
Figure 3. The following compounds, displaying a wide range of 
inhibitory potencies, were chosen for validation of the CYP1A2 EAD 
system: αNF, ellipticine, 9-hydroxy-ellipticine (9OH-ellipticine), 
fluvoxamine, phenacetin and caffeine. Concentration-response 
curves were obtained by plotting the concentration of the inhibitor in 
the reaction coil against the S/N ratio of the resulting response 
according to Kool et al [24]. Figure 4A shows a cumulative plot 
presenting the concentration-response curves of all inhibitors tested. 
The respective IC50 values and the detection limits are presented in 
Table I. For caffein and phenacetin, quenching of fluorescence at 
high concentrations prevented the measurement of complete IC50 
curves, but estimates of the affinities could still be made [24]. For 
potent inhibitors, such as αNF, ellipticine and 9OH-ellipticine, IC50 
values obtained with the CYP1A2 EAD system were in accordance 
with those from the microplate assays (Table I). When compared to 
the rat liver CYP1A EAD system, previously described [24], similar 
IC50’s were found for the test compounds. Since rat liver CYP1A 
enzymes resembles human CYP1A2 [32, 33], similar IC50’s may be 
expected and therefore our experiments demonstrate the applicability 
of the present CYP1A2 EAD system in measuring IC50 values for 
human CYP1A2.  
For CYP2D6 EAD, the following inhibitors were used: quinidine, 
quinine, tripolidine, sparteine, dextromethorphan and codeine. The 
resulting IC50 curves are shown in Figure 4C, and the calculated 
IC50 values together with literature IC50 values in Table II. The IC50 
values of the inhibitors quinidine and quinine obtained with the 
CYP2D6 EAD system were in accordance with IC50 values of 
quinidine (0.04 ± 0.01 μM) and quinine (0.76 ± 0.17 μM) determined 
previously by Keizers et al [28]. No significant quenching was 
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observed for the CYP2D6 inhibitors at the concentrations used for 
construction of the IC50 curves. 
It is concluded that both the CYP1A2 and the CYP2D6 EAD 
system in FIA mode can be used to screen compounds for affinity 
and moreover to relatively accurately measure the IC50 values of 
those compounds.  
 
 
Table II: IC50 values of 6 CYP2D6 inhibitors measured with the P450 
2D6 EAD system in FIA mode, 4 CYP2D6 inhibitors measured with 
the P450 2D6 EAD system in HPLC mode. Detection limits for both 
modes are also given. N.D. = Not Determined. Det. Lim. = Detection 
Limit (S/N = 3). 
 
CYP2D6 in FIA mode CYP2D6 in HPLC mode Inhibitor 
IC50’s (µM ± 
SEM; n=3) 
Det. Lim. in pmol. IC50’s (µM; n=4) Det. Lim. in pmol. 
Quinidine   0.028±0.009 0.8 0.014 5 
Quinine   0.57±0.33 6 0.83 28 
Triprolidine   2.3±0.5 39 1.3 126 
Sparteine   9.8±2.8 93 N.D. N.D. 
Dextromethorphan   0.64±0.18 19 2.5 80 
Codeine 151±29 3900 N.D. N.D. 
 
 
On-Line coupling of gradient HPLC to the CYP EAD systems 
 
For on-line coupling of the CYP EAD systems after gradient 
HPLC (Figure 1 B), two additional LC-pumps operating post-column 
with a counteracting gradient were employed, thus resulting in a 
constant concentration of organic modifier entering the biochemical 
assay. First, several inhibitors were individually injected in different 
concentrations in the CYP1A2 EAD system in HPLC mode. 
Representative superimposed chromatograms of different 
concentrations of αNF are shown in Figure 5A. The CYP EAD 
responses were used for plotting IC50 curves (Figure 4B) and 
calculation of the IC50 values (Table I). In case of the potent CYP1A2 
inhibitors αNF, ellipticine, 9OH-ellipticine and fluvoxamine, the IC50 
values were in agreement with those obtained with the CYP1A2 EAD 
system in FIA mode as well as results from the microplate reader 
assay. For the low affinity inhibitors phenacetin and caffein, 
fluorescence quenching at high concentrations prevented accurate 
determination of complete IC50 curves. Similar effects were observed 
previously [24]. Mixtures of ligands for CYP1A2 were also injected 
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into the CYP1A2 EAD system in HPLC mode. Figure 5B shows a 
typical CYP1A2 EAD trace resulting from a mixture of αNF, 
fluvoxamine, 9OH-ellipticine and phenacetin. Due to measures to 
prevent band broadening (i.e. the use of organic modifiers, PEG and 
Tween), similar resolutions were obtained as in previous on-line 
biochemical assay formats that used soluble enzymes [23] or 
receptors [22] instead of the membrane bound CYP enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: (A) Superimposed CYP1A2 EAD traces of α-NF injected in 
different amounts (50, 150, 500 and 1500 pmol from top to bottom 
chromatogram, respectively) in the on-line CYP1A2 EAD HPLC 
system. (B) CYP1A2 EAD trace of a mixture of 4 compounds  
injected in  the CYP1A2 EAD HPLC system (injected compounds are 
subsequently: 1: 9-OH-ellipticine (100 pmol; 17.0 min), 2: 
fluvoxamine, (10 nmol; 20.0 min), 3: phenacetin (2000 nmol; 21.0 
min) and 4: α-NF (1000 pmol; 26.0 min)). 
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Similar experiments were performed for CYP2D6 EAD in HPLC 
mode. Representative superimposed chromatograms of different 
concentrations of the inhibitor tripolidine are shown in Figure 6A. IC50 
values of several CYP2D6 inhibitors measured with this system with 
corresponding IC50 curves are shown in Table II and Figure 4D, 
respectively. The IC50 values were in agreement with those obtained 
with the CYP2D6 EAD system in FIA mode. The IC50 values 
obtained for quinidine and quinine were also compared with literature 
values and found to be in accordance as well [28, 34].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: (A) Superimposed CYP2D6 EAD traces of tripolidine 
injected in different amounts (5, 20 and 200 nmol) in the CYP2D6 
EAD system in HPLC mode. (B) CYP2D6 EAD trace of a mixture of 4 
compounds injected in the CYP2D6 EAD system in HPLC mode 
(injected compounds are: 1: codeine (2 μmol; 7.5 min), 2: sparteine, 
(250 nmol; 9.0 min), 3: quinidine (1 nmol; 12.0 min) and 4: tripolidine 
(50 nmol; 14.5 min).). 
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Next, the CYP2D6 EAD in HPLC mode was used for screening 
mixtures. A typical result is shown in Figure 6B with a mixture 
containing the inhibitors codeine, sparteine, quinidine and tripolidine. 
The resolution obtained was lower than that of the CYP1A2 EAD 
system. This was mainly due to the lower enzymatic conversion rate 
of the probe substrate MAMC, obligating the use of longer reaction 
coils thereby causing more band broadening. 
It is concluded that the two on-line human CYP EAD systems in 
gradient HPLC mode constitute new valuable tools in the drug 
discovery and development area. The systems can efficiently be used 
for the sensitive and reproducible screening of inhibitory properties of 
individual compounds in mixtures (e.g. metabolic mixtures) towards 
human CYP’s.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: (A) UV trace of a chiral HPLC separation of a mixture of 5 
methylenedioxy-alkyl-amphetamines. (B) Corresponding super-
imposed CYP2D6 EAD traces of the same mixture injected at three 
different concentrations (10 mM; 2.5 mM and 0.5 mM). 
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On-Line coupling of Chiral HPLC to CYP2D6 EAD 
 
The inhibitory properties of a set of CYP2D6 ligands with 
different alkyl substituents varies with the chain length of the alkyl 
group [35]. Moreover, different stereoisomers of a ligand may inhibit 
isoenzymes in different ways, which in turn may lead to varying 
pharmacokinetic and drug-drug interactions characteristics of the two 
stereoisomers [36]. Methylenedioxy-alkylamphetamine (MDMA, also 
known as XTC), for instance is a known chiral substrate for CYP2D6 
and also are the chiral analogs methylenedioxy-ethylamphetamine 
(MDEA) and methylenedioxy-amphetamine (MDA), which are high 
affinity CYP2D6 substrates [37]. In the present study, chiral HPLC 
was used to separate the methylenedioxy-alkylamphetamine (MDAA) 
enantiomers, which were then analyzed for CYP2D6 affinity using the 
post-column on-line CYP2D6 EAD. 
When injecting a mixture of MDA, MDMA, MDEA, 
methylenedioxy-propylamphetamine (MDPA) and methylenedioxy-
butylamphetamine (MDBA), these analogs were baseline separated 
into 10 stereoisomers by chiral HPLC (Figure 7A). Corresponding 
superimposed CYP2D6 EAD traces show the inhibitory properties of 
all individual stereoisomers injected at three different concentrations 
(Figure 7C). From the CYP2D6 EAD traces it can be concluded that 
the enantiomeric forms of each analog have more or less the same 
inhibitory potency for CYP2D6. The chainlength of the N-substituent, 
however, affects the affinity of the ligand giving higher inhibitory 
potencies with longer chainlength [35, 37]. According to Sadeghipour 
et al [38], who used similar chromatographic separations of the 
different analogs together with polarimetric detection, the R-(-)- 
isomers eluted prior to the S(+)-isomers. This polarimetric detection 
allows the relative affinity appointments of the enantiomers. It is 
demonstrated that the on-line coupling of chiral HPLC to CYP2D6 
EAD results in a valuable system capable of separating mixtures of 
MDAA’s into their respective enantiomers and screen each individual 
enantiomer for affinity towards CYP2D6.  
 
 
Conclusion 
 
 This study shows the applicability of recombinant human CYP’s 
for on-line Enzyme Affinity Detection (EAD) after gradient HPLC. It 
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was demonstrated that recombinant human CYP1A2, fused to the 
NADPH CYP-reductase as a single membrane-bound protein, as well 
as recombinant human CYP2D6 coexpressed with  NADPH CYP-
reductase, could successfully be used on-line as EAD systems in 
Flow Injection Analysis (FIA) mode as well as in gradient HPLC 
mode. After optimization of both systems, they were validated with 
known ligands for both CYP’s. The IC50 values of the ligands, 
determined with either EAD system in FIA mode, corresponded well 
with IC50 values measured with traditional microplate reader assays. 
For the CYP1A2 EAD system, detection limits of 0.4 to 1.0 pmol were 
found for potent CYP1A2 inhibitors (αNF, ellipticine and 9OH-
ellipticine). For CYP2D6, the detection limit of the ligand with the 
higest affinity, quinidine, was 0.8 pmol. When the CYP EAD systems 
coupled on-line to gradient HPLC were used to screen mixtures of 
compounds, it was shown that both the systems were able to 
separate the ligands prior to sensitive and reproducible determination 
of individual affinities for the CYP used. Moreover, with the CYP2D6 
EAD system coupled on-line to chiral column chromatography, we 
were able to separate five methylenedioxy-alkylamphetamine analogs 
into their enantiomers and subsequently to screen their individual 
CYP2D6 affinity on-line. We conclude that the current CYP EAD 
systems in HPLC mode can be used for the sensitive and 
reproducible screening of individual substrates and inhibitors in 
mixtures of compounds (e.g. metabolic mixtures) to determine human 
CYP enzyme affinities and/or possible drug-drug interactions rapidly 
and efficiently. 
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Chapter 5 
 
Rapid on-line profiling of Estrogen Receptor 
binding metabolites of tamoxifen 
 
Jeroen Kool, Rawi Ramautar, Sebastiaan M. van Liempd, Joran 
Beckman, Frans J. J. de Kanter, John H. N. Meerman, Tim Schenk, 
Hubertus Irth, Jan N. M. Commandeur and Nico P. E. Vermeulen 
 
Adapted from: Journal of Medicinal Chemistry, 2006, 49(11), p. 3287-3292 
 
Abstract 
 
Here we present a High Resolution Screening (HRS)-methodology 
for post-column on-line profiling of metabolites with affinity for the 
estrogen receptor α (ERα). Tamoxifen, which is metabolized into 
multiple metabolites, was used as model compound. Rat and pig liver 
microsomal incubations were shown to produce several mono-, di- 
and tri-oxygenated as well as demethylated tamoxifen metabolites. 
Rates of parent compound metabolism and bioactive metabolite 
formation could rapidly and easily be determined. Most of the 14 
metabolites detected exhibited affinity for ERα. The affinities of the 
metabolites were at least as high as that of the parent tamoxifen. We 
were also able to identify endoxifen, an important metabolite of 
tamoxifen that was discovered approximately 30 years after the 
launch of tamoxifen. Typically the metabolic mixtures were separated 
and analyzed by the HRS platform within 30 min. As is described 
here the developed HRS-based screening system represents a rapid 
methodology for metabolite profiling, i.e. for assessing the bioactivity 
of metabolites for a pharmacological target of interest and 
concomitant MS-based identification of the metabolites. 
Consequently, the developed metabolic profiling methodology shows 
great perspectives for application in drug discovery and development. 
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Introduction 
  
 As biotransformation of drugs may lead to metabolites with 
different pharmacological and toxicological effects, profiling and 
screening for active metabolites are important in drug discovery and 
development to asses their contribution to the overall therapeutic and 
adverse effects on drugs [1]. While chemically reactive metabolites 
can also be named as active metabolites that might cause 
toxicological effects, in the context of this article active metabolites 
are primarily pharmacologically active metabolites. A major 
bottleneck in metabolic profiling remains the detection and 
identification of active metabolites in complex metabolic mixtures. 
One approach is organic synthesis of individual metabolites or 
isolation of biosynthetical metabolites by (semi) preparative HPLC, 
followed by bioactivity measurements in in vitro assays. These 
approaches, however, are very time consuming. 
Several years ago, a novel on-line High Resolution Screening 
(HRS) (Figure 1) technology was developed enabling screening of 
individual estrogenic compounds in mixtures [2]. HRS is based on a 
separation technology, usually gradient HPLC, coupled on-line to a 
post column biochemical assay. For on-line determination of 
estrogenic activity this assay is based on the interaction between the 
Estrogen Receptor (ER), more specifically the ERα and the native 
fluorescent ligand coumestrol, which shows fluorescence 
enhancement when bound to the active site of the ERα. Estrogenic 
analytes injected into the HRS-system bind to the ERα. 
Subsequently, the coumestrol added binds to the remaining free 
binding sites of the ERα thereby showing a profound negative 
fluorescence enhancement [2]. This setup allows a sensitive way of 
detection [3], while similar affinities are measured [2] as in real 
competitive assays, where receptor, radio-tracer and ligand are 
added simultaneously. In the present study, this HRS-ERα 
technology was applied for screening and simultaneous identification 
of estrogenic metabolites of tamoxifen. Tamoxifen is a non-steroidal 
antiestrogen that is used in the hormonal therapy of human breast 
cancer and it is widely used as a chemopreventive agent in women at 
risk for developing this disease [4]. Studies have shown that 
tamoxifen is metabolized by cytochrome P450’s (CYP’s) [5] and 
Flavin-containing Monooxygenases (FMO’s) [6] to multiple mono- 
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and dihydroxylated and N-demethylated derivatives. In Table I, the 
most important primary [5-13] and secondary metabolites [11, 14-19] 
of tamoxifen are tabulated. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic view of the HRS system: LC-gradient with pump 
water and pump organic; Make up gradient with make up pump water 
and pump organic; Flowsplit (S) to MS, UV detector and ERα affinity 
assay; Injection via autoinjector (A.I.); ERα in superloop ‘ER-α’ and 
probe ligand coumestrol in superloop ‘probe’ are pumped into the 
ERα affinity assay with HPLC pumps. ERα affinity readout with a 
fluorescence detector (FLD). 
 
 
It is now well established that besides the parent compound, 
several of its metabolites play an important role in the 
antiestrogenicity of tamoxifen. The major metabolite in human serum, 
N-desmethyltamoxifen, has about the same antiestrogenic activity as 
tamoxifen itself [20]. However, several minor metabolites, such as 3-
hydroxytamoxifen [8], 4-hydroxytamoxifen [15, 20, 21], and 4-
hydroxy-N-desmethyltamoxifen (endoxifen) [16] even show a 10 to 
100-fold higher affinity to ERα than the parent compound. For this 
reason, tamoxifen is considered as a prodrug [22]. Genetic 
polymorphisms of enzymes forming the active metabolites, such as 
CYP 2D6 [7], therefore may explain the wide interindividual variability 
in the clinical efficacy and side effects of tamoxifen. 
 
 
 
 139
On-line ERα affinity detection of tamoxifen metabolites       Chapter 5 
Table I: Structures of tamoxifen and primary and secondary 
metabolites, as derived from literature. 
 
C C
CH CH3
R5
R4
R3
R2
R1
 
            ---- 
Compound   R1 R2 R3 R4 R5 Mr (anti)estrogen. ref. 
            ---- 
Tamoxifen   (CH3)2N(CH2)2O H H H H 371 antiestrogen 
  
Primary metabolites 
N-Desmethyltamoxifen (CH3)NH(CH2)2O H H H H 357 antiestrogen 5, 6 
4-Hydroxytamoxifen  (CH3)2N(CH2)2O OH H H H 387 potent antiestrogen 5, 7 
3-Hydroxytamoxifen  (CH3)2N(CH2)2O H OH H H 387 antiestrogen 7, 8 
(=droloxifene) 
Tamoxifen-N-oxide  (CH3)2NO(CH2)2O H H H H 387 antiestrogen 6, 9 
4’-Hydroxytamoxifen  (CH3)2N(CH2)2O H H OH H 387 partial antiestrogen 10 
α-Hydroxytamoxifen  (CH3)2N(CH2)2O H H H OH 387   11 
Metabolite E  OH  H H H H 300 weak estrogen 12 
3,4-epoxytamoxifen  (CH3)2N(CH2)2O (epoxide)  H H 387   13 
Secondary metabolites 
N-Didesmethyltamoxifen NH2(CH2)2O H H H H 343 antiestrogen 11, 
15  
4-Hydroxy-N-desmethyl- (CH3)NH(CH2)2O OH H H H 373 potent antiestrogen 16 
tamoxifen (= endoxifen) 
α-Hydroxy-N-desmethyl- (CH3)NH(CH2)2O H H H OH 373   17 
tamoxifen 
3,4-dihydroxytamoxifen (CH3)2N(CH2)2O OH OH H H 403 antiestrogen 18 
4-Hydroxytamoxifen-N-oxide (CH3)2NO(CH2)2O OH H H H 403   17 
α-Hydroxytamoxifen-N-oxide (CH3)2NO(CH2)2O H H H OH 403   19 
α-Hydroxytamoxifen-  NH2(CH2)2O H H H OH 359   14 
     N,N-didesmethyltamoxifen           
          ------------------------------ 
 
 
Since tamoxifen forms multiple (anti)estrogenic metabolites, we 
considered this compound as an adequate model compound to 
demonstrate the ability of the HRS technology for rapid ERα affinity 
profiling and concomitant MS-based metabolite identification. 
Metabolite mixtures were generated by incubating tamoxifen with rat 
or pig liver microsomes. Pig liver microsomes were included because 
they were used for large scale incubations to produce sufficient 
metabolites for additional NMR experiments. Metabolism of (Z)-4-
hydroxytamoxifen, a potent antiestrogenic metabolite of tamoxifen, 
was also studied to identify secondary metabolites derived from this 
metabolite.  
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Experimental Section 
 
Materials 
 
β-Nicotinamide adenine dinucleotide phosphate (NADPH) tetra 
sodium salt was from Applichem (Lokeren, Belgium). Acetic acid 
(AcOH), Methanol (MeOH) and acetonitrile (MeCN) were purchased 
from Baker (Deventer, The Netherlands). Both the MeOH and MeCN 
were of HPLC reagent grade. Tamoxifen and (Z)-4-hydroxytamoxifen 
were obtained from Sigma (Zwijndrecht, The Netherlands). 
Coumestrol was bought from Fluka (Zwijndrecht, The Netherlands). 
All other chemicals were of the highest grade commercially available. 
 
Biological materials 
 
Microsomes: Rat and pig liver microsomes were prepared as 
described previously [23]. The protein concentration in the 
microsomes was 13 and 26 mg/ml, respectively.  
Estrogen receptor-α: The Ligand Binding Domain (LBD) of the 
Estrogen Receptor-α (ERα; a kind gift of Dr Marc Ruff; Laboratoire 
de Biologie et Génomique Structurales 1, IGBMC, Illkirch, France) 
was expressed in E-coli according to Eiler et al [24], but without 
estradiol in the medium. All subsequent steps were carried out at 4 
°C. The cells were centrifuged at 4600 rpm for 60 min and the pellet 
was subsequently suspended in 50 ml sodium phosphate buffer (10 
mM; pH 7.4; adjusted with KOH) containing 150 mM NaCl. The cells 
were again pelleted at 4000 rpm for 15 min and the pellet was 
resuspended in 50 ml of the same buffer. This washing step was 
repeated twice. After the last washing step, the pelleted cells were 
suspended in 25 ml of the same buffer. Cells were disrupted by use 
of three French Press cycles (700 bar) followed by ultrasonic sound 
(microtip, 30% duty cycle output 7, 10 cycles). Finally, 
ultracentrifugation (100,000 g) for one hour resulted in the soluble 
receptor in the supernatant. The ERα concentration (500 nM) was 
estimated by determining the Bmax value (by titration with 
radiolabelled estradiol) [25]. The Bmax value was measured as the 
maximum amount of ligand binding extrapolated to a very high 
concentration of ligand. The soluble receptor stock solution was 
stored at -80°C.  
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Microsomal incubations 
 
All liver microsomal incubations were performed according to 
Lim et al [26] with slight modifications: 0.65 mM of NADPH was used 
instead of NADP+. A potassium phosphate buffer (100 mM; pH 7.4) 
with 2 mM EDTA and 10 mM magnesium chloride was used. 
Incubations were performed with 200 μM tamoxifen. The microsomal 
protein concentration was 2.6 mg/ml both with the pig and rat liver 
microsomes. At different time points (0, 15, 30, 45, 60, 90, 120 and 
180 min.), 20 ml fractions were taken from the incubation mixtures 
and subsequently extracted with 5 ml of ice-cold acetonitrile followed 
by two extractions with 10 ml isopropylether each time. After 
evaporation in round-bottomed flasks with help of a rotary evaporator 
(45ºC), the residues were dissolved in 1 ml 65% (v/v) aqueous 
ethanol and used directly for injection in the on-line post-column ERα 
and MS/MS detection system (HRS system). A large-scale incubation 
(1 L) with pig liver microsomes was performed for a 3-hour period 
under the same conditions as described above. The major 
metabolites were purified with preparative HPLC and subsequently 
used for NMR identification (See supporting information). 
 
Chromatography 
 
Unless stated otherwise, a 75 μl injection volume was used. 
The HPLC column was eluted at a flow rate of 250 μl/min with a 
mixture of H2O : MeOH : AcOH (94.9 : 5 : 0.1) for 1 min. 
Subsequently, the MeOH concentration was increased to 95 % in 18 
min via a linear gradient. A post-column gradient of 5 min at H2O : 
MeOH : AcOH (4.9 : 95 : 0.1) was subsequently applied. The organic 
modifier percentage in the HPLC effluent was diluted continuously to 
bioassay compatible levels. For this purpose a counteracting MeOH - 
H2O make-up gradient at a flow rate of 750 μl/min was applied post-
column to the HPLC eluate as reported previously [27].  The total 
flow rate after adding the make-up gradient was 1000 μl/min. The 
MeOH percentage directly after the make-up gradient was constant 
at 24%. This flow was then splitted into three directions at flow rates 
of respectively 750, 150 and 100 μl/min. 750 μl/min was splitted 
towards an UV detector, 150 μl/min towards the MS detector and 100 
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μl/min was introduced into the ERα affinity assay. The final MeOH 
concentration in the reaction coils of the bioassay after mixing in ERα 
and ligand (coumestrol) solutions was 9.6 %. 
 
HRS apparatus 
 
A schematic view of the HRS-apparatus is shown in Figure 1. 
Two Agilent 1100 HPLC pumps (Waldbronn, Germany) were used for 
the HPLC-gradient and two Agilent 1100 HPLC pumps (make up 
pumps) directly after the HPLC-column for the counteracting gradient 
to compensate for the increasing organic modifier concentration 
during the gradient HPLC runs before delivery of the eluent with a 
constant concentration of organic modifier to the ERα affinity assay. 
Injections were performed with a Gilson 234 autoinjector (Middleton, 
USA) equipped with a Rheodyne (Bensheim, Germany) six-port 
injection valve (injection loop, 75 μl or 450 μl). An Agilent 1100 series 
fluorescence detector (λex 340 nm; λem 410 nm) was used for 
monitoring the ERα-bound coumestrol. An Agilent 1100 series UV 
detector monitored the HPLC eluent parallel to the ERα affinity signal 
at 220 nm. All hardware was controlled by Kiadis B.V. software 
(Groningen, The Netherlands). For HPLC separations of the 
metabolic mixtures, a Phenomenex Prodigy C18 (100×3.2) 5μ 
analytical column (Torrance, USA) with a Phenomenex Security 
Guard column (C18-ODS, 4mm L × 2 mm I.D.) AJO-4286 was used. 
The ERα affinity assay (Figure 1) consisted of two Agilent 1100 
HPLC pumps for delivery of the ERα and coumestrol via two 150 ml 
Pharmacia superloops (Uppsala, Sweden) housed at 0 ºC. A 
Shimadzu CTO-10AC column oven (Duisburg, Germany) was used 
to control the temperature of the reaction coils (37 ºC). 
 
On-line Estrogen receptor α affinity assay 
 
A modified version of the on-line ERβ affinity assay previously 
described by Oosterkamp et al [2] was used. ERα (10 nM; 100 
μl/min) was mixed with HPLC effluent via a T-split and was allowed to 
react with the eluting ligands for 10s in a Tefzel reaction coil (0.25 
mm I.D.). Subsequently the native fluorescent ERα-ligand coumestrol 
was added (373 nM; 50 μl/min) to the mixture via a T-union to 
saturate the remaining free binding sites of ERα. This reaction 
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proceeded for 15s in a 0.25 mm I.D. Tefzel reaction coil. The 
difference in fluorescence intensity between free and ERα-bound 
coumestrol enables homogeneous measurement of ERα ligand 
binding [2]. The ERα and coumestrol solutions were prepared in 
sodium phosphate buffer (10 mM; pH 7.4; adjusted with KOH) 
containing 150 mM NaCl. 
 
Mass spectrometry 
 
Mass spectrometry (MS) was performed using a Thermo 
Finnigan LCQ Deca MS detector (San Jose, CA). The ion trap MS 
was operated in positive ion electrospray ionization (ESI) mode. 
Under these conditions the sheath gas and auxiliary gas (both 
nitrogen) were 70 AU and 30 AU, respectively. Helium was applied to 
flush the collision cell. The temperature of the heated capillary was 
220°C, and the tube lens offset was set at 50 V. All scans were 
recorded in the data dependent scan mode which allowed normal MS 
data, recorded in the 50 – 600 m/z range and MS/MS fingerprints to 
be obtained in an alternating manner. The MS/MS scan was set in 
such a way as to obtain MS/MS data of the first five most intense 
ions recorded in the previous MS scan.  
 
Nuclear Magnetic Resonance (NMR) spectroscopy (CD3OD) 
 
1H NMR spectra were recorded on a Bruker Avance 400 
MHz spectrometer. Metabolite 8: δ 7.35 (t, 2H), 7.27 (t, 1H), 7.20 (d, 
2H), 6.95, 6.60 (AB, 4H), 6.80, 6.63 (AB, 4H), 4.05 (t, 2H), 2.18 (s, 
6H), 0.95 (t, 3H), (NCH2 and CH2(ethyl) signals are obscured by 
impurities) Metabolite 12: δ 7.37 (t, 2H), 7.28 (d, 1H), 7.23 (d, 2H), 
7.20-7.08 (m, 5H), 6.83, 6.65 (AB, 4H), 4.39 (m, 2H), 3.74 (m, 2H), 
3.24 (s, 6H), 2.47 (q, 2H), 0.92 (t, 3H). 
 
 
Results 
 
On-line Estrogen Receptor α (ERα) affinity screening 
 
Extracts (75 μl) from microsomal incubations were used and 
injected into the HRS system. Figure 2A shows the UV trace for 
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tamoxifen and the metabolites formed after 90 min incubation with rat 
liver microsomes. One major metabolite (peak 12) was observed at 
18.2 min, whereas very small peaks (peaks 6, 8 and 14) were 
observed at 14.5, 15.0 and 23.5 min., respectively. The ERα affinity 
profile shown in Figure 2B, however, demonstrated that all four 
metabolites produced a strong ERα affinity signal. In addition, a 
significant ERα affinity signal was observed at 20.5 min (peak 13). 
The HRS analysis was repeated with a large volume injection (450 
μl) to also enable detection of minor metabolites. The resulting UV 
chromatogram showed the appearance of at least three additional 
metabolites between 12 and 14 min. (Figure 2C, peak 1, 2 and 3). 
These three minor metabolites also showed ERα affinity responses 
(Figure 2D). Because of a complete occupation of the ERα upon 
injecting a large volume of the extract, the resolution of the ERα 
affinity chromatogram was reduced profoundly due to tailing of the 
parent compound tamoxifen. As shown in Figure 2E and F, all 
metabolites observed in incubations with rat liver microsomes, except 
for metabolite 1, were also observed after HRS analysis of pig liver 
microsomal incubations. The relative intensities of metabolites 
formed were significantly different, however. Most notably, the 
intensities of peaks 2 and 3 in pig liver microsomes were strongly 
increased when compared to the rat liver microsomes.  
  (Z)-4-hydroxytamoxifen, previously considered as a metabolite 
of tamoxifen with the highest affinity towards the ER [10] was also 
incubated with rat and pig liver microsomes to identify possible 
secondary metabolites. Figure 3A and 3B show the UV trace and 
ERα affinity trace of an extract of a pig liver microsomal incubation. 
Three intense peaks, corresponding to metabolites with retention 
times of 13.1, 13.9 and 16.3 min were observed with UV-detection. 
These metabolites also showed a high response in the ERα affinity 
assay. In addition, a significant ERα affinity response was observed 
at 20.5 min., corresponding to metabolite 13, which was also 
observed in tamoxifen incubations (Figure 2B and F). The ERα 
affinity response observed at 16.3 min was caused by metabolite 10 
and 11. The ERα affinity responses observed at 16.3 and 20.5 min 
were also seen with rat liver microsomes. The peaks at 13.1 and 13.9 
min, however, were not observed in the rat liver microsomes (data 
not shown).  
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Figure 2: A; HPLC-Chromatogram of tamoxifen incubated for 90 
minutes with rat liver microsomes. Injection volume of 75 μl. B; The 
corresponding ERα affinity trace. C; HPLC-Chromatogram of 
tamoxifen incubated for 90 minutes with rat liver microsomes. 
Injection volume of 450 μl. D; The corresponding ERα affinity trace. 
E; HPLC-Chromatogram of tamoxifen incubated for 90 minutes with 
pig liver microsomes. Injection volume of 75 μl. F; The corresponding 
ERa bio-affinity trace. 
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Figure 3: A; HPLC-Chromatogram of (Z)-4-hydroxytamoxifen 
incubated for 180 minutes with pig liver microsomes. Injection volume 
of 75 μl. B; The corresponding ERα affinity trace. 
 
 
Time course of metabolite formation 
 
Using the HRS-system, the time course of formation of the 
various tamoxifen metabolites was also determined in order to 
distinguish between primary and secondary metabolites. As is shown 
in Figure 4A, metabolites 6, 8, 12 and 14 were formed soon after the 
start of the incubation of tamoxifen with rat liver microsomes, thus 
indicating that these metabolites are likely primary metabolites. 
Metabolite 13 was clearly formed at a later stage during the 
incubation. With pig liver microsomes (Figure 4B), metabolites 6 and 
12 again were formed early and were predominant species. 
Metabolites 8 and 14 showed similar time response profiles in pig 
liver microsomes when compared to the rat liver microsomes. 
Metabolite 13 was formed to a lesser extent and appeared later on in 
the incubations. A similar metabolic pattern was seen for metabolite 
3, which was only present in significant amounts after 90 min. of 
incubation in the pig liver microsomes, thus indicating that metabolite 
3 and 13 are most likely secondary metabolites. A major species 
difference in formation was also observed for metabolite 2. While this 
metabolite was only formed in minor amounts in rat liver microsomes, 
it was one of the important metabolites contributing to the observed 
ERα affinity, in pig liver microsomes.   
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Figure 4: A; Relative ERα binding of the metabolites formed in time 
resulting from tamoxifen (T) with rat liver microsomes and B; with pig 
liver microsomes. 
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Identification of tamoxifen metabolites 
 
A simultaneously operated mass spectrometer (MS) allowed 
the parallel identification of the metabolites measured with the on-line 
ERα affinity assay. The ion traces of the expected pseudomolecular 
ions ([M+H]+) of previously identified metabolites (Table I) are shown 
in Figure 5. We have identified the metabolites 1 – 13 by MS, and 1H-
NMR where appropriate. A summary of all metabolites identified, 
together with their retention time, pseudomolecular ion and 
corresponding fragmentation pattern of their pseudomolecular ion are 
listed in Table II.  
 A  
 
 
 
 
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Ion-traces:  (A); Ion-traces of pseudomolecular ions [M+H]+ 
of known metabolites of tamoxifen  (in rat liver microsomes). (B); Ion-
traces corresponding to metabolites of tamoxifen (in pig liver 
microsomes). 
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The major metabolite (12) according to the UV trace eluted at 
18.2 min (Figure 2) produced a clear pseudomolecular ion at m/z 
388. Tamoxifen N-oxide was previously identified as the major 
metabolite in rat liver microsomes [28]. With its abundance, mass 
spectral data (Table II) and 1H NMR data, peak 12 was demonstrated 
to correspond to tamoxifen N-oxide. The MS/MS fragments were also 
consistent with this structure, as indicated by the loss of fragments of 
16 (m/z 371) and 60 amu (CH3)2NO m/z 327). Other important 
metabolites known to be formed in rat liver microsomes are 4-
hydroxytamoxifen and N-desmethyltamoxifen [28], The retention time 
and LC/MS/MS data (i.e. pseudomolecular ion at 388 and 
fragmentation; Table II) of peak 6 appeared to be identical to those of 
4-hydroxytamoxifen. 4-Hydroxytamoxifen was also available as 
reference compound.   
 
 
Table II: Tamoxifen and (Z)-4-hydroxytamoxifen metabolites found 
upon incubation of the respective parent compounds in rat and/or pig 
liver microsomal incubations. Retention times and mass spectral data 
are given. N.D. = not determined. 
 
Metabolite 
Nr. 
Metabolite Name Ret time 
UV 
[M+H]+ MS/MS 
1 α−hydroxytamoxifen 12.6 388 370, 325, 247 
2 Di-oxygenated tamoxifen 13.1 404 359, 332, 315, 265, 239, 223, 166, 145 
3 Di-hydroxy tamoxifen 13.8 404 359, 332, 249, 239, 161 
4 Tri-oxygenated tamoxifen 13.9 420 N.D. 
5 Mono-hydroxy tamoxifen 14.2 388 343, 316, 249, 223, 145, 129 
6 (Z)-4-Hydroxy tamoxifen 14.5 388 343, 316, 249, 223, 166, 145, 129 
7 N-desmethyl-oxygenated 
tamoxifen 
14.7 374 N.D. 
8 4’-Hydroxy tamoxifen 15.0 388 343, 316, 249, 223, 129  
9 Desmethyltamoxifen  16.1 358 N.D. 
10 Di-oxygenated tamoxifen 16.3 404 N.D. 
11 Tri-oxygenated tamoxifen 16.3 420 N.D. 
12 Tamoxifen N-oxide 18.2 388 371, 343, 327, 300, 129 
13 N-desmethyl (Z)-4-
hydroxytamoxifen 
20.5 374 279, 371 
14 N.D. 23.5 N.D. N.D. 
T Tamoxifen 16.1 372 327, 209 
 
 
The ion-trace of m/z 358 showed a peak with a retention time 
close to that of the parent tamoxifen, and represented N-
desmethyltamoxifen (peak 9). Because peak 9 overlapped with that 
of tamoxifen, this metabolite was not seen as a separate peak in the 
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ERα affinity traces. Other metabolites with a pseudomolecular ion at 
m/z 388 were observed at 12.6 (peak 1) and 15.0 (peak 8) min. Peak 
8 showed a similar fragmentation pattern as 4-hydroxytamoxifen 
(peak 6). The 1H NMR data obtained confirmed that peak 8 was 4’-
hydroxytamoxifen. Peak 1, which eluted at 12.6 min., showed a 
significant fragment at m/z 370, resulting from the loss of water from 
a pseudomolecular ion at m/z 388. This fragmentation is expected for 
α-hydroxytamoxifen, previously also identified as a minor metabolite 
of tamoxifen [29]. The reconstructed ion current of m/z 404 showed 
peaks at 13.1, 13.8 and 16.3 min., and these are most likely due to 
di-oxygenated metabolites of tamoxifen (i.e. metabolite 2, 3 and 10, 
respectively). The peak at 16.3 min was also observed in microsomal 
incubations of 4-hydroxytamoxifen, and corresponds most likely to 
3,4-hydroxytamoxifen or 4-hydroxytamoxifen N-oxide (Table I). The 
MS/MS fragment at m/z 145 found in metabolite 2 (at 13.1 min.) 
indicates a fragment containing a mono-hydroxylated benzene ring, 
while the fragment at m/z 161 suggests a fragment containing a 
benzene ring with two hydroxy groups attached to it (metabolite 3). 
The reconstructed ion current of m/z 420, which was shown to be the 
pseudomolecular ion of metabolite 4 and 11 (at 13.9 and 16.3 min., 
respectively), indicated tri-oxygenated tamoxifen species. Metabolite 
4 is probably formed from metabolite 3, as is based on the 
observation that metabolite 3 and 4 were only formed from (Z)-4-
hydroxytamoxifen incubations with pig liver microsomes. 
Analogously, this leads to the suggestion that the tri-oxygenated 
metabolite 11 is formed from the di-oxygenated metabolite 10. The 
MS/MS fragment of m/z 145 found for metabolite 2 and 6 was also 
seen for metabolite 5 indicating the presence of a hydroxylated 
benzene ring. Metabolite 13 and 14, which were only detected via 
their ERα affinity response, were not unequivocally identified by MS 
and UV, probably due to low abundance. Metabolite 13, however, did 
show fingerprint ions at m/z 279 and m/z 371 formed from the 
pseudomolecular ion of m/z 374. Since metabolite 13 was present at 
a very low abundance, but nevertheless produced an intense ERα 
affinity signal, this metabolite is probably N-desmethyl-(Z)-4-
hydroxytamoxifen [16]. The same molecular ion was seen for 
metabolite 7 eluting at 14.7 min. This metabolite is likely the 
secondary metabolite N-desmethyl α-hydroxytamoxifen resulting 
from N-desmethyltamoxifen biotransformation [7].  
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Discussion 
 
The primary aim of the present study was on-line HRS-based 
ERα affinity profiling of metabolic mixtures, with parallel MS-based 
identification. Tamoxifen, a frequently used antiestrogenic drug 
known to be metabolized to multiple metabolites by CYP’s, some of 
which with previously demonstrated affinities to the ERα, was used 
as model compound for this purpose. Metabolic mixtures of 
tamoxifen were generated with rat and pig liver microsomes. The 
present HRS technology allowed on-line ERα affinity detection of 14 
individual metabolites in rat and pig liver metabolic mixtures. The 
abundances and ERα affinities of the individual metabolites could 
rapidly be detected in a single run. This not only held true for major 
metabolites formed, but also for minor metabolites. Other ERα 
screening technologies [30, 31], based on dereplication processes, 
do also allow receptor affinity screening of individual components in 
mixtures, but they are usually not capable of detecting low affinity 
compounds in the presence of high affinity metabolites due to tailing 
effects. Moreover, the latter type of technologies are rather time 
consuming. Another reported receptor affinity screening strategy 
concerns the binding of active metabolites to the estrogen receptor 
followed by off-line centrifugal ultrafiltration, thus resulting in the 
collection of bound ligands and allowing characterization by LC-MS. 
With this methodology, Lim et al [26] detected three ERα binding 
mono-hydroxylated tamoxifen metabolites and N-desmethyl-
tamoxifen in rat liver microsomal incubations. Similar methodologies 
were reported by Sun et al [32]. Those technologies however, lack 
the ability of efficient trapping of low affinity ligands in the presence of 
high affinity ligands or in the presence of high concentrations of the 
parent compound.  
The present HRS-technology allowed on-line ERα affinity 
detection and identification of 14 individual metabolites in rat and pig 
liver metabolic mixtures. The relative abundances and ERα affinities 
of the individual metabolites could rapidly be detected in a single run. 
Affinity screening technologies based on dereplication processes do 
also allow receptor affinity screening of individual components in 
mixtures. However, they are usually not capable of detecting low 
affinity compounds in the presence of high affinity compounds due to 
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tailing effects. Other screening technologies based on binding of 
active metabolites to e.g. the estrogen receptor followed by off-line 
centrifugal ultrafiltration also allowed active metabolite 
characterization by LC-MS [26, 32]. Those technologies, however, 
lack the ability of efficient trapping of low affinity ligands in the 
presence of high affinity ligands or high concentrations of the parent 
compound. 
The present results clearly showed that a wide range of 
tamoxifen metabolites contributed to the ERα affinity in microsomal 
liver fractions (Figure 2). Metabolite 13, identified as endoxifen, gave 
a significant contribution to the ERα affinity profile (Figure 2 and 3), 
despite the fact that it was present only in very low concentrations. 
The relevance of this metabolite in terms of ERα affinity was recently 
discussed by Stearns et al [33] and Johnson et al [16] who stressed 
the importance of this secondary metabolite for the antiestrogenic 
action of tamoxifen. Besides endoxifen (metabolite 13), we found that 
another metabolite (metabolite 14), present in low concentrations as 
well, contributed significantly to the ERα affinity. Further studies are 
needed to elucidate the structure and characteristics of this 
metabolite. Although the exact concentrations of the metabolites in 
the microsomal mixtures were unknown and it is difficult to asses 
their relative abundance accurately based on the UV response, 
estimates about the relative affinities based on abundance and 
corresponding affinity trace were made. Our results indicate that (Z)-
4-hydroxytamoxifen and N-desmethyl (Z)-4-hydroxytamoxifen are 
indeed metabolites with a high affinity compared to tamoxifen, which 
is widely described in literature [16]. Besides these two metabolites, 
(Z)-4’-hydroxytamoxifen and metabolite 14 also show a high affinity 
for the ERα. The metabolites 2, 3 and tamoxifen N-oxide show 
affinities similar to tamoxifen, while α-hydroxytamoxifen has a lower 
affinity. The di- and tri-oxygenated tamoxifen metabolites, which were 
formed from (Z)-4-hydroxytamoxifen all show high affinities towards 
the ERα. These affinities are comparable to (Z)-4-hydroxytamoxifen. 
While affinities and/or (anti)estrogenicities for most metabolites have 
been described in literature (Table I), this study shows that also α-
hydroxytamoxifen, at least three di-oxygenated, two tri-oxygenated 
tamoxifen metabolites and metabolite 14 show affinity for the ERα. Of 
these, only one di-hydroxytamoxifen species (3,4-hydroxytamoxifen) 
with affinity for the ERα has been described in literature to our 
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knowledge [34]. The relative affinities of the other metabolites that 
were found in this study seem to correspond with the 
(anti)estrogenicities previously reported in literature (Table I). 
Interestingly, the time-dependency of metabolite formation in 
the microsomal mixtures could also be followed relatively easily and 
completely with the present HRS-system (Figure 4). When comparing 
rat and pig liver microsomal incubations, similar metabolic profiles 
were found, although significant differences were seen in the 
formation rates of the metabolites. Generally speaking, pig liver 
microsomes produced more and faster metabolites contributing to the 
total ERα affinity. However, when (Z)-4-hydroxytamoxifen was 
incubated by pig liver microsomes, at least 5 metabolites were 
formed, this in contrast to results reported by Desta et al [7] who 
showed that only 2 metabolites were formed in human liver 
microsomes. In this case, rat liver microsomes resemble human liver 
microsomes to a larger extent.  
Although this study only gives information regarding the ERα 
binding properties of tamoxifen and its microsomal metabolites, it can 
be envisioned that the metabolites formed play also a role in the 
complex Selective Estrogen Receptor Modulator (SERM) nature of 
tamoxifen [35]. Species differences in metabolic conversion [35] and 
tissue specific metabolism [36] might also add to the complexity of 
explaining different effects seen with SERMs. Additional information 
in terms of functional activities of relevant metabolites binding 
towards the ERα (and ERβ) and species and tissue specific 
metabolic profiles therefore would add to the explanation of the 
complex pharmacology of these SERMs. 
 
 
Conclusions 
  
This study demonstrates the strength of the HRS technology for 
active metabolite screening and profiling. The HRS-ERα platform is 
clearly capable of on-line and simultaneous detection of estrogen 
receptor α affinity (ERα) and identification (by MS) after 
chromatographic separation of individual components in metabolic 
mixtures of a complex model compound like tamoxifen. Knowledge of 
compound metabolism and concomitant knowledge of affinities of the 
metabolites formed towards certain enzymes and/or receptors can 
support early selection of lead compounds in drug discovery or drug 
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candidates in drug development programs. The metabolites of 
tamoxifen formed upon incubation with rat or pig liver microsomes all 
showed ERα affinity. By incubating (Z)-4-hydroxytamoxifen in rat and 
pig liver microsomes, 5 secondary metabolites with corresponding 
ERα affinities were detected.  
It is concluded that the present HRS technology allows the 
screening of metabolites in metabolic mixtures with ERα affinity in a 
very sensitive, selective and rapid way. The HRS technology even 
allows to quickly screen active metabolite formation in time. 
Consequently, clear pictures arise of the relative importance of 
receptor affinities of individual components in complex metabolic 
mixtures in time. 
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Abstract 
 
We have developed a fully automated bioreactor coupled to an on-
line receptor affinity detection system. This analytical system provides 
detailed information on pharmacologically active metabolites of 
selective estrogen receptor modulators (SERMs) generated by 
cytochromes P450 (CYPs). We demonstrated this novel concept by 
investigating the metabolic activation of tamoxifen (TAM) and 
raloxifene (RAL) by CYP-containing pig and rat liver microsomes. The 
high resolution screening (HRS) system is based on the coupling of a 
CYP-bioreactor to an HPLC-based estrogen receptor alpha (ERα) 
affinity assay. CYP-derived metabolites of the SERMs were 
generated in the bioreactor, subsequently on-line trapped with solid 
phase extraction (SPE) and finally separated with gradient HPLC. 
Upon elution the metabolites were screened on affinity for ERα with 
an on-line HRS assay. With this HRS-system, we were able to follow 
time-dependently the formation of ERα-binding metabolites of 
tamoxifen and raloxifene. By analyzing the bio-affinity chromatograms 
with LC-MS/MS structural information of the pharmacologically active 
metabolites was obtained as well. For tamoxifen, 15 active and 6 
non-active metabolites were observed of which 5 were of primary, 10 
of secondary and 6 of as yet unknown order of metabolism. 
Raloxifene was biotransformed in 3 primary and 3 secondary 
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metabolites. Tandem MS/MS analysis revealed that three of the 
observed active metabolites of raloxifene were not described before. 
This present automated HRS-system on-line coupled to a CYP-
containing bioreactor and an ERα-affinity detector proved very 
efficient, sensitive and selective in metabolic profiling of SERMs. 
 
 
Introduction 
 
The Estrogen Receptor alpha (ERα) plays a crucial role in the 
development of breast cancer [1] and osteoporosis in 
postmenopausal women [2]. Therefore, selective estrogen receptor 
modulators (SERMs) are extensively used in treatment and 
prophylaxis of these disorders. Tamoxifen (TAM) is the most 
commonly used SERM in the treatment of postmenopausal, hormone 
sensitive advanced breast cancer. TAM can also halve the threat of 
breast cancer in women at high risk for this disorder [3, 4]. Raloxifene 
(RAL) on the other hand is generally used in the prevention of 
osteoporosis in postmenopausal women. A beneficial effect of the 
treatment with RAL is that it also reduces the risk of breast cancer [5]. 
Additionally, RAL has a protective effect on the cardiovascular 
system by reducing levels of LDL-cholesterol and homocysteine [3]. 
It is now well known that most SERMs, like other drugs and 
xenobiotics, are metabolized by membrane bound Cytochrome P450 
enzymes (CYPs) [6, 7]. For TAM it has been shown that CYPs in 
endometrial tissue play a role in the formation of DNA reactive α-
hydroxytamoxifen, possibly causing endometrial cancer [8]. RAL is 
metabolized by CYPs into three possible quinones with alkylating 
properties towards macromolecules [9]. Alternatively, both for TAM 
and RAL it has been shown that their metabolites can also have 
affinity for ERα [10, 11]. Biotransformation of both TAM and RAL is 
mainly catalyzed by CYP3A4 [12, 13]. Polymorphisms in CYPs or 
drug-drug interactions at the level of CYPs can cause altered 
pharmacological effects in humans [14]. Hence, efficient and 
sensitive screening methods for detection and identification of 
pharmacologically active metabolites are desirable. 
Generation of metabolites and subsequent analysis of 
metabolite mixtures is usually performed by off-line incubation, 
extraction and HPLC separation, coupled to various on- or off-line 
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detection techniques. The methods used are usually based on time-
consuming manual operations [15]. However, we recently developed 
and validated a novel bioanalytical system which is   based on the 
hyphenation of a small scale (500 μl) CYP-containing bioreactor to 
solid phase extraction (SPE) and gradient HPLC [16]. This system 
proved very efficient in the formation, trapping and separation of 
CYP-generated metabolites. If this method could be combined with a 
post-column bioaffinity detection system, generated metabolites could 
be screened instantaneously on selected pharmacological properties. 
At present, there are several of these so called high resolution 
screening (HRS) detection systems available. Recently, for example 
a CYP inhibition and a phosphodiesterase inhibition HRS detection 
system were developed [17, 18]. Both methods are based on 
enzymatic conversion of model substrates in highly fluorescent 
products. When this reaction is inhibited by substrates or inhibitors, 
less fluorescent product will be formed and a negative peak in the 
assay baseline is observed. For the present study we made use of an 
HRS assay for the detection of ERα-binding compounds [19-21]. This 
HRS bioaffinity assay is based on the increase of fluorescent signal 
of the tracer compound coumestrol upon binding to the ERα ligand 
binding domain. When coumestrol is displaced by a compound with 
ERα-affinity that elutes from the HPLC column, it is seen as a 
negative peak in the base line of the bioassay. 
 The objective of the present study was the development of a 
hyphenated and automated HRS system that provides information 
about the time-dependent formation and the ERα-affinity of on-line 
generated metabolites of SERMs. Metabolites were generated in an 
adapted version of a recently developed on-line CYP bioreactor, 
coupled to SPE and gradient HPLC [16]. For the biotransformation of 
TAM, easily available CYP-containing pig liver microsomes were 
used. Especially CYP1A2, CYP3A4 and CYP2E1 activities of these 
microsomes show great resemblance to those in human liver [22]. 
For the biotransformation of RAL, phenobarbital (PB) induced rat liver 
microsomes were used, because they contain high levels of  CYP2A 
and 3A subtypes [23]. By coupling the CYP bioreactor to an HRS 
ERα affinity detection system, it is possible to screen the on-line 
metabolites for ERα-affinity in a post column detection mode. By 
analyzing the detected active metabolites with LC-MS/MS structural 
features of these metabolites could be resolved. 
 163
On-line bioreactor coupled to ERα affinity detection                                Chapter 6 
Experimental section 
 
Materials 
 
Tamoxifen (TAM), raloxifene (RAL), phenobarbital (PB), 
Glucose-6-phospate (G6P) and Glucose-6-phosphate 
dehydrogenase (GDH) were obtained from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Riedel de Häen (Seelze, Germany) 
supplied sodium hydroxide, sodium chloride, magnesium chloride, 
potassium dihydrogenphosphate, dipotassium hydrogenphosphate, 
sodium thiosulphate, acetic acid (AA), HPLC grade methanol and 
ammonium acetate. β-Nicotinamide adenine dinucleotide phosphate 
(NADPH) tetra sodium salt and ethylenediaminetetraacetic acid 
(EDTA) were purchased from Applichem (Lokeren, Belgium). Bovine 
serum albumin (BSA) was obtained from Gibco/BRL (Breda, The 
Netherlands). 
 
Biomaterials 
 
CYP reaction buffer consisted of 100 mM potassium phosphate 
(pH=7.4), 10 mM MgCl2, 16.0 mg/ml BSA and 2 mM EDTA. The 
buffer used in the HRS ERα-affinity assay consisted of 10 mM KPi 
(pH=7.4) and 150 mM NaCl (EB). The regenerating system (RS) for 
the CYP reaction contained 10 mM NADPH, 30 mM G6P and 3 u/ml 
GDH dissolved in CYP reaction buffer. TAM and RAL were dissolved 
in 0.1% AA upon injection. Pig liver microsomes (LMs) were prepared 
as described by Kool et al. [21] and contained 20 μM CYP as 
determined according to Sato et al.[24] PB induced rat LMs were 
prepared according to Yenes et al [25] and contained 11 μM CYP. 
The ERα ligand binding domain (LBD) was produced with 
recombinant E. coli BL21(DE3)-expressing His6-ER_LBD according 
to Eiler et al [26]. The concentration of ERα_LBD was measured by 
determination of estradiol binding ability in a saturation radioligand 
binding assay described by Eiler et al [26] and yielded 250 nM. 
 
SPE-HPLC-coupled CYP Bioreactor 
 
Formation and separation of metabolites took place in a  slightly 
modified model (Figure 1) of a recently developed and validated on-
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line bioreactor, coupled to SPE and HPLC [16]. All pumps used in the 
system were Knauer K-500 HPLC pumps. Injections were performed 
with a Gilson 234 autoinjector (50 μl injection loop) equipped with a 
Rheodyne 6-port injection valve. Autoinjector, pumps and switch 
valves were operated by ScreenControl software (Kiadis, Groningen, 
The Netherlands).  
 
 
Figure 1: Schematic representation of the on-line bioreactor. P1: 
water pump; P2, P3: HPLC gradient pumps; P4: SPE wash pump;SV 
1, 2, 5: 6-way dead-end switch valves; SV 3, 4: 2-position 6-port 
switch valves, closed lines indicate reaction mode and dotted lines 
wash mode; A.I.: autoinjector; SL: superloop 1 contained 
microsomes, SL 2 contained regenerating system, SL 3 contained 
0.1% (v/v) AA and SL 4 contained 250 mM NaOH/0.5% (w/v) SDS; S: 
flow splitter (split ratio 1:8:1); bold lines originating from SV 1 are flow 
restrictors. After HPLC separation, eluted compounds are introduced 
in the bioassay (Figure 2).  
 
 
The HPLC columns, SPE columns and reaction coils were 
thermostated with a Shimadzu CTO-10AC column oven. Superloops 
were purchased from GE Healthcare (Roosendaal, The Netherlands). 
Knitted 1/16” × 0.75mm PTFE reaction coils, PEEK tubing, 6-way 
dead-end switch valves and 2-position 6-port switch valves were 
obtained from VICI Jour (Amstelveen, The Netherlands). Flow 
splitters were made of 1/16” × 0.5 mm PEEK tubing with 50 μm I.D. × 
375μm O.D. fused silica inserts. Polyethersulphone (PES) 0.22µm 
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membrane filters were purchased from Sterlitech (Kent, WA, USA). 
The filter was embedded between PEEK inserts with pore size of 150 
μm in order to fixate the flexible PES membrane. Filter and inserts 
were enclosed by a PEEK filter holder, described in a preceding 
publication [16]. The inserts and filter holder were manufactured in 
house. SPE cartridges were prepared in house. A slurry of 100 mg/ml 
SPE materal in MeOH was prepared. SPE materials used were Luna 
C18(2) 10 μm (Bester, Amstelveen, The Netherlands), StrataX 
(Bester, Amstelveen, The Netherlands) and C8 Bakerbond (J.T 
Baker, Deventer, The Netherlands). The slurry was transferred in a 
10 × 3 mm column by applying underpressure at the end of the 
column. The bottom was sealed with a 0.2 μm stainless steel screen. 
When the column was filled, the top was sealed with a similar screen. 
 
 
 
Figure 2: Schematic representation of the HRS ERα affinity assay. 
Compound, generated in the on-line bioreactor are introduced to the 
HPLC column. After separation, eluted compounds were screened 
separately on ERα affinity. P3, 4: HPLC gradient pumps; P5, 6: Make 
up gradient pumps; P7: water pump; SL: superloop 5: ERα solution, 
6: coumestrol solution; S: flow splitters (split ratio 1:9); FLD: 
fluorescence detector. 
 
 
Optimization of the CYP Bioreactor 
 
Since different substrates were used in this bioreactor set-up 
when compared to the one previously developed [16], the reactor had 
to be revalidated. First, absorption of the RAL and TAM to flow path 
components (tubing, reaction coil, filter unit) was evaluated. 
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Therefore, the filter outlet was directly coupled to the UV detector. 
Next, the substrate (50 μl, 500 μM) or control was injected and mixed 
with CYP reaction buffer (without microsomes) in the reaction coil. 
The flow path was then emptied through the UV detector with water 
or with 0.1 % (v/v) acetic acid. The obtained signals were subtracted 
from controls and compared to the signal obtained by direct injection 
of substrates in the detector. Subsequently, properties of various SPE 
materials were assessed. SPE materials were tested on 
breakthrough volumes with a method previously described [16]. 
During separation the SPE column is placed in series with the HPLC 
column, therefore the effect of the SPE material on separation had to 
be determined. For this purpose, peak widths of substrate peaks 
were compared for different SPE materials, i.e Strata-X, Luna C18(2) 
10 μm and C8 Bakerbond.  
 
 
Table I: Table of events in the on-line bioreactor. 
Switch valve position 
Time (min) 
SV1 SV2 SV3 SV4 SV5
Events 
0 b a a a e Control (no RS) 
2  b    Reaction  
4  c    Reaction 
6  d    Reaction 
⎬ Injection and mixing of  
substrates in reaction coil 
8 a e a a d SPE conditioning 
9 c b    Coil emptying on SPE 
13 e  b   Back flush filter and coil with water 
14 d     Back flush filter and coil with NaOH/SDS 
15 e     Back flush filter and coil with water          
18 a e a  c Start same procedure for respectively reaction coil c, dand a 
48 e a b a a SPE wash (5% MeOH) 
50    b  Beginning of gradient HPLC (70 min) 
120    a b Start same procedure for respectively SPE column b, c and d
 
 
On-line Metabolite Formation and Separation 
 
The SPE-HPLC-coupled CYP bioreactor can be divided in a 
CYP reactor unit and a chromatographic unit (Figure 1). In the 
bioreactor unit the actual CYP reaction takes place while in the 
 167
On-line bioreactor coupled to ERα affinity detection                                Chapter 6 
chromatographic unit analytes are trapped and separated. For the 
present study, we applied a few alterations in both the bioreactor and 
the chromatographic unit.  
 
 
Table 2: Masses of tamoxifen metabolites with structural data 
obtained from MS/MS spectra. 
Metabolites with traceable ERα-affinity RT 
(min)
[M+H]+ 
(m/z) 
Δ 
(m/z)
MS/MS a (m/z) 
 -N   -N,-d   cde    abd     ad         other 
TAM Tamoxifen  52.7 372 0 327 299 218 207 129  
TM 1   21.9 ND  ND      
TM 2   24.2 ND  ND      
TM 3   25.0 ND  ND      
TM 4   25.4 ND  ND      
TM 5 3 or 4-OH  3’ or 4’ -OH 28.0 404 +32 359 331  239 145 265 166
TM 6   29.2 ND  ND      
TM 7   32.0 ND  ND      
TM 8 N-desmethyl 3 or 4 or α-OH 35.1 374 +2 343   223 145 152  
TM 9 N-desmethyl OH 37.9 374 +2 329   209  235 166
TM 10 N-desmethyl 3 or 4 or α-OH 38.4 374 +2 343   223 145 316  
TM 11 3 or 4 -OH  40.9 388 +16 343 315 234 223 145 166  
TM 12 3 or 4 -OH  43.6 388 +16 343 315  223 145 296  
TM 13 N-desmethyl  44.9 358 -14 327   207 129 152  
TM 14 -OH  48.1 388 +16 ND      
TM 15 N-oxide  49.5 388 +16 327 299  207  370  
Metabolites without traceable ERα-affinity     
 
     
TM 16 -OH -OH 35.2 404 +32 ND      
TM 17 α-OH c-ring-OH 40.3 404 +32 359 315  223 145 387 237
TM 18 -OH -OH 42.4 404 +32 ND      
TM 19 α-OH -OH 43.9 404 +32 358 315    386 199
TM 20 N-desmethyl -OH 47.5 374 +2 ND      
TM 21 Quinone  55.5 402 +30      387 215
a Letters (a-e) correspond to those assigned to moieties in the structure of TAM in Figure 
6A, N corresponds to the N-dimethyl group. Minus signs indicate the loss of the moiety 
in MS/MS. 
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For the reactor unit this included incorporation of three extra 
reaction coils with accompanying switch valve (SV2). Additionally, in 
the chromatographic unit three extra SPE cartridges, a switch valve 
(SV5) and an SPE wash pump (P4) were introduced. 
In more detail, the bioreactor unit consisted of a pump (P1), 
switch valves (SV1-SV3), an autoinjector, reaction coils, a filter unit 
and 50 ml superloops. A Superloop (SL) is a hydraulic driven syringe 
that can introduce various solutions in the system. SL 1 was filled 
with CYP containing microsomes and SL 2 contained regenerating 
system (RS). Both SL 1 and 2 were kept on ice. During filling of the 
reaction coil, the flow of P1 was split between the autoinjector, SL 1 
and SL 2 in a 1:8:1 ratio. Control runs were carried out by blocking 
the RS flow by means of a manual operated switch valve (not 
indicated in Figure 1) between SL 3 and the 7-way junction. The total 
reaction volume amounted 500 μl. Following incubation, analytes 
were applied to the SPE column with a degassed 0.1% AA solution 
from SL 4. All parts in the reactor unit were connected with 1/16” ×0.5 
mm I.D. PEEK tubing. 
The bioreactor and the chromatographic unit were separated by 
a filter unit containing a 0.22 μm polyethersulfone (PES) filter in order 
to remove microsomes that otherwise could clog the SPE and HPLC 
columns. After reconcentration of analytes on the SPE column the 
filter unit and reaction coil were rinsed by a series of cleaning steps. 
First, the filter was back flushed with water at a flow rate of 1 ml/min 
for 1 min followed by a solution of 250 mM NaOH/0.5% SDS (SL 4) at 
the same flow rate for 1 min. Finally, the system was rinsed with 
water at a rate of 1 ml/min for 3 min which proved to be sufficient for 
total removal of the washing solution (pH went back to 7). 
 
Chromatography 
 
Prior to HPLC separation, the SPE column, containing Luna 
C18(2) 10 μm particles, was washed with 2 ml of a 5% MeOH 
solution. Next, the compounds were separated in the 
chromatographic unit, which consist of gradient pumps (P2, P3), an 
SPE wash pump (P4), switch valves (SV4, SV5), SPE columns and 
an HPLC column. For TAM and its CYP generated metabolites a 
linear gradient from 50% MeOH to 90% MeOH in 40 min, constant for 
20 minutes and back to 30% MeOH in 10 min was applied. RAL and 
its metabolites were separated with a gradient from 30% MeOH to 
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80% MeOH in 40 min, constant for 20 min and back to 30% MeOH in 
10 min. For both gradients, organic and aqueous phases contained 
10 mM ammonium acetate. All separations were carried out on a 150 
×  mm I.D. Luna C18(2) column protected with a 2.0 × mm I.D. 
C18 guard column (Phenomenex, Amstelveen, The Netherlands). 
The HPLC flow rate for all separations was 250 μl/min. After the 
HPLC column, the eluent was split in a 9 to 1 ratio to respectively a 
Agilent 1100 series UV detector (Agilent Technologies, Amstelveen, 
The Netherlands) and the on-line ERα affinity assay. The UV detector 
was set to 280 nm when TAM was used as a substrate and to 254 
nm when RAL was used. HPLC column and SPE cartridges were 
thermostated at 37°C and 22°C respectively. All parts in the 
chromatographic unit were connected with 1/16” ×0.13 mm I.D. PEEK 
tubing. 
 
Reaction Conditions 
 
For one reaction procedure with one control run and three 
reaction runs, the first coil (a) was filled only with microsomes and 
substrate (TAM or RAL) at a flow rate of 0.5 ml/min (Table I). The 
other coils (b-d) were filled with microsomes, substrate and RS. The 
final coil concentrations in the reaction runs with TAM were 50 μM 
TAM, 1.6 % (v/v) pig LMs (360 nM), 1.0 mM NADPH, 3.0 mM G6P 
and 0.3 u/ml GDH in a total volume of 500μl. Coil concentrations for 
RAL incubations were 25 μM RAL and 8% (v/v) rat LMs (880 nM) 
whereas all the other components were kept the same as in TAM 
incubations. Reaction coils were thermostated at 37°C. Next, the coils 
were emptied one after another, starting with d ending with a. The 
mixture in the reaction coils was applied to corresponding SPE 
columns (e.g coil a to SPE column a) with 0.1% (v/v) AA from SL 4 at 
a flow rate of 1.0 ml/min. The injection and coil emptying procedures 
were programmed such that incubation times in the different coils 
were 7, 15 and 24 min. When all coils were emptied on SPE columns, 
the trapped compounds were further separated on an HPLC column. 
 
HPLC and Mass Spectrometry 
 
To identify metabolites, reaction or control mixtures were 
trapped on the SPE columns as described. Subsequently, the SPE 
columns were transferred to the LC-MS/MS setup and placed in front 
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of the HPLC column. The same gradients were used as in the on-line 
ERα affinity assay. For both TAM and RAL MS was performed on an 
LCQ Deca mass spectrometer (Thermo Finnigan, Breda, The 
Netherlands) in full scan (m/z 100-800) and positive electrospray 
ionization (ESI) mode. The most abundant ion was selected for 
collision-induced dissociation (CID). Eluent from the HPLC column 
was sprayed into the mass spectrometer at +4.5 kV. The temperature 
of the heated capillary was set at 240 °C; sheath and auxiliary gas 
flows were 10 and 50, respectively. An UV detector was placed in 
series with the MS. By aligning UV spectra obtained with the 
bioassay setup and those obtained prior to MS, masses could be 
appointed to compounds, responsible to ERα-affinity signals. 
 
 
Table 3: Masses of raloxifene metabolites with structural data 
obtained from MS/MS spectra. 
Metabolites with traceable ERα-affinity RT 
(min)
MS 
(m/z) 
Δ 
(m/z) 
MS/MS (m/z) 
 -d      -e       ab     b             other 
RAL Raloxifene  43.1 474  389 362 269 147 197   
RM 1 -OH -OH 33.0 506 +32 ND       
RM 2 Piperidine-OH c-ring-OH 34.7 506 +32   269  363 406  
RM 3 Piperidine-OH Piperidine-OH 36.9 506 +32 389  269  470 144  
RM 4 
OH in a or b-
ring 
 38.9 490 +16 405 378 285     
RM 5 
OH in a or b-
ring 
 40.0 490 +16  378 285  472 418 269
RM 6 c-ring-OH  42.0 490 +16 405  269  472 389  
Metabolites without traceable ERα-affinity       
RM 7 Diquinone 52.0 472 -2  360 269  388  
a Letters correspond to those assigned to moieties in the structure of RAL in fig. 6b. The 
minus sign indicates the loss of the moiety in MS/MS. 
 
 
Estrogen Receptor Alpha Affinity Assay 
 
The present homogenous ERα-affinity detection assay was 
performed according to Kool et al [21]. The ERα-affinity detection 
system is based on the competition of a fluorescent tracer compound 
(coumestrol) with HPLC-eluted compounds for the ligand-binding 
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domain of ERα (LBD). When coumestrol is bound to the receptor, 
fluorescence is enhanced. When binding of coumestrol is decreased 
due to competition of an eluting ERα ligand, fluorescence intensity 
decreases. This decrease is a measure of affinity of the ligand 
towards ERα.  A setup was used that consisted of make up pumps 
(P5, P6), superloops (SL 5, 6), reaction coils (1/16” ×0.25 mm I.D., 
Tefzel) and a Agilent 1100 series fluorescence detector (Agilent 
Technologies, Amstelveen, The Netherlands) (Figure 2). The HPLC 
eluent was split in a 1:10 ratio where one tenth of the flow (25μl/min) 
was directed to the assay. In the 4-way junction, this flow was 
combined with the ERα solution (10 nM ERα in EB, SL 5) flow of 150 
μl/min and a make up flow. One tenth of the total make up flow was 
directed to the assay (135 μl/min). The make up flow consisted of an 
opposite H2O/MeOH gradient compared to the HPLC gradient in 
order to keep the MeOH concentration in the assay constant at 15%. 
ERα and eluted compounds were allowed to bind in the first reaction 
coil (25 μl). This mixture was combined with the flow of coumestrol 
solution (0.43 μM in EB, SL 6) of 150μl/min. The final equilibrium 
between ERα, ligand and coumestrol was established in the second 
reaction coil (50 μl). Detection took place directly after the second coil 
with a fluorescent detector set to λex = 340 nm and λem = 410 nm. 
 
Data analysis 
 
For both substrates, three consecutive reaction procedures 
including HPLC separation and on-line ERα affinity screening were 
performed in order to measure metabolite formation in time. Areas of 
negative peaks in the baselines of the ERα affinity assay, caused by 
eluted, active metabolites and corresponding UV traces were 
integrated with ACD/SpecManager 6.0 (Advanced Chemistry 
Development Inc., Toronto, Canada). A threshold of S/N > 3 was 
applied for appointing negative peaks. For obtaining the relative ERα 
affinity, all integrated areas of all ERα-affinity traces were expressed 
as a percentage of the largest area (parent compound excluded). 
Relative affinities of corresponding signals were averaged and 
relative standard deviations (RSD) were calculated with Prism 3.0 
(GraphPath Software inc, San Diego, CA). Deviations of ERα-affinity 
signals after 24 min incubations from controls were checked on 
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significance with a two-tailed t-test. LC–MS data of the metabolites 
were processed with Xcalibur/Qual Browser v 1.2 (Thermo Finnigan).  
 
 
Results 
 
We have developed a new and fully automated, on-line system, 
which is able to metabolize two representative SERMs with CYP 
enzymes and to screen the metabolites formed for ERα-affinity. To 
that end, two recently developed and validated methodologies i.e., an 
on-line bioreactor [16] (Figure 1) and an on-line ERα-affinity bioassay 
[19] (Figure 2), were combined into one hyphenated system. The 
metabolites generated in the multi-coil CYP-bioreactor could be 
trapped on-line with a SPE unit and separated with gradient HPLC. 
Subsequently, the separated metabolites were screened for ERα-
affinity with the on-line ERα-affinity bioassay. Overall, this approach 
resulted in the generation and detection of 15 ERα-binding and 6 
non-binding metabolites for TAM (Figure 3). Moreover, the multi-coil 
CYP-containing bioreactor was able to produce metabolites of RAL or 
TAM in a time-dependent way (Figure 5). For RAL, 6 binding and two 
non-binding metabolites were detected (Figure 4). The concentration 
of all metabolites of both TAM and RAL increased in time except for 
metabolites TM6 and TM 15, which decreased after 7 min incubation. 
The m/z values of most metabolites formed could be determined by 
analyzing the SPE trapped compounds with mass spectrometry. For 
identification, subsequent MS-MS spectra provided further 
information about the structure of the metabolites (see below). 
 
Optimization of the analytical method 
 
In the present bioreactor set-up, the liver microsomal 
incubations took place prior to the corresponding HPLC runs instead 
of after each HPLC run. As a consequence, we were able to 
decrease the total run time with 10% compared to the previous 
bioreactor set-up [16] where HPLC gradients of 70 min were applied. 
The newly developed bioreactor system with multiple reaction coils 
and multiple SPE units was optimized for two SERM substrates. To 
that end, we tried to diminish adsorption of substrates and 
metabolites to flow path components of the bioreactor and the SPE 
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unit as much as possible. Flow path flushing with MilliQ  water only 
resulted in a recovery of 75% for both TAM as RAL, while flushing 
with 0.1 % (v/v) acetic acid resulted in a recovery of >99% of both 
substrates (data not shown). During reaction coil flushing in the 
presence of liver microsomes, the pressure over the filter increased 
from 0 to 10 bars when a 2% (v/v) pig LM solution was used and from 
0 to 20 bars when a 10% (v/v) rat LMs solution was used. When the 
filter membrane was cleaned with MilliQ water and NaOH/SDS 
solution the pressure returned to normal.  
Figure 3: TIC chromatograms of mass ranges corresponding to 
tamoxifen metabolites with or without ERα-affinity (A). ERα affinity 
traces at increasing incubation time. From top to bottom the affinity 
traces correspond to 0, 7, 17 and 26 min incubation with Pig LMs (B). 
TIC chromatograms are correlated with ERα affinity traces of the on-
line affinity assay. 
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Evaluation of SPE materials showed that all materials tested, 
i.e. Luna C18(2), C8 Bakerbond and Strata-X, were able to trap both 
TAM and RAL (50 μl, 500μM) and could trap both substrates 
completely. However, only Luna C18(2) 10 μm material did not alter 
peak widths during HPLC separation when compared to the same 
separation without SPE column. The use of other SPE materials 
resulted in wider peaks for TAM and RAL, i.e. 1.6 times for Strata-X 
and 1.9 times for C8 Bakerbond. 
After the optimization, the SPE-HPLC combination coupled to 
the CYP-bioreactor could be used for the metabolic conversion of the 
two substrates. This resulted in the generation of 21 metabolites of 
TAM and 7 for RAL. Besides the unchanged substrates, many 
metabolites with affinity for ERα were eluting from the HPLC column 
and causing negative peaks in the baseline of the  ERα-affinity trace 
(Figure 3B and 4B). Tamoxifen was metabolized by pig LMs in 15 
ERα-binding metabolites (TM1-TM15, Figure 3) and 6 non-ERα-
binding metabolites (TM16-TM20). Relative ERα-affinity progress 
curves showed that the formation of ERα-binding metabolites was 
time dependent (Figure 5). We arbitrarily distinguished ERα-binding 
metabolites in highly active (TM6, TM8, TM11, TM12, TM13, Figure 
5A), moderately active (TM5, TM9, TM10, TM14, Figure 5B) and low 
active metabolites (TM1-TM4, TM7, TM15, Figure 5C) according to 
their relative affinity for ERα after 24 min of incubation in the 
bioreactor. Relative ERα-affinities for the strong binding metabolites 
varied from 97 ± 5% for TM11 to 15 ± 4% for TM12. The 4 
moderately active metabolites showed affinities varying from 8.4 ± 
1.4% to 5.6 ± 3.0%. The low active metabolites possessed activities 
from 4.0 ± 1.2% to as little as 1.6 ± 0.9%. When the five TAM 
metabolites with high relative ERα-affinities were taken into account 
the total relative standard deviation (RSD) of the data points 
amounted 28%. For metabolites with moderate ERα-affinity, a RSD of 
37% was calculated while for slightly active metabolites the RSD was 
43%. After 24 min of incubation of TAM with pig LMs, all active 
metabolites showed a significant rise in activity compared to control 
incubations (p<0.05). Moreover, from the relative ERα-affinity 
progress curves (Figure 5) upward trends of ERα-affinity in time, 
indicative of increasing production of active metabolites, were 
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obvious. Biotransformation of RAL by rat LMs resulted in the 
formation of 6 active metabolites (RM1-RM6) and one none-active  
metabolite (RM7) (Figure 3B). The pooled RSD of all six active RAL 
metabolites was 18%. Again, upward trends in the formation of ERα-
binding metabolites were evident (Figure 5D).  
 
Identification of Tamoxifen and Raloxifene Metabolites 
 
In Figure 6, a provisional scheme of the metabolism of TAM by 
CYP enzymes is presented. Not all TAM metabolites, detected by UV 
and the ERα-affinity assay, were detected by LC–ESI–MS. The minor 
metabolites TM1 to TM4, TM6 and TM7 were all visible on the ERα-
affinity traces, but could not be detected with LC-MS. Masses of the 
protonated molecules of metabolites TM5, TM8 to TM21 were 
subsequently determined by LC-MS (Table II). Structural properties of 
the TAM metabolites formed based on CID mass spectra are 
discussed in the next section. The ERα-binding metabolite TM5 is a 
dihydroxylated secondary metabolite, as is indicated by the m/z value 
of 404. The m/z value of 374 for ERα-binding metabolites TM8, TM9 
and TM10 indicates a secondary oxygenated N-desmethyl species. 
The ERα-binding metabolites TM11, TM12, TM14 and TM15 were 
identified as primary monohydroxy-TAM metabolites according to a 
protonated molecule  with m/z 388. Based on m/z 358, TM13 was 
identified as a primary N-desmethyl-TAM metabolite which also 
showed significant binding to ERα. TM16 to TM19 were all identified 
as dihydroxy-TAM metabolites, which however did not show any 
traceable affinity in the ERα-affinity assay. The protonated molecule 
at m/z 374 for TM20 was assigned to an oxygenated N-desmethyl 
metabolite. According to the protonated molecule mass of 402, TM21 
was a quinone. In Figure7 the metabolic scheme of the metabolism of 
RAL by rat LM is depicted. We were able to measure protonated 
molecule masses from six ERα-binding and one non-ERα-binding 
metabolite of RAL. The first three metabolites eluting (RM1-RM3), are 
all dihydroxy-RAL species according the protonated molecules at m/z 
506. RM4 to RM6 at m/z 480 are primary, monohydroxylated RAL 
metabolites. The protonated molecule  at m/z 472 implies that RM7 is 
probably one of the two quinones recently described in literature [9]. 
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Figure 4: TIC chromatograms of mass ranges corresponding to 
raloxifene metabolites with or without ERα-affinity (A). ERα affinity 
traces at increasing incubation time. From top to bottom the affinity 
traces correspond to 0, 7, 17 and 26 min incubation with Rat LMs (B). 
TIC chromatograms are correlated with ERα affinity traces of the on-
line affinity assay. 
 
 
Discussion 
 
Our primary aim was the development of a hyphenated and 
automated HRS system that can provide information of time-
dependent formation and ERα-affinity of CYP-generated metabolites 
of SERMs. The CYP-bioreactor on-line coupled to SPE-HPLC 
enabled us to generate and swiftly trap and separate a substantial 
amount of CYP generated metabolites of both TAM and RAL. The 
metabolites were trapped very efficiently on SPE columns and 
isolated from air and light, they stayed protected from oxidation or 
 177
On-line bioreactor coupled to ERα affinity detection                                Chapter 6 
UV-degradation. Additionally, because the incubation of the drugs 
took place prior to HPLC runs, microsomes were directly used which 
reduced degradation of CYP enzymes to a minimum. CYP enzymes 
are known to degrade to some extent, even when stored on ice [27]. 
For the detection of ERα-binding metabolites we made use of a 
previously developed and optimized on-line HRS ERα-affinity assay. 
Displacement of coumestrol from the ERα ligand binding domain 
results in a decreased fluorescence intensity of coumestrol [19, 20]. 
From the HPLC column eluting TAM and RAL metabolites with affinity 
for the ERα caused clear and reproducible negative peaks in the 
baseline of the bioaffinity trace (Figure 3B and 4B). The peak height 
depends on the concentration of the eluting compound and its ERα-
affinity. According to the upward trends in the ERα progress curves 
(Figure 5A-C), TAM was time-dependently metabolized by pig liver 
microsomes in 15 ERα-binding metabolites (Figure 3B). The ERα-
affinity detection system proved to be very sensitive according to the 
response signals of TM1 to TM4, TM6 and TM7 since these 
metabolites were only detected by their ERα-affinity response and not 
by UV. The high relative standard deviations of the ERα-affinity 
signals with these low and moderate ERα-binding metabolites can be 
explained by the fact that variations between ERα-affinity signals tend 
to increase when the respective bioaffinity signals are decreasing 
(Figure 5B and 5C). When bioaffinity signals approach the lowest 
level of detection, noise is obviously becoming a prominent factor, 
leading to increased standard deviations and as a consequence 
higher RSDs. Biotransformation of RAL in the CYP-bioreactor by rat 
liver microsomes resulted in the formation of six ERα-binding 
metabolites (RM1-RM6, Figure 4B). Again, upward trends in the 
formation of ERα-binding metabolites were evident (Figure 5D). 
Consequently, the present bioanalytical method is not only useful for 
the screening and identification of individual metabolites in mixtures, 
but also for measuring the time-dependent formation of CYP-
generated ERα-binding metabolites of compounds like TAM and 
RAL. 
 
Metabolic Profiling of Tamoxifen 
 
Interpretation of the MS-MS spectra of the metabolites was 
performed using the profile group concept proposed by Kerns et al 
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[28]. Of the 21 TAM metabolites observed, 5 were identified as 
primary metabolites (TM11 to TM15) (Table II, Figure 6). Leveling of 
ERα-affinity progress curves (Figure 5) can be explained by primary 
metabolites reaching steady state conditions as they are further 
metabolized into secondary metabolites. The primary metabolite 
TM13 was identified as N-desmethyl-TAM which, in humans, is 
catalyzed by CYP3A4 [12]. On the basis of UV data (not shown) it 
appeared to be the most abundant metabolite of TAM. According to 
their MS-MS spectra TM11 and TM12 were monohydroxylated on the 
aromatic 3 or 4 position (Table II, Figure 6) which are known to be 
catalyzed in humans by CYP3A4 (3-position) or CYP2D6 (4-position) 
[6, 12]. 
 
Figure 5: Relative ERα-affinity progress curves where relative ERα-
affinity is plotted against incubation time. Curves of highly active (A), 
moderately active (B) and slightly active metabolites (C) of TAM, 
generated by pig liver microsomes. Activity progress curves of RAL 
metabolites generated by PB-induced rat liver microsomes (D). Error 
bars represent 1 SD (n=3), data points at t=0 min represent 
incubations without  regenerating system. 
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TM11 and TM12 are the second most abundant metabolites 
according to UV data. Considering the high relative affinity of TM11 
for ERα, this metabolite is likely to be 4-hydroxy-TAM since previous 
studies showed that this metabolite of TAM is 30 - 100 times more 
potent than TAM itself [11]. The CID mass spectrum of TM14 did not 
provide structural information. TM15 was identified as TAM-N-oxide 
by its MS–MS spectrum (Table II, Figure 6) and is mainly formed by 
flavin-containing monooxygenases (FMOs) [29]. The abundance of 
this metabolite was comparable to TM12, however, its ERα-affinity 
was very low (Figure 3 and 5). The decreasing slope of its ERα-
affinity progress curve can be explained by reduction of the N-oxide 
by CYP enzymes which is in line with the suggestion that N-oxide-
TAM is a storage form of TAM in vivo [29].   
 
 
Figure 6: Proposed metabolic scheme of the biotransformation of 
TAM by pig LM. The letters  in the parent compound structure 
correspond to fragments of the molecule as seen in the tandem MS 
spectra (Table 2). The CYP subtypes indicated in the diagram 
correspond to the major contributing human isoforms. 
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Several primary metabolites of TAM are further metabolized into 
the secondary metabolites TM5, TM8 to TM10 and TM16 to TM21. 
The MS–MS spectrum of the dihydroxylated metabolite TM5 revealed 
hydroxylation in the a-ring and b-ring of TAM (Table II, Figure 6A), 
respectively yielding 4 (or 3), 4’ (or 3’)-dihydroxy-TAM. TM5 probably 
originates from TM11/TM12and is catalyzed in humans by CYP3A 
[12]. The MS–MS spectra of the oxygenated N-desmethyl metabolites 
TM8 and TM10 point to hydroxylation either in the a-ring of TAM (3 or 
4 position) or on the alpha position of the ethylene moiety. Since the 
amount of TM8 formed is 150 times as low as TAM  while its relative 
ERα-affinity is high, this metabolite is most likely endoxifen which is 
known to be as potent as 4-hydroxy-TAM [30]. The MS-MS spectrum 
of TM9 did not provide additional structural information. The CID 
spectrum of the dihydroxylated metabolite TM17 suggested that 
besides the ethyl moiety, the c-ring or ether linkage (e) in TAM is also 
hydroxylated, which is an observation hitherto not described. CID 
spectra of the dihydroxylated metabolites TM16, TM18 and TM20 did 
not reveal the positions of the hydroxyl group introduced. For the 
dihydroxylated metabolite TM19 we could identify hydroxylation of the 
ethyl moiety (d). The MS-MS spectrum of TM21 suggested that this 
metabolite is a diquinone of TAM, species also known to be produced 
by CYPs [31]. Finally, he fast elution times of the ERα-binding 
metabolites at the beginning of the chromatogram (TM1-TM4) 
indicate that these are most likely tertiary metabolites. Introduction of 
additional hydroxyl groups or cleavage of methyl groups increase 
polarity and therefore shorten retention times in reversed phase 
chromatography. 
In order to unambiguously substantiate the suggested 
structures of TAM metabolites, additional experiments should be 
carried out. For example standards of the suggested metabolites 
should be synthesized and their retention times and MS-MS spectra 
could be compared to those obtained with the present bioanalytical 
system. Furthermore, preparative HPLC and subsequent NMR 
analysis of the metabolites could provide more definite structural 
information. 
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Figure 7: Proposed metabolic scheme of the biotransformation of 
RAL by rat LM. The letters  in the parent compound structure 
correspond to fragments of the molecule as seen in the tandem MS 
spectra (Table 3). The CYP3A subtype in the diagram correspond to 
the human isoform. 
 
 
Metabolic Profiling of Raloxifene 
 
The metabolic profile of RAL is less complex than that of TAM. 
Only four primary and three secondary metabolites were observed 
when incubated with rat liver microsomes (Figure 7). Formation of 
several ERα-binding metabolites showed clear upward trends 
according to Figure 5D. Interpretation of the MS–MS spectra of the 
monohydroxylated RAL metabolites RM4 and RM5 lead to the 
conclusion that hydroxyl groups were introduced in either the a or b-
ring of RAL as expected upon biotransformation by CYPs [10] (Table 
III, Figure 7). The fragments at m/z 405 and 269 suggest that RM6 is 
hydroxylated on the aromatic c-ring. This metabolite has not yet been 
described previously, despite the fact that CYPs are very well 
capable of hydroxylating aromatic moieties. MS–MS spectra of the 
dihydroxy-RAL species RM2 and RM3 provided also structural 
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information. For RM2, fragments at m/z 363 and 269 point to 
hydroxylation in the piperidinic d-ring (Figure 7) and aromatic c-ring. 
The m/z 389, 269 and especially m/z 144 fragments of RM3 strongly 
indicate that the d-ring is dihydroxylated. Both RM2 and RM3 have 
not yet been described in literature. The ion at m/z 472 implies that 
RM7 is likely one of the two quinine-metabolites recently described in 
literature [9]. Interestingly, except for the diquinone, all observed 
metabolites show significant ERα-affinity, which may have 
consequences for the in vivo effect of RAL. Additional experiments 
should be performed in order to find definite proof. 
 
 
Conclusion 
 
We developed a fully automated on-line bioanalytical system for 
the metabolic profiling of SERMs.  This system is based on the 
hyphenation of a gradient SPE-HPLC, a CYP-containing bioreactor 
and an on-line, HRS ERα-affinity assay. The system was validated 
with the two clinically used SERMs as model compounds, namely 
tamoxifen and raloxifen. The present bioanalytical method was able 
to provide simultaneously information about the time-dependent 
formation as well as about the ERα-affinity of CYP generated 
metabolites of TAM and RAL. For TAM we were able to identify 15 
ERα-binding metabolites and 6 non-ERα-binding metabolites varying 
from trace amounts of tertiary metabolites to major primary ones. 
Amongst the ERα-binding metabolites we identified 4-hydroxy-TAM, 
N-oxide-TAM, N-desmethyl-TAM and the recently characterized, very 
potent endoxifen. We also could identify potentially carcinogenic α-
hydroxy-TAM species. By analyzing RAL with the presented sytem, 
we were able to identify 6 ERα-binding metabolites of which three 
novel ones and one non-binding metabolite. These RAL metabolites 
include species that are hydroxylated on the piperidine ring. Overall, 
biotransformation of the SERMs analyzed, yields a very complex 
profile of ERα-binding and non-ERα-binding metabolites which might 
have considerable consequences for the pharmacological properties 
of these drugs. The hyphenated and fully automated bioanalytical 
system presented here, could be very useful for elucidation of 
convoluted metabolic profiles, and by inference become a novel tool 
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in active metabolite screening e.g. for the purpose of drug discovery 
and development and for safety assessment research. 
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On-line biochemical detection of Glutathione 
S-Transferase Pi inhibitors in complex 
mixtures 
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Liempd, Danny A. van Elswijk, Hubertus Irth, Jan N. M. 
Commandeur, John H. N. Meerman and Nico P. E. Vermeulen 
 
Adapted from: Journal of Biomolecular Screening, In Press 
 
Abstract 
 
A High-Resolution Screening (HRS) technology is described, which 
couples two parallel enzyme affinity detection (EAD) systems for 
substrates and inhibitors of rat cytosolic glutathione-S-transferases 
(cGSTs) and purified human GST Pi to gradient reversed-phase high-
performance liquid chromatography (HPLC). The cGSTs and GST Pi 
EAD systems were optimized and validated first in flow-injection 
analysis (FIA) mode and optimized values were subsequently used 
for HPLC mode. The IC50-values of 8 ligands thus obtained on-line 
agreed well with the IC50-values obtained with microplate reader 
based assays. For ethacrynic acid, an IC50-value of 1.8 ± 0.4 μM 
was obtained with the cGSTs EAD system in FIA mode and of 0.8 ± 
0.6 μM in HPLC mode. For ethacrynic acid with the GST Pi EAD 
system, IC50-values of 6.0 ± 2.9 and 3.6 ± 2.8 μM were obtained in 
FIA and HPLC mode, respectively. A HRS GST EAD system, 
consisting of both the cGSTs and the GST Pi EAD system in HPLC 
mode in parallel, was able to separate complex mixtures of 
compounds and to determine on-line their individual affinity for cGSTs 
and GST Pi. Finally, a small library of GST inhibitors, synthesized by 
reaction of several electrophiles with glutathione (GSH), was 
successfully screened with the newly developed parallel HRS GST 
EAD system. It is concluded that the present on-line gradient HPLC-
based HRS-screening technology offers new perspectives for 
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sensitive and simultaneous screening of general cGSTs and specific 
GST Pi inhibitors in mixtures. 
 
 
Introduction 
 
The elimination of hydrophobic xenobiotics from the body often 
depends on their biotransformation to water-soluble compounds. 
Gluthatione S-transferases (GSTs) constitute an important class of, 
predominantly cytosolic,  enzymes that play a role in the 
biotransformation of a wide variety of electrophilic compounds by 
catalyzing their conjugation to glutathione (GSH) [1, 2]. Substrates for 
cytosolic GSTs range from naturally occurring xenobiotics [3, 4], 
(such as ethacrynic acid derivatives) [5], anticancer drugs [6, 7], 
electrophilic reactive intermediates [8] and endogenous compounds, 
such as prostaglandines [1] and lipid peroxidation products [9], that 
are metabolized to GSH conjugates [10]. GSTs have also been 
suggested to be involved in anticancer drug resistance [6, 11, 12]. 
Elevated GST Pi levels in neoplastic tissues were shown to impart 
resistance to alkylating antitumour drugs. Overexpression of different 
GSTs, demonstrated in several human tumors, signalled for drug 
resistance as well [13, 14]. The observation that GST inhibitors, such 
as ethacrynic acid, sensitize cancer cells to anticancer drugs, such as 
melphalan [15], has compelled investigators to the development of 
inhibitors as adjuvants for chemotherapy with alkylating agents [16-
18]. However, in such a strategy using broad-range inhibitors such as 
ethacrynic acid, one must take into consideration possible cytotoxic 
effects in normal cells due to diminished GST-mediated responses as 
well. Specific GST inhibitors are expected to cause fewer problems in 
this regard [18, 19]. The expression levels of the different classes of 
GSTs differ highly in different cell types and organs. The induced 
expression of certain classes of GSTs [20, 21] are meant to facilitate 
the excretion of toxicants through GSH conjugation. A well known 
example is the over-expression of GST Pi in multi drug resistant 
tumour cells [22]. Although this over-expression might implicate the 
resistance of the cells to chemotherapy, this is not yet fully elucidated 
and over-expression might also be a cellular stress response. These 
observations still indicate GST Pi inhibitors to be potential co-
assisting drugs together with cytostatics [19, 23-28]. 
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Due to the fact that mixtures of GST inhibitors display complex 
inhibitory responses in the usual GST-inhibition assays, little can be 
concluded about the specificity of individual inhibitors in such 
mixtures. Selectivity and affinity of individual inhibitors in mixtures 
therefore have to be evaluated after cumbersome, mainly HPLC-
based dereplication processes [29]. The ability to detect bio-affinities 
in a HPLC effluent stream may eliminate much of the time and labor 
taken in dereplication strategies. Several of such on-line post-column 
HPLC-based biochemical detection systems, referred to as High-
Resolution Screening (HRS) systems, have been developed during 
the last decade [30-32]. HRS-based bio-affinity assays have been 
based on enzymes like angiotensin converting enzymes [33], 
phosphodiesterases [31] and cytochromes P450 [32], on soluble 
receptors such as the estrogen receptor [34] and on antibodies such 
as for leukotrienes [30]. 
Here we describe the development of a HRS-technology 
comprising gradient HPLC coupled on-line with two parallel Enzyme 
Affinity Detection (EAD) systems containing GSTs. One EAD system 
monitors the HPLC eluent for ligands of cytosolic GSTs (cGSTs) and 
the other system for ligands of GST Pi. This parallel placed EAD 
(HRS GST EAD) system is operated by continuous mixing of cGSTs 
or GST Pi with substrate mono-chlorobimane, cofactor glutathione 
(GSH) and carrier solution, in separate reaction coils (one for the 
cGSTs and one for GST Pi). In the reaction coils, mono-chlorobimane 
is converted into the fluorescent product glutathione-bimane (GSH-
bimane) [35]. Ligands eluting from the upstream HPLC system 
compete with mono-chlorobimane for the active site of the GSTs, 
thus causing temporary decreases in the formation of fluorescent 
GSH-bimane product resulting in temporarily decreases in the 
baseline fluorescence signal ('negative peaks'). The cGSTs and the 
GST Pi EAD systems were first evaluated and optimized individually 
with pure GST ligands in a flow-injection analysis (FIA) mode and 
subsequently analyzed with the total HRS GST EAD system. 
Specific GST Pi inhibitors in mixtures also containing non-
specific GST inhibitors were easily identified with the total HRS GST 
EAD system. Finally, a library of GSH-derivatives, assembled by 
reaction of electrophilic compounds with GSH, was screened on-line 
for potential  cGSTs and GST Pi inhibitors. 
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Experimental section 
 
Materials 
 
Mono-chlorobimane, Tween 20, Tween 80, saponin (from 
Quillaja Bark),  polyethylene glycol 6000 (PEG 6000), polyethylene 
glycol 3350 (PEG 3350), reduced glutathione (GSH), phenacetin, 
ethacrynic acid, crotonaldehyde, chloro-2,4-dinitrobenzene (CDNB) 
and curcumine were purchased from Sigma (Zwijndrecht, The 
Netherlands). 2-Chloro-5-nitropyridine and 2-chloro-5-
nitrobenzaldehyde came from Fluka (Zwijndrecht, The Netherlands). 
Acrolein was obtained from Acros (Den Bosch, Netherlands). 4-
Chloro-3-nitro-benzoic acid butyl ester [36] and n-butyl-2-chloro-5-
nitrobenzoate [37] were synthesized as described by Van der Aar et 
al. Sodium cholate, cinnamaldehyde, 4-chloro-3-nitrobenzaldehyde 
and 2-chloro-5-nitrobenzonitrile were obtained from Aldrich 
(Zwijndrecht, The Netherlands). ELISA blocking reagent was 
purchased from Roche (Mannheim, Germany) and bovine serum 
albumin (BSA) was from Life Technologies (Paisley, United 
Kingdom). Methanol (MeOH), isopropanol (IPA), acetic acid, glycol 
and acetonitrile (MeCN) were purchased from Baker (Deventer, 
Netherlands) and were of HPLC reagent grade. 
The four GSH-analogues DB1, 2, 3 and 4 were a kind gift of Dr. 
D. Burg (Division of Toxicology; LACDR-Leiden, Netherlands): DB1: 
5-(4-Amino-4-carboxy-butyryl-amino)-5-(1-methyl-hexylcarbamoyl)-
pentanoic acid; DB2: 2-Amino-4-[1-(carboxymethyl-carbamoyl)-2-
hexylsulfanyl-ethylcarbamoyl]-butyric acid; DB 3: 2-Amino-4-{2-
benzylsulfanyl-1-[(carboxy-phenylmethyl)-carbamoyl]-ethyl-
carbamoyl}-butyric acid and DB 4: 2-Amino-4-[2-[2-(4-
carboxymethoxy-2,3-dichloro-benzoyl)-butylsulfanyl]-1-(carboxy-
methyl-carbamoyl)-ethylcarbamoyl]-butyric acid. 
GST enzymes: Rat liver cytosol was prepared from untreated 
rats as described by Rooseboom et al [38]. The GST concentration in 
the cytosolic fraction was 34 mg/ml. Purified human GST Pi (5.3 
mg/ml potassium phosphate buffer pH 7.3) isolated from E. coli 
expressing high concentrations of GST Pi, was a kind gift of Prof. M. 
Lo Bello (Department of Biology, University of Rome, Italy) [39].  
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Instrumentation 
 
The cGSTs and GST Pi EAD systems consisted of identical 
instrumentation (Figure 1). Per EAD system, two 100 ml superloops, 
made in house, were used. Superloop A (SL-A) contained enzyme 
(rat liver cGSTs or purified human GST Pi) and superloop B (SL-B) 
co-factor (GSH) and substrate (mono-chlorobimane). For each EAD 
system, two Knauer K-500 HPLC pumps (Berlin, Germany) were 
used to control the superloops and one for delivery of the injected 
samples in flow injection analysis (FIA) mode.  
 
Figure 1: Schematic view of the total HRS GST EAD system. After 
HPLC, the make-up pumps produce a counteracting gradient, 
resulting in a constant GST EAD compatible organic modifier 
concentration. The eluent is then split 1:2:7 to the GST Pi EAD 
system, the cGSTs EAD system and the UV detector, respectively. 
Eluting ligands cause a temporary inhibition of the formation of GSH-
bimane, which is monitored with a fluorescence (FLD) detector. When 
operated in FIA mode (not shown in this Figure), the HPLC system 
including the flow split is replaced by only a carrier solution. Ligands 
are injected in the carrier solution with an autosampler (A.S.) and 
transported directly to a single GST EAD system. 
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The superloops were kept on ice. Proper operation of the 
pumps at low flow rates was achieved in a similar way as described 
by Kool et al [32]. When operated in HPLC mode, Knauer K-500 
HPLC pumps controlled the HPLC and the counteracting gradient 
flows. In this case, an Agilent 1100 series UV detector (220 nm) 
monitored the HPLC eluent parallel to one of the GST EAD systems 
that was used for optimization or parallel to the total HRS GST EAD 
system. Sample injections were performed with a Gilson 234 
autoinjector (Villiers-le-Bel, France) equipped with a Rheodyne 
(Bensheim, Germany) six-port injection valve (injection loop, 50 μl in 
FIA mode or 500 μl in HPLC mode). Agilent 1100 (Waldbronn, 
Germany) series fluorescence detectors (λex 390 nm; λem 465 nm) 
were used for monitoring of the fluorescence. The temperature of the 
reaction coils was controlled by a Shimadzu CTO-10AC column oven 
(Duisburg, Germany). During optimization, the carrier solution was 
water (100 μl/min). Samples were injected in the carrier solution prior 
to mixing with a buffer solution containing the enzyme (100 μl/min) 
and the co-factor/substrate solution (100 μl/min). Knitted PEEK 
reaction coils (internal volumes of 75 μl (cGSTs) and 500 μl (GST Pi) 
were used for the on-line enzymatic reactions. All hardware was 
integrated in one system by Kiadis B.V. and was controlled by 
software developed by Kiadis B.V. (Groningen, Netherlands). 
 
GST enzyme affinity detection in flow-injection analysis mode 
 
In FIA mode, both EAD systems are operated by continuous 
mixing of GST enzymes (cGSTs or GST Pi in SL-1), substrate (mono-
chlorobimane; in SL-2) and glutathione (GSH; in SL-2) with a carrier 
solution instead of the effluent of a gradient HPLC system (Figure 1). 
After mixing of the various solutions in a knitted reaction coil, the 
substrate monochlorobimane is converted into the highly fluorescent 
GSH-conjugate GSH-bimane [35]. Eluting ligands (i.e. both inhibitors 
and substrates) that compete with mono-chlorobimane for the active 
site of the GSTs cause a (temporarily) decreased production of GSH-
bimane, a process monitored by fluorescence detection.  
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GST enzyme affinity detection coupled on-line to HPLC 
 
For operation of the cGSTs and GST Pi EAD systems in HPLC 
mode (Figure 1) two pumps were used to control the HPLC-gradient. 
After the HPLC-column, two pumps compensated for the increasing 
concentrations of organic modifier by applying a counteracting 
gradient before delivery of the eluent to the GST EAD systems. HPLC 
separations were performed using a Phenomenex (Torrance, USA) 
30 mm × 2 mm i.d. stainless-steel column (Luna 3μ C18(2)) with a 10 
mm × 2 mm i.d. C18 Luna pre-column. With the total HRS GST EAD 
system, the eluent of the HPLC was connected to a three way splitter 
and splitted at a 1:2:7 ratio. The first fraction was directed to the GST 
Pi EAD system, the second to the cGSTs EAD system and the 
remaining fraction to the UV detector. For HPLC analysis, test 
compounds were dissolved in 40 % (v/v) MeOH in water. Compounds 
on the HPLC column were eluted as follows: a flow-rate of 200 μl/min 
with H2O-MeOH (95:5) for 1 min was followed by a gradient of 10 min 
to H2O-MeOH (5:95) except for the separation of the compound 
library reacted with GSH where a gradient of 20 min was used. Then 
a 25 min post gradient isocratic flow with H2O-MeOH (5:95) was used 
before equilibration back to starting conditions in 5 min. To maintain a 
constant concentration of organic modifier in the HRS GST EAD 
system, a decreasing concentration gradient of organic modifier was 
mixed with the eluent from the HPLC column prior to the flow splitter. 
This gradient was as follows: 2 min at H2O- MeOH (3:1), a 
decreasing concentration gradient of organic modifier of 10 min to 
H2O- MeOH (100:0) and finally 25 min at H2O-MeOH (100:0). 
Equilibration was performed during 5 min. The H2O and MeOH of the 
counteracting post-column gradient both contained 500 mg/l Tween 
20. The concentration of MeOH in the eluent after addition of the 
compensating gradient was 20 % (v/v) with a constant flow rate of 
1000 μl/min. Different concentration ranges of compounds to be 
tested were prepared by serial dilution of compounds dissolved in 40 
% (v/v) MeOH and further diluted with mobile phase in the ratio 1:4.  
 
 197
On-line GST Enzyme Affinity Detection                                                   Chapter 7 
Microplate reader assays for GST affinity 
 
Microplate reader assays were used for optimization of the GST 
EAD systems in FIA and HLPC mode. The fluorescence of GSH-
bimane conjugate was measured at excitation and emission 
wavelengths of 390 nm and 465 nm, respectively, on a Victor2 1420 
multilabel counter (Wallac, Turku, Finland). Different concentrations 
of cGSTs or GST Pi, GSH and mono-chlorobimane were tested. 
Since blocking reagents and detergents may improve the resolution 
of the on-line EAD systems [32] and since organic modifiers are 
necessary for the gradient HPLC system, all of these parameters 
were varied for both cGSTs and for GST Pi. The experiments were 
carried out at 37 °C with well volumes of 150 μl potassium phosphate 
buffer (100 mM; pH 6.5). The enzymatic reactions were started by 
addition of 50 μl of GSH (30 mM). All measurements were done in 
quadruplicate. The initial linear increase in fluorescence upon 
reaction of mono-chlorobimane with GSH was a measure for the 
enzyme activity. The effect of varying GSH concentration was 
investigated for cGSTs and GST Pi at concentrations of 17 and 5 μg 
protein/ml, respectively, and a mono-chlorobimane concentration of 
50 μM. GSH concentrations tested were 0, 0.4, 1, 2, 4, 7, 14 and 27 
mM. Enzyme concentrations of 0.002 to 300 μg protein/ml cGSTs or 
GST Pi were examined. For mono-chlorobimane, concentrations of 5 
nM to 100 μM were investigated. The effect of organic modifiers, 
blocking reagents and detergents was tested under the following 
conditions: 14 μg protein/ml cGSTs or 6 μg protein/ml GST Pi, a 
mono-chlorobimane concentration of 22 μM for cGSTs or 88 μM for 
GST Pi, and a GSH concentration of 7 mM. The organic modifiers 
MeOH, MeCN and IPA were tested at final concentrations of 25, 12.5, 
6.3, 3.1, 1.6, 0.8, 0.4 and 0 % (v/v). The blocking reagents PEG3350, 
PEG6000, ELISA BB and BSA were tested at final concentrations of 
120, 60, 30, 15, 7, 3 and 1 mg/ml. The detergents Tween 20, Tween 
80, sodium cholate and saponin were tested at final concentrations of 
4, 2, 1, 0.5, 0.3, 0.1 and 0.05 mg/ml. The optimized parameters were 
finally used for both GST EAD systems. 
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Synthesis of a library of GST inhibitors 
 
A mixture of acrolein, cinnamaldehyde, crotonaldehyde and 
ethacrynic acid (at a concentration of 1000 μM) was reacted for 2 
hours with GSH (10 mM) in TRIS buffer (0.3 M; pH 9). The resulting 
GSH-conjugate library was directly injected in the GST EAD systems 
in gradient HPLC mode. 
 
 
Results 
 
The development and validation of a parallel Enzyme Affinity 
Detection (EAD) system consisting of a cGSTs and a GST Pi EAD 
system was the primary goal of this study. Figure 1 shows the final 
HRS configuration with the parallel GST EAD system coupled on-line 
to gradient HPLC (HRS GST EAD system). The experimental 
reaction conditions of the cGSTs and GST Pi EAD systems were first 
optimized with microplate reader based assays. Then, both GST EAD 
systems were validated in FIA and HPLC mode and finally the two 
GST EAD systems were coupled in parallel and on-line to gradient 
HPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Triplicate injections of ethacrynic acid in the cGSTs EAD 
system in FIA mode. Concentrations of 520, 260, 120, 60, 40, 20, 8 
and 4 μM of ethacrynic acid were injected sequentially at intervals of 
7 min. 
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Optimization of GST EAD conditions in microplate reader format 
 
Taking into account that the cofactor GSH can be rate limiting in 
the enzymatic conjugation of GSH to mono-chlorobimane, the 
minimal GSH concentration to obtain Vmax of the reactions was 
determined first. This concentration was found to be 7 mM for both 
cGSTs and for GST Pi. The optimal concentrations of substrate and 
enzyme were determined subsequently. The optimal enzyme 
concentrations were 6 μg protein/ml for cGSTs and 14 μg protein/ml 
for GST Pi. These values were a compromise between fluorescence 
S/N ratios obtained at these concentrations, the amount of enzyme 
used for screening and clogging of the detector cell at high enzyme 
concentrations. The mono-chlorobimane substrate concentration 
showed nice Michaelis-Menten kinetics both for cGSTs as for GST Pi. 
The apparent Km-values found for the cGSTs (Km = 22 μM) and GST 
Pi (Km = 88 μM,) were taken as optimal concentrations for the on-line 
GST EAD systems. GSTs and lipophilic compounds may in principle 
adsorb to the reaction coils, thus resulting in peak broadening. To 
reduce this type of adsorption, the effect of blocking reagents, 
detergents and organic modifiers on the enzyme activity of the cGSTs 
and GST Pi were tested. All blocking reagents tested (i.e. PEG3350 
and PEG6000, ELISA blocking reagent and BSA) showed a less than 
5 % decrease in enzyme activity upto 6 mg/ml. From the detergents 
tested at concentrations of 100-200 mg/l, sodium cholate and saponin 
decreased the enzymatic GST activity for more than 50 %. Tween 20 
and Tween 80 gave better results in terms of remaining enzyme 
activity. At 200-400 mg/l, a less than 5 % decrease in enzyme activity 
was observed for both cGSTs and GST Pi. Subsequently, the organic 
modifiers methanol (MeOH), acetonitrile (MeCN) and isopropylalcohol 
(IPA) were tested. Increasing organic modifier concentrations initially 
led to slightly increased fluorescent signals, with an optimum at 0.5 % 
for all organic modifiers tested. Higher concentrations of the organic 
modifiers decrease the enzyme activity. Organic modifier 
concentrations of 10 and 4 % MeOH (v/v) in the reaction coil, 
respectively, resulted in about 15 to 20 % loss in cGSTs and GST Pi 
activity. For IPA and MeCN, about the same percentages were found. 
Optimized conditions: The optimized conditions for the on-line 
GST EAD systems, derived from the above mentioned optimization 
process, were as follows: For cGSTs, superloop A contained 18 μg 
protein/ml cGSTs and 0.5 mg/ml PEG6000 in 100 mM potassium 
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phosphate buffer at pH 6.5 and superloop B contained 66 μM 
monochlorobimane, 0.5 mg/ml PEG6000 and 21 mM GSH in 100 mM 
potassium phosphate buffer at pH 6.5. For GST Pi, superloop A 
contained 42 μg protein/ml GST Pi and 0.5 mg/ml PEG6000 in 100 
mM potassium phosphate buffer at pH 6.5 and superloop B contained 
264 μM monochlorobimane, 0.5 mg/ml PEG6000 and 21 mM GSH in 
100 mM potassium phosphate buffer at pH 6.5. The H2O and MeOH 
of the counteracting post-column gradient both contained 500 mg/l 
Tween 20. 
 
Figure 3: IC50 concentration-response curves (means ± SD; n=3) 
obtained for different GST inhibitors upon measurement with the two 
GST EAD systems in FIA mode. (A) cGSTs EAD system. (B) GST Pi 
EAD system. 
 
 
The GST EAD systems in flow-injection analysis mode 
 
A basic property of both GST EAD systems is the continuous 
mixing of the enzymes (GSTs), non-fluorescent substrate (mono-
chlorobimane) and eluent from a carrier flow in the reaction coils 
(Figure 1). In the reaction coils, a continuous formation of GSH-
bimane conjugate [35] takes place, which is measured by 
fluorescence detection at the end of the reaction coil. When 
substrates or inhibitors of GSTs elute from the carrier solution (in FIA 
mode) or from a HPLC column (in HPLC mode), they cause a 
temporary decrease in the formation of fluorescent GSH-bimane 
conjugate. Both the cGSTs and the GST Pi EAD system were first 
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tested by cooling the reaction coils to 0°C. A reduced GST enzyme 
activity resulted in a decreased GSH-bimane conjugate formation and 
hence a lower baseline. After equilibration of the reaction coils to 
37°C, the baseline levels rose as a result of increased product 
formation due to increased enzyme activities. Injection of the inhibitor 
ethacrynic acid temporarily inhibited both enzyme activities as can be 
seen from the negative peaks on the baseline (Figure 2). Blank 
injections showed no significant changes in the baseline levels. 
Injections of ethacrynic acid with the reaction coils at 0°C gave no 
peaks at the baseline signal, thus proving that the fluorescence 
signals were GST enzyme and ethacrynic acid dependent and not 
caused by fluorescence quenching (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Superimposed GST EAD traces of acrolein injected at three 
different concentrations in the total HRS GST EAD system. (A) 
cGSTs EAD traces. (B) GST Pi EAD traces. 
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Variability 
 
Inter-day and intra-day variability of the cGSTs and the GST Pi 
EAD assays in FIA mode were determined as follows: Intra-day 
variability was determined by injecting ethacrynic acid (6 μM) in 
triplicate at 4 hour time intervals, under optimized conditions for each 
GST EAD system and without changing the content of the 
superloops. For inter-day variability, ethacrynic acid (6 μM) was 
injected daily, in triplicate for three days, with fresh solutions in the 
superloops each day. Intra-day and inter-day variability were found to 
be less than 3 % in the case of the cGSTs EAD system. For the GST 
Pi EAD system, the intra-day and inter-day variability were found to 
be less than 4 %.  
 
Validation of the cGSTs and GST Pi EAD systems 
 
Microplate reader assays for cGSTs and GST Pi inhibition: The 
cGSTs and GST Pi EAD systems FIA and HPLC-mode were 
validated by comparing IC50-values of several substrates and 
inhibitors with those obtained with the corresponding microplate 
reader assays. For this purpose, 8 test compounds were used, 
namely: ethacrynic acid, 2-chloro-5-nitrobenzaldehyde, 4-chloro-3-
dinitrobenzaldehyde, acrolein and the GSH-analogues DB1, DB2 
DB3 and DB4 (Table I). All 8 compounds resulted in sigmoidal 
concentration-response curves. To determine possible differences in 
their inhibitory properties, the compounds were measured under 
standard conditions (Setup 1) and under GST EAD conditions (Setup 
2).  
GST EAD systems in FIA mode: The performance of both GST 
EAD systems in FIA mode was evaluated using the same GST 
ligands and by comparing the results obtained with those of the 
microplate reader assays. The GST ligands were injected in triplicate 
in concentrations ranging from 0 to 100 % inhibition. A typical result, 
obtained with ethacrynic acid and the cGSTs EAD system in FIA 
mode, is shown in Figure 2. The total amount of ligand injected was 
used to calculate the maximum concentration in the reaction coil, in 
the same way as described by Kool et al [32]. The dilution factor was 
9 in the case of cGSTs EAD and 20 in the case of GST Pi EAD. 
Using these dilution factors, the IC50-values of the GST-ligands were 
calculated. 
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Table I: IC50-values of 9 GST inhibitors towards cGSTs and GST Pi 
as measured with the two GST EAD systems in FIA mode, in on-line 
HPLC mode and in two different microplate reader assay formats. EA 
= ethacrynic acid; 4-C-3-NB = 4-chloro-3-nitrobenzaldehyde; 2-C-5-
NB = 2-chloro-5-nitrobenzaldehyde; A = Acrolein; 2-C-5-NBN = 2-
chloro-5-nitrobenzonitrile; DB1-4 are synthetical GST inhibitors (see 
materials); ND = not determined. Setup 1 = with MeOH. Setup 2 = 
with MeOH, PEG6000 and Tween 20. 
 
 
Compound cGSTs GST Pi   
 
 FIA EAD 
system 
HPLC EAD 
system 
Microplate 
setup 1 
Micropla
te setup 
2 
FIA EAD 
system 
HPLC EAD 
system 
Microplate 
setup 1 
Microplate 
setup 2  
 IC50 (μM ± 
SEM; n=3) 
IC50 (μM ± 
SEM; n=2) 
IC50 (μM  ± 
SEM; n=4) 
IC50 (μM  
± SEM; 
n=4) 
IC50 (μM ± 
SEM; n=2) 
IC50 (μM ± 
SEM; n=2) 
IC50 (μM  ± 
SEM; n=4) 
IC50 (μM  ± 
SEM; n=4) 
EA    1.8 ± 0.4    0.8 ± 0.6   2.6 ± 1.0  1.6 ± 0.6   6.0 ± 2.9    3.6 ± 2.8   4.5 ± 1.8   4.1 ± 2.7 
2-C-3-NB  214 ± 15 194  ± 70 177 ± 54 201 ± 42 225 ± 96   112  ± 113   267 ± 101 258 ± 97 
2-C-3-NB 456  ± 73   202  ± 100   401 ± 103 356 ± 77  476  ± 206 268  ± 48 387 ± 89   301 ± 114 
A   558  ± 105   636  ± 573   701 ± 207 498 ± 238 988  ± 2900   570  ± 388   798 ± 301   912 ± 386 
DB1 15.7  ± 3.0   11  ± 10 ND ND   77  ± 116   70  ± 68 ND ND 
DB2   7.6  ± 3.0      6  ± 5.0   9.4 ± 4.8 13.2 ± 5.9 56  ± 19   40  ± 22   78 ± 34   67 ± 31 
DB3   8.6  ± 1.0    14  ± 8.0 10.3 ± 3.1 12.6 ± 4.9 1.5  ± 0.7   0.7  ± 0.5   0.6 ± 0.1   0.9 ± 0.3 
DB4    0.4 ± 0.1   0.3  ± 0.2   0.5 ± 0.1   0.4 ± 0.2 2.0  ± 0.6   2.6  ± 4.3   3.0 ± 1.1   3.2 ± 1.5 
2-C-3-NBN    193 ± 828    64  ± 40 ND ND ND ND ND ND 
 
The results of all 8 test compounds in terms of IC50-curves are 
shown in Figure 3. Table I lists all IC50-values obtained. 1-Chloro-
2,4-dinitrobenzene (CDNB), a commonly used substrate for GSTs 
[36], was also tested. CDNB, however, gave significant quenching of 
fluorescence at high concentrations (> 0.5 mM) and hence prevented 
the construction of accurate IC50 curves. For ethacrynic acid, 
detection limits (n = 3; S/N = 3) of 40 nM and 300 nM were obtained 
with the cGSTs and the GST Pi EAD systems in FIA mode, 
respectively.  
Total HRS GST EAD system: The same 8 ligands as tested in 
both GST EAD systems in FIA mode were also injected at 5 different 
concentrations on to the total HRS GST EAD system. The resulting 
IC50-values calculated in a similar way as described above are also 
presented in Table I. Representative superimposed chromatograms 
of different concentrations of one of the ligands, namely acrolein, are 
shown in Figure 4A (cGSTs) and 4B (GST Pi).  
Figure 5A (cGSTs) and 5B (GST Pi) show the corresponding 
GST EAD traces from a mixture of GST-ligands consisting of 
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pentanoic acid, 4-chloro-3-nitrophenyl ester, 4-chloro-3-nitrobenzoic 
acid butyl ester, 4-chloro-3-nitrobenzaldehyde, 2-chloro-5-
nitropyridine and acrolein. Similar chromatograms were obtained with 
a mixture containing 4-chloro-3-nitrobenzoic acid butyl ester, 2-
chloro-5-nitropyridine, acrolein, cinnamaldehyde, crotonaldehyde and 
ethacrynic acid (Figure 6A and 6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: GST EAD traces of a mixture of 5 compounds  injected in 
the total HRS GST EAD system. Injected compounds are: acrolein 
(4400 μM; 12.5 min), 2-chloro-5-nitropyridine (1000 μM; 24.0 min), 4-
chloro-3-nitrobenzaldehyde (1000 μM; 26.5 min), pentanoic acid 4-
chloro-3-nitrophenyl ester (100 μM; 27.0 min) and 4-chloro-3-nitro-
benzoic acid butyl ester (1500 μM; 33.0 min). (A) cGSTs EAD trace. 
(B) GST Pi EAD trace. 
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Using the present total HRS GST EAD system, it should also be 
possible to screen rapidly and systematically for specific GST Pi 
inhibitors in compound mixtures. To prove this concept, four GST 
inhibitors, one of which is known to be a specific GST Pi inhibitor [40, 
41], were combined and analyzed with the total HRS GST EAD 
system. The GST inhibitors, DB 1-4, together with their relative 
affinities as well as the resulting cGSTs and GST Pi EAD traces are 
given in Figure 7A and 7B, respectively. 
Screening of electrophilic compound libraries reacted with GSH: 
Since many GSH-conjugates inhibit GSTs, it can be envisioned that 
reaction of GSH or GSH-analogs with libraries of electrophilic 
compounds will result in new libraries of GST-inhibitors [42]. Such 
libraries could be screened with the total HRS GST EAD system for 
specific GST Pi inhibitors. This hypothesis was tested by reacting 
GSH at pH 9 with a compound library consisting of α,β-unsaturated 
carbonyl derivatives, which are all known GST substrates [4]. The 
resulting compound mixture, consisting of unreacted electrophiles 
and their corresponding GSH-conjugates, was analysed with the total 
HRS GST EAD system. Figure 8A shows the UV chromatograms of 
the library unreacted with GSH (top chromatogram) and reacted with 
GSH (bottom chromatogram). The corresponding cGSTs and GST Pi 
EAD traces are shown in Figure 8B and 8C, respectively. 
 
 
Discussion 
 
We have developed a gradient reversed phase HPLC-based 
post-column bio-affinity detection system suited for on-line and 
simultaneous separation and detection of non-selective cGST 
inhibitors and selective GST Pi inhibitors in mixtures (HRS GST EAD 
system; Figure 1). The concept is based on the inhibition of the 
enzymatic formation of a fluorescent GSH-conjugate. During the 
optimization of the fluorescence-based GST assay formats, it was 
shown that for cGSTs, increasing concentrations of organic modifiers 
decreased the fluorescent signals upon inhibition, probably as a 
result of enzyme denaturation. On the other hand, for GST Pi, 
increasing organic modifier concentrations initially led to slightly 
increased fluorescent signals upon inhibition, with maximum signals 
at 0.5 % for all organic modifiers tested. Higher concentrations of the 
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organic modifiers decreased the fluorescent signals upon inhibiton, 
probably due to reduced enzyme activity. Higher concentrations of 
organic modifier, however, do enable higher concentrations of 
inhibitory compounds to flow into the GST EAD systems and are 
essential to achieve good chromatographic separations on standard 
C18 columns. Higher concentrations of organic modifiers may also 
have beneficial effects on compound/enzyme adsorption to reacton 
coil walls [32]. In the present system, organic modifier concentrations 
of 10 and 4 % (v/v) in the reaction coil were found to be acceptable 
compromises for the cGSTs and GST Pi EAD system, respectively, 
resulting in about 15 to 20 % loss in enzyme activity. These 
percentages of organic modifier indicate that GSTs are rather stable 
towards the various organic modifiers compared to other enzymes 
used in HRS-technologies [31, 32].  
The IC50-values obtained with the microplate reader assays 
under the two different experimental conditions (Setup 1 and 2) were 
found to result in similar IC50-values (Table I). Therefore, the 
conditions necessarily to be used in the on-line GST EAD systems 
(Setup 2; i.e. with PEG6000, Tween 20 and organic modifier) were 
also expected to give similar results in terms of the GST-affinities as 
obtained in the microplate reader assay (Setup 1; without PEG6000, 
Tween 20 and organic modifier). The IC50-values obtained with both 
GST EAD systems in FIA mode were also in accordance with those 
obtained with the corresponding microplate reader assays. The IC50-
value of ethacrynic acid was also found to be similar with literature 
[43, 44]. The intra-day and inter-day variabilities of both GST EAD 
systems, both less than 4 %, are well within the range of previously 
reported on-line bio-analytical screening methods [34, 45]. The IC50-
values finally determined with the total HRS GST EAD system were 
also found to be in good agreement with those determined with the 
corresponding microplate reader assays. Apparently, the total HRS 
GST EAD system can be used for efficient and relatively sensitive on-
line determination of IC50-values of individual ligands to cGSTs and 
GST Pi in mixtures (Figure 2 and Table I).  
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Figure 6: GST EAD traces of a mixture of 6 compounds  injected in  
the total HRS GST EAD system. Injected compounds are: acrolein 
(3600 μM; 12.5 min), crotonaldehyde (2900 μM; 16.5 min), 2-chloro-
5-nitropyridine (2400 μM; 24.0 min), cinnumaldehyde (1500 μM; 26.5 
min), 4-chloro-3-nitro-benzoic acid butyl ester (300 μM; 33.0 min) and 
ethacrynic acid (300 μM; 38.5 min). (A) cGSTs EAD trace. (B) GST Pi 
EAD trace. 
 
 
Compared to other HRS-based systems, similar resolutions in 
terms of peak widths were obtained [30, 31]. The present total HRS 
GST EAD system did not show much peak broadening of eluting 
ligands, as was recently also seen with a HRS EAD system based on 
Cytochromes P450, i.e. membrane-bound enzymes [32]. This clearly 
showed the potential of the currently developed total HRS GST EAD 
system for the determination of affinities of substrates and inhibitors 
of cGSTs and GST Pi. The present total HRS GST EAD system is 
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relatively easy to handle and able to rapidly identify GST inhibitors in 
mixtures. It allowed for the separation and simultaneous screening for 
cGSTs and GST Pi affinities of individual GST inhibitors or substrates 
in mixtures.  
 
igure 7: GST EAD traces of a mixture of 4 compounds injected in 
m
 
 
F
the total HRS GST EAD system. Injected compounds are: DB1 (1400 
μM; 25 min; GST Pi -, GST Mu **, GST Alpha ***), DB2 (1000 μM; 29 
in; GST Pi ***, GST Mu ****, GST Alpha ****), DB3 (400 μM ; 31 
min; GST Pi *****, GST Mu *, GST Alpha *) and DB4 (400 μM; 37 
min; GST Pi **, GST Mu ****, GST Alpha ****). (A) cGSTs EAD trace. 
(B) GST Pi EAD trace. (Right of chromatograms) Structures of 4 
synthetical GST inhibitors, with different (relative) affinities to GST Pi 
and other GSTs. *** marks the relative affinities for the GSTs 
indicated. 
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With the present total HRS GST EAD system, it was also 
possi
on of mixtures of electrophilic compounds with GSH may 
result
ly 
and 
 
ble to identify specific GST Pi inhibitors amongst non-selective 
cGSTs ligands in mixtures, as was demonstrated with a mixture of 
known GST inhibitors, of which one (DB3) was specific for GST Pi 
(Figure 7). This conclusion, and the observed lack of selectivity of 
DB1, DB2 and DB4 for GST Pi, are in agreement with results found 
by D. Burg (Leiden, personal comunication) and with literature [40, 
41, 46, 47]. 
Reacti
 in new libraries or mixtures of GSH-conjugates with potentially 
interesting GST Pi specific inhibitors. This was demonstrated by 
screening of a mixture of a series of α,β-unsaturated carbonyl 
derivatives reacted with GSH, with the present total HRS GST EAD 
platform. The corresponding cGSTs (Figure 8B) and GST Pi EAD 
(Figure 8C) traces of the un-reacted and the reacted mixtures clearly 
showed that in the reacted mixture new, possibly interesting GST 
inhibitors were formed. It was also shown that the formed GSH-
conjugate of ethacrynic acid, eluting at 45 min., inhibited cGSTs to 
about the same extent as ethacrynic acid self, since both compounds 
were present in similar concentrations according to the UV-trace. This 
observation was previously also described in literature [43, 44, 46]. 
The present total HRS GST EAD system can relatively easi
rapidly be applied to screen mixtures or libraries for GST 
inhibitors, which may contain specific GST Pi inhibitors. It is 
concluded that the total HRS GST EAD system constitutes a valuable 
new bio-analytic tool for rapid, simultaneous and sensitive screening 
of mixtures for compounds with general cGSTs and/or specific GST 
Pi binding properties. Moreover, this technology allows the 
determination of IC50 values. 
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Figure 8: Superimposed UV and GST EAD chromatograms of 
mixtures of electrophilic compounds with and without prior reaction 
with GSH. -GSH chromatograms: before reaction with GSH. +GSH 
chromatograms: after reaction with GSH, resulting in formation of 
new GSH inhibiting compounds. (A) UV traces. (B) cGSTs EAD 
traces. (C) GST Pi EAD traces. Reacting electrophilic compounds 
are: acrolein (12.5 min), crotonaldehyde (18.0 min), cinnamaldehyde 
(32.0 min) and ethacrynic acid (48.5 min). EA = Ethacrynic Acid. 
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Conclusions 
 
We have developed a gradient reversed phase HPLC-based on 
post-column on-line bioaffinity detection system suited for 
simultaneous detection of individual cGST inhibitors and GST Pi 
inhibitors in mixtures. The on-line GST EAD systems in flow injection 
analysis (FIA) mode retain the potential to measure IC50-values as is 
the case in traditional microplate reader based GST assays. The 
IC50-values found with the GST EAD systems were similar to those 
found with the microplate reader assays. This also holds true when 
GST EAD systems were coupled on-line to gradient HPLC. In this 
case, the resulting HRS GST EAD system allowed for the screening 
for cGST and GST Pi affinity of individual GST ligands or substrates 
in mixtures. Because of this type of parallel screening, it is possible to 
identify specific GST Pi inhibitors in mixtures. This was demonstrated 
by HPLC separation and simultaneous post-column analysis of a 
mixture of 4 known GST inhibitors, of which one was very specific for 
GST Pi. Reaction of libraries or mixtures of electrophilic compounds 
with GSH may result in new libraries or mixtures of GSH-conjugates 
with potentially interesting GST Pi specific inhibitors. This was 
demonstrated by reaction of a series of α,β-unsaturated carbonyl 
derivatives with GSH. It is concluded that the novel GST EAD 
systems in gradient HPLC mode, i.e. total HRS GST EAD system, 
constitutes a valuable new bioanalytic tool for rapid and relatively 
sensitive screening of individual components in complex mixtures for 
GST inhibition in general and for GST Pi specific inhibitors.  
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Abstract 
 
Reactive oxygen species (ROS) are able to damage proteins, 
cause lipid peroxidation and react with DNA ultimately resulting in 
harmful effects. Antioxidants constitute one of the defense systems 
for the neutralization of pro-oxidants. Since pro-oxidants and 
antioxidants are found ubiquitously in nature, pro- and antioxidant 
effects of individual compounds and of mixtures receive much 
attention in scientific research. A major bottleneck in these studies, 
however, is the identification of the individual pro-oxidants and 
antioxidants in mixtures.  
Here, we describe the development and validation of an on-line 
post-column biochemical detection system for ROS producing 
compounds and antioxidants in mixtures. Inclusion of cytochrome 
P450’s and cytochrome P450 reductase allowed also the screening 
of compounds that need bioactivation to exert their ROS producing 
properties. This pro-oxidant and antioxidant detection system was on-
line integrated with gradient HPLC. The resulting High Resolution 
Screening technology was able to separate mixtures of ROS 
producing compounds and antioxidants to individually characterize 
them rapidly and sensitively. 
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Introduction 
 
The potentially toxic and beneficial properties of pro-oxidants 
and antioxidants make them subject of many studies. Pro-oxidants 
may represent a threat to health, whereas antioxidants may 
counteract these effects by scavenging pro-oxidants [1, 2]. 
Antioxidants are very important in industrial processes as well as in 
biological systems. They are known to possess anti-inflammatory [3], 
anti-cardiovascular disease [4], anti-neurogenerative [5] and 
anticancer properties [6]. Imbalances between pro-oxidants and 
antioxidants in favor of the pro-oxidants may result in oxidative stress, 
which in turn may result in oxidative damage [7] of cellular 
components in the form of lipid peroxidation, protein denaturation or 
DNA conjugation [8]. Oxidative stress has been associated with many 
diseases like cancer [6], post-ischemic and neural degradation [2], 
Parkinson’s and Alzheimer disease [5], AIDS [9], aging and 
cardiovascular diseases [4]. Metabolism of pro-oxidants by 
cytochrome P450’s is also an important process that can result 
Reactive Oxygen Species (ROS) formation [10, 11].  
Because antioxidants may neutralize the potentially harmful 
effects of direct pro-oxidants or pro-oxidants formed upon 
bioactivation, major focus has been directed to the synthesis of 
antioxidants, in some cases organ or tissue specific ones [12-14]. In 
addition, the food industry pays much attention on antioxidants in 
foods. Examples like phenols in tea [15] and fish oils [16], curcumin in 
curry [17] and flavanoids in plants [18] are only a few in the huge list 
of natural compounds that are studied for their positive, antioxidant 
based, effects. If pro-oxidant or antioxidant effects of natural extracts 
or synthetical compounds are investigated, normally batch assay 
formats are utilized [19-21]. Also on-line assays that measure either 
the pro-oxidant or antioxidant effects of compounds are described 
[22-24]. However, when with these techniques individual compounds 
in mixtures have to be analyzed for their pro-oxidant or antioxidant 
properties, cumbersome gradient HPLC separations have to take 
place before the purified compounds can be characterized. Moreover, 
care has to be taken that the purified compounds are not oxidized in 
air before analysis. One strategy to overcome this cumbersome 
process might be the use of High Resolution Screening (HRS), which 
stands for on-line post-column biodetection after HPLC separation. 
HRS methodologies, which screen individual compounds in mixtures 
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for affinity, have been developed for receptors (e.g. the estrogen 
receptor [25]), enzymes (e.g. cathepsin B [26] and Cytochrome 
P450s [27]) and antibodies (e.g. digoxin antibodies [28]). These HRS 
strategies have proven to be very useful in rapid profiling and 
identifying of the individual ligands in active mixtures, especially when 
HRS systems are run simultaneously with MS [29]. 
  
 
 
Scheme 1: Schematic representation of the biochemical assay 
principles. 
 
 
This paper presents the development and validation of a HRS-
based on-line post-column detection system for the detection of ROS 
producing compounds and on the other hand antioxidants in 
mixtures. This so-called pro-oxidant and antioxidant detection (PAD) 
system is based on the oxidation of 4-hydroxyphenylacetic acid 
(4HPAA) by H2O2 in the presence of  horseradish peroxidase (HRP) 
to a highly fluorescent dimer [30, 31]. Scheme 1 shows the general 
assay principles. H2O2 may be present as such or be formed from 
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superoxide anion radicals (resulting from ROS producing 
compounds) in the presence of super oxide dismutase (SOD). After 
optimization, the on-line detection system was validated with the well 
known ROS producing compounds paraquat, menadione and 
duroquinone and the antioxidants L-ascorbic acid and glutathione in 
Flow Injection Analysis (FIA) mode. Finally, the on-line PAD system 
was coupled to gradient HPLC and thus in HRS mode used to screen 
individual compounds in mixtures for their ROS producing and/or 
antioxidant properties. 
 
 
Experimental Section 
 
Materials 
 
L-ascorbic acid, L-glutathione (reduced; GSH) and 4-
hydroxyphenylacetic acid (4-HPAA) were purchased from Aldrich 
(Zwijndrecht, NL). Tween 20, menadione, polyethyleneglycol 6000 
(PEG6000), polyethyleneglycol 3350 (PEG3350), methylviologen 
(paraquat dichloride), peroxidase (horseradish, type I; HRP) and 
superoxide dismutase (from bovine erythrocytes; SOD) were 
purchased from Sigma (Zwijndrecht, NL). β-Nicotinamide adenine 
dinucleotide phosphate tetra sodium salt (NADPH) was from 
Applichem (Lokeren, B). Methanol (MeOH) and isopropanol (IPA) 
were purchased from Riedel de Haën (Seelze, D). Acetonitrile (ACN) 
was from Baker (Deventer, NL). The MeOH, ACN and IPA were of 
HPLC reagent grade. Rat liver microsomes (β-NF induced) were 
prepared as described elsewhere [32]. In short: livers from β-NF 
induced rats were homogenized at 4 °C in 2 volumes of 50 mM 
potassium phosphate buffer (pH 7.4) with 0.9% sodium chloride using 
a Potter-Elvehjem homogenizer. The homogenate was centrifuged for 
20 min at 12.000g, and the supernatant obtained was further 
centrifuged for 60 min at 100.000g. The resulting pellet was washed 
twice and subsequently resuspended in 50 mM potassium phosphate 
buffer (pH 7.4), 0.9% sodium chloride, and 25% glycerol and stored 
at -80 °C. Protein concentration in the microsomes was determined to 
be 13.1 mg/ml. 
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Instrumentation 
 
A Gilson 234 auto injector (Villiers-le-Bel, France) equipped 
with a Rheodyne (Bensheim, Germany) six-port injection valve 
(injection loop, 50 μl) was used for sample injections. A Knauer K-500 
HPLC pump (Berlin, Germany) was used for delivery of the injected 
samples into the on-line PAD system in FIA mode. Two Knauer K-
500 HPLC pumps were used for delivery of cofactors, substrate and 
enzymes by means of superloops (SL-A and SL-B) (50ml, 
Pharmacia), which were kept on ice, into the PAD system. Prior to 
detection by an Agilent 1100 (Waldbronn, Germany) series 
fluorescence detector (λex 320 nm; λem 409 nm), a knitted reaction 
coil (0.25 mm i.d.; 1.59 mm o.d.; internal volume of 75 μl) positioned 
in a Shimadzu CTO-10AC column oven (Duisburg, Germany), was 
used for the on-line enzymatic reaction. For reducing pulsing of the 
pumps, flow restrictors were inserted between the pumps and the 
superloops. The flow restrictors were made in a similar way as the 
ones used by Kool et al [27].  
 
Pro-oxidant and antioxidant assay optimization 
  
The initial optimization process of the biochemical assay for the 
PAD system was performed off-line on a Shimadzu RF-1501 
spectrofluorometer (λex 320 nm; λem 409 nm), before the biochemical 
assay was transferred to the on-line format for further optimization. All 
measurements were performed in triplicate at 37oC in quarts cuvettes 
with total volumes of 2 ml. Different concentrations of enzymes (rat 
liver microsomal cytochrome P450’s and cytochrome P450 
reductase, SOD and HRP), cofactor NADPH and 4-HPAA were 
tested. Blocking reagents and detergents (that may improve the 
resolution of the PAD system) [27] and organic modifiers (that are 
necessary when the PAD system is operated in on-line gradient 
HPLC mode), were investigated as well. For all experiments, 
potassium phosphate buffer (50 mM; pH 7.8) was used. Initial 
conditions were rat liver microsomes (50 μg/ml), NADPH (40 μM), 4-
HPAA (1 mM), SOD (10 U/ml) and HRP (10 U/ml). Reactions were 
started after 5 min. of pre-incubation with the addition of paraquat (70 
μM). Optimizations of the different parameters were conducted in the 
above mentioned order. The optimal (or compromised) concentration 
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of every parameter was subsequently used in the optimization of the 
next parameter. After the optimization process, the optimized 
conditions were used in the PAD system in FIA and HPLC mode. 
 
Pro-oxidant and antioxidant detection system in flow-injection 
analysis mode 
 
A schematic view of a similar on-line detection system as the 
PAD system in FIA mode is shown and described elsewhere [27]. 
The main difference between the PAD system in FIA mode and in 
HPLC mode is the replacement of a carrier solution used in FIA mode 
for a gradient reversed HPLC system. A general scheme of a PAD 
system coupled on-line to gradient reversed-phase HPLC (described 
in the next paragraph) is shown in Figure 1, which thus also shows 
the schematics of the PAD system in general. Continuous mixing of 
enzymes (cytochrome P450’s and cytochrome P450 reductase, HRP 
and SOD) from SL-A and cofactors/substrate (NADPH/4-HPAA) from 
SL-B with a carrier solution into a reaction coil is the basic property of 
the PAD system (in FIA mode). After mixing in a knitted reaction coil, 
ROS formed from pro-oxidant compounds (after cytochrome P450 / 
cytochrome P450 reductase mediated bioactivation) are converted by 
SOD to the relatively stable H2O2. Subsequently, the H2O2 dependent 
conversion of the non-fluorescent compound 4-HPAA to its 
fluorescent dimer by HRP yields a spectroscopic handle for efficient 
measurement of ROS formation. Thus, the ROS formed by eluting 
compounds give rise to a temporarily increased formation of 
fluorescent product, which is seen on the PAD system as a peak. If 
SL-B also contains a ROS producing compound, continuous 
oxidation of the 4-HPAA results in an elevated fluorescent baseline. 
In this situation, injection of antioxidants causes a temporary 
decrease in 4-HPAA oxidation and results in a negative peak on the 
PAD system. Thus, the system is sensitive towards ROS producing 
compounds as well as antioxidants. 
 
Liquid chromatography coupled to the pro-oxidant and 
antioxidant detection system  
 
A general scheme of a PAD system coupled on-line to gradient 
reversed-phase HPLC is shown in Figure 1. Gradient HPLC 
separations were performed using a 30 mm length × 2 mm i.d. 
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stainless-steel column (Phenomenex Luna 3μ C18(2)). If the PAD 
system was operated in HPLC mode, two pumps were used to 
control the LC-gradient and two pumps were used directly after the 
HPLC-column for compensation of the increasing concentration of 
organic modifier (during the gradient) before delivery of the effluent to 
the PAD system. The following gradient was used for the HPLC 
separations: an initial flow rate of 300 μl/min with a water:MeOH 
”decreasing flow rate” gradient as follows: 3 min at H2O:MeOH (95:5); 
a decreasing flow rate gradient of 6 min to 150 μl/min H2O:MeOH 
(5:95); 14 min at H2O:MeOH (5:95) with a flow rate of 150 μl/min.  
 
 
Figure 1: Schematic view of the PAD system in HPLC mode. 
Superloop-A (SL-A) and superloop-B (SL-B) are used to deliver 
enzymes and substrates to the reaction coil, respectively. ROS 
producing pro-oxidants and antioxidants are introduced into the 
system by a gradient reversed phase HPLC system. Antioxidants and 
ROS producing compounds temporarily change the formation of 
fluorescent product, which is monitored with a fluorescence (FLD) 
detector. After HPLC, the make-up pumps produce a counteracting 
gradient, resulting in a PAD compatible constant organic modifier 
concentration. The effluent is then split 1:9 (90% to UV detection and 
10% to CYP EAD). AS = autosampler. 
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Thereafter, the column was re-equilibrated again to the starting 
conditions in 5 min. To maintain a constant concentration of MeOH 
after the HPLC column, a second gradient with an increasing flow-
rate was included in the system, after HPLC separation, with an initial 
flow-rate of 700 μl/min H2O:MeOH (4:1) for 4.5 min. An increasing 
flow-rate gradient of 6 min to 850 μl/min H2O:MeOH (100:0) was then 
followed by a post gradient flow of 850 μl/min. H2O:MeOH (100:0) for 
14 min. Finally, re-equilibration to starting conditions occurred in 5 
min. The H2O and MeOH of the increasing flow-rate gradient 
contained 100 mg/L Tween 20. The final constant flow-rate was 1000 
μl/min. with a MeOH concentration of 15 % in H2O. This was 
connected to a T-piece and splitted 1/9 with a flow splitter. The 90% 
fraction was directed to the UV detector, while the 10% fraction was 
pumped into the PAD system. For HPLC analysis, all tested 
compound were dissolved in 30 % MeOH in water. 
 
  
Results and Discussion 
 
The primary aim of this study was the development and 
validation of a HRS-based on-line post-column detection system for 
the detection of ROS producing compounds and on the other hand 
antioxidants in mixtures. The biochemical assay is based on the 
oxidation of 4-hydroxyphenylacetic acid (4HPAA) to a highly 
fluorescent dimer (see Scheme 1). After optimization, the on-line 
detection system was validated with the well known ROS producing 
compounds paraquat, menadione and duroquinone and the 
antioxidants L-ascorbic acid and glutathione in Flow Injection 
Analysis (FIA) mode. Then, the on-line PAD system was coupled to 
gradient HPLC and thus in HRS mode used to screen individual 
compounds in mixtures for their ROS producing and/or antioxidant 
properties. 
 
Optimization of pro-oxidant and antioxidant detection assay 
 
The optimization process of the biochemical assay for the PAD 
system was conducted first in an off-line format before the optimized 
biochemical assay was transferred to the PAD system in FIA and 
HPLC mode. Paraquat was used as model ROS producing 
compound. The following parameters were optimized: enzyme 
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concentrations (rat liver microsomes, SOD and HRP), cofactor 
NADPH and substrate 4-HPAA, blocking reagents PEG3350 and 
PEG6000, the detergent Tween 20 (that may improve the resolution 
of the on-line PAD system) and organic modifiers (that are necessary 
when the on-line PAD system is operated in on-line gradient HPLC 
mode).  
First, the concentration of cytochrome P450s / cytochrome 
P450 reductase containing rat liver microsomes was evaluated. 
Insertion of this important, mainly hepatic, biotransformation system 
allows the reductive bioactivation of compounds that need to be 
bioactivated before exerting their ROS producing effects (e.g. 
paraquat [33]). For the liver microsomes, it was found that higher 
concentrations resulted in increased fluorescence signals up to at 
least 150 μg/ml (microsomal protein concentration). This is due to 
increased cytochrome P450’s / cytochrome P450 reductase mediated 
redox cycling [33]. Since the use of high concentrations of rat liver 
microsomes increased the risk of clogging on-line biochemical 
detection systems [27], a concentration of 50 μg/ml rat liver 
microsomes was used for further experiments. For SOD, 
concentrations higher than 14 U/ml did not increase the fluorescence 
signal significantly. Therefore, this SOD concentration was used 
further. For HRP, the same effect was observed at a concentration of 
18 U/ml, which was therefore used further. Increasing the 
concentration of 4-HPAA led to an increased formation of fluorescent 
dimer up to a concentration of 1.2 mM, after which the additional 
increase in sensitivity was counteracted by an increase in noise. A 4-
HPAA concentration of 1.2 mM was therefore used further. An 
NADPH concentration higher than 44 μM did not increase the assay 
performance significantly and was therefore used in the optimized 
conditions. For the polymers PEG3350 and PEG6000, concentrations 
up to 5 mg/ml did not show significant differences in assay 
performance. Since a PEG6000 concentration of 1 mg/ml was 
sufficient for reducing possible peak broadening in on-line 
biodetection systems [27], this concentration was used further. 
Detergents, such as Tween 20, can be used to prevent (membrane-
bound) enzymes from adhering to reaction coils in on-line 
biodetection systems, thereby resulting in less peak broadening [27]. 
Solubilization of membrane-bound enzymes, such as cytochrome 
P450’s, may occur at high detergent concentrations and will 
inactivate the microsomes under the present conditions. A Tween 20 
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concentration of 100-200 mg/l showed minimal (5-20%) enzyme 
denaturation. These Tween 20 concentrations are known to efficiently 
reduce peak broadening when used in cytochrome P450 containing 
on-line biodetection systems [27]. A Tween 20 concentration of 100 
mg/l was therefore used further. Organic modifiers may be useful in 
preventing enzymes and lipophilic compounds from adhering to the 
walls of reaction coils hence preventing peak broadening [27]. 
Moreover, when on-line biodetection systems are operated in HPLC 
mode, organic modifiers are automatically introduced via the HPLC 
gradient. When testing MeOH, ACN and IPA in the off-line 
biochemical assay format, they were tolerated up to concentrations of 
10%, resulting in approximately half the fluorescence signal 
compared to the use of no organic modifiers.  
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Figure 2: Triplicate injections of serial dilutions series (dilution factor 
of 4) of different compounds in the PAD system in FIA mode. (A): The 
pro-oxidant paraquat (starting with 1.0 mM) (B): The pro-oxidant 
menadione (starting with 0.15 mM) (C): The antioxidant ascorbic acid 
(starting with 1.0 mM) (D): The antioxidant glutathione (starting with 
25 mM). 
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From the above mentioned experiments in the off-line assay 
format, optimized conditions were derived and subsequently 
translated in the on-line PAD system in FIA mode. These final 
conditions were: A carrier solution consisting of 10% MeOH and 100 
mg/l Tween 20 at a flow rate of 100 μl/min, SL-A containing 
potassium phosphate buffer (50 mM; pH 7.8), rat liver microsomes 
(50 μg/ml), HRP (18 U/ml) and SOD (14 U/ml) and SL-B the same 
buffer containing PEG6000 (1 mg/ml), NADPH (44 μM) and 4-HPAA 
(1.2 mM). For continuous ROS production (resulting in a stable 
fluorescent baseline), paraquat was present in SL-B in a 
concentration of 0.036 mM. Both superloops had a flow-rate of 100 
μl/min. 
 
PAD system in flow-injection analysis mode 
 
Before coupling the on-line PAD system to gradient HPLC, it 
was first evaluated and validated in FIA mode. Evaluation of the PAD 
system was done with three well known model ROS producing 
compounds (i.e. paraquat, menadione and duroquinone) and two well 
known model antioxidants (L-ascorbic acid and glutathione). First, 
paraquat was injected in triplicate at different concentrations (10, 2.5, 
0.6, 0.15, 0.04, 0.01, 0 mM) in the PAD system in FIA mode. Figure 
2A shows the resulting signals. The highest concentration of paraquat 
resulted in fluorescence quenching. An analogous FIA trace for the 
redox cycling compound menadione is depicted in Figure 2B.  
 
 
Table I: Initial relative increases or decreases in fluorescence units 
(FU) of different ROS producing pro-oxidant compounds and 
antioxidants compared to paraquat for the PAD system in FIA mode, 
in gradient HPLC mode and for a traditional batch assay. The 
detection limits (Det. lim.) of the PAD system in FIA and HPLC mode 
are also given. 
Pro-
oxidant/ 
Antioxidant 
FIA PAD 
system 
(FU/mol ± SEM) 
Det. lim. FIA 
PAD system 
(nmol) 
HPLC PAD 
system 
(FU/mol ± SEM)
Det. lim. HPLC 
PAD system 
(nmol) 
Batch Assay 
setup 
(FU/mol ± SEM)
Paraquat   1,00 ± 0,08  0.07   1,00 ± 0,33 0.9   1,00 ± 0,05 
Menadione   1,55 ± 0,20  0.01   0,56 ± 0,01 0.4   1,60 ± 0,33 
Duroquinone   0,13 ± 0,02  0.04   0,36 ± 0,19 1.3   0,16 ± 0,07 
Glutathione  -2,20 ± 0,03 1.9  -0,67 ± 0,18 8.0  -1,01 ± 0,04 
Ascorbic acid  -4,58 ± 0,22 0.1  -1,35 ± 0,13 0.2  -1,22 ± 0,12 
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Figure 2C and 2D show the resulting PAD traces when L-
ascorbic acid and glutathione (well known antioxidants) were injected 
in triplicate in a dose-response manner, respectively. It was shown 
that ascorbic acid acted as a pro-oxidant compound at low 
concentrations (Figure 2C). Pro-oxidant effects of ascorbic acid at low 
concentrations were previously demonstrated by Abudu et al [34], 
who described that ascorbic acid can undergo one-electron reduction 
to form an ascorbyl radical. Ascorbic acid can also switch from an 
antioxidant into a pro-oxidant in the presence of transition metals [35]. 
The direct antioxidant effect of L-ascorbic was also shown with 
the PAD system (without paraquat in SL-B) by first injecting paraquat 
only followed by injection of a mixture of paraquat and L-ascorbic 
acid. Figure 3 shows that the addition of L-ascorbic acid neutralizes 
the ROS formed from paraquat. The same effect is shown for 
menadione (Figure 3). 
To determine effects of the test compounds paraquat, 
menadione, L-ascorbic acid and glutathione on the fluorescence 
baseline, injections of different concentrations of the test compounds 
were performed on the PAD system without HRP and SOD in SL-A. 
Menadione and duroquinone caused fluorescence signals when 
injected in concentrations larger then 0.8 and 0.4 mM, respectively.  
 
Figure 3: Injections (triplicates) of different compounds in the PAD 
system in FIA mode (without continuous addition of a pro-oxidant). : 
1) paraquat (0.05 mM); 2) paraquat (0.05 mM) and ascorbic acid (0.1 
mM); 3) menadione (0.03 mM); 4) menadione (0.03 mM) and 
ascorbic acid (0.1 mM). 
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This implicates that at these concentrations and higher, these 
compounds can only be measured efficiently if a parallel signal 
measuring their auto-fluorescence is used for subtraction from the 
PAD signal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: (A) Superimposed PAD traces of menadione injected in 
different amounts in the PAD system in HPLC mode (12.5, 50 and 
200 μM from bottom to top chromatogram, respectively). (B) 
Superimposed PAD traces of ascorbic acid injected in different 
amounts in the PAD system in HPLC mode (50, 200 and 800 μM 
from top to bottom chromatogram, respectively). 
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In order to determine the relative pro-oxidant or antioxidant 
effect of the compound, the fluorescence signals per mole of test 
compound were determined from the data obtained in the batch 
assay and the PAD system in FIA mode (Table I). When comparing 
the relative fluorescence signals per mole of test compound in both 
systems, it appeared that the relative fluorescence signals differ 
significantly for some compounds. This difference might be explained 
by the pre-incubation step, which was only performed for the batch 
assays and not for the on-line PAD measurements. In contrast, with 
both the off-line assay and the on-line PAD system formats, the 
measured pro-oxidant or antioxidant effects were similar for all test 
compounds. Therefore, it may be concluded that the off-line assay 
format can be transferred to the present PAD system for the 
screening of antioxidants and ROS producing compounds. 
 
Variability 
  
Inter-day and intra-day reproducibility were determined as 
follows: Intra-day variability was determined by injecting paraquat (0.2 
mM) in triplicate at 3.5 hour time intervals in the PAD system. The 
intra-day variability was determined without changing the content of 
the superloops. For inter-day reproducibility, paraquat (0.2 mM) was 
injected daily in triplicate for three days with fresh solutions in the 
superloops each day. Intra-day and inter-day reproducibility were 
both less than 5 %, which is within the range of bio-analytical 
screening methods [27, 29]. 
The sensitivities obtained for the different compounds, which 
are intrinsically also determined by their pro-oxidant or antioxidant 
potency, are indicated as well in Table I. These sensitivities were in 
the same order as those obtained with the batch assay format (data 
not shown). Thus, also in this respect the present PAD system is 
suited as a novel rapid screening tool in pro-oxidant and antioxidant 
activities of individual compounds in mixtures. 
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Figure 5: (A) PAD trace of a mixture of 3 pro-oxidants injected in the 
PAD system in HPLC mode (injected compounds are: paraquat (0.12 
mM; 3.5 min), menadion, (0.05 mM; 17.5 min) and duroquinone (0.17 
mM; 18.5 min).) (B) PAD trace of a mixture of 2 pro-oxidants and 2 
antioxidants injected in the PAD system in HPLC mode (injected 
compounds are: ascorbic acid (0.14 mM; 5 min), glutathione (0.4 mM; 
8 min), menadion, (0.05 mM; 17.5 min) and duroquinone (0.17 mM; 
18.5 min).) 
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On-line coupling of the PAD system to gradient HPLC 
 
The PAD system in gradient HPLC mode was evaluated by 
analysis of the five test compounds after HPLC separation. First, the 
individual test compounds were analyzed. The test compounds were 
injected (triplicates) in five different concentrations prepared by serial 
dilution of 100 μl stock solution with 300 μl MeOH (30 % v/v). Typical 
superimposed chromatograms of menadione and L-ascorbic acid are 
shown in Figure 4A and 4B, respectively. At high concentrations of L-
ascorbic acid, two peaks were seen. This was a result of overloading 
the analytical column as additional mass spectrometry data showed 
that both peaks were from L-ascorbic acid (data not shown). The 
relative pro-oxidant or antioxidant response of every test compound 
in the PAD system in gradient HPLC mode is shown in Table I. 
Sensitivities obtained for the test compounds are also depicted in 
Table I. When comparing the PAD system in HPLC mode with the 
PAD system in FIA mode and with the batch assays, similar trends 
are observed. It can be concluded that the PAD system in gradient 
HPLC mode can be used easily and sensitively for screening of 
individual compounds for their ROS producing capacity and 
antioxidant potential.  
The PAD system in HPLC mode was also used for the 
detection of individual antioxidants and ROS producing compounds in 
mixtures. Typical PAD traces of two different mixtures that were 
injected and separated on HPLC are shown in Figure 5A and 5B, 
respectively.  Figure 5A shows that all three ROS producing 
compounds, i.e. paraquat, menadione and duroquinone, were 
individually identified as oxidant species. The compounds in the 
second mixture, which contained two antioxidants and two ROS 
producing compounds, were individually identified as antioxidant, i.e. 
L-ascorbic acid and glutathione and pro-oxidant i.e. menadione and 
duroquinone. Thus, mixtures in which ROS producing compounds are 
present together with antioxidants could effectively be measured 
individually with the present PAD system in gradient HPLC mode. 
When analyzing such mixtures with traditional off-line batch assay 
formats, antioxidants can counteract the effects of pro-oxidants 
thereby reducing or even totally removing ability to detect the pro-
oxidants. The present PAD system in HPLC mode therefore opens 
new perspectives for the efficient and rapid screening of complex 
mixtures for individual pro-oxidant and antioxidant components. 
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Conclusion 
 
This paper presents the development and validation of a HRS-
based on-line post-column detection system for the detection of ROS 
producing compounds and on the other hand antioxidants in 
mixtures. Different parameters, such as substrate (4-HPAA) and 
enzyme concentrations, reaction time, temperature, additives and 
organic modifier concentrations were first optimized for the PAD 
system in FIA mode. Several ROS producing compounds as well as 
antioxidants were successfully measured with the optimized system. 
Intra-day and inter-day reproducibility of the PAD system in FIA mode 
were determined and both found to be lower than 5 %. Good 
sensitivities, at least comparable with similar off-line assay formats for 
individual compounds, were obtained. On-line coupling of the novel 
PAD system to gradient HPLC allowed screening of individual 
compounds in mixtures for ROS producing and antioxidant 
properties. This PAD system in gradient HPLC mode is of potentially 
great added value in drug discovery and toxicology and food 
research. 
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Summary 
 
Biotransformation enzymes play a crucial role in the metabolism of 
both endogenous compounds and xenobiotics. Usually, the detoxication 
of these compounds by biotransformation enzymes results in harmless 
metabolites, which are more readily excreted from the body due to their 
enhanced hydrophilicity. In some cases, however, biotransformation 
does not yield metabolites that are less toxic than the parent compounds 
but rather more toxic [1, 2]. Metabolites may be chemically reactive 
metabolites or intermediates that react with proteins, RNA or DNA or 
metabolites that show high affinity towards enzymes, receptors or other 
macromolecules [3]. Cytochromes P450 (CYPs) are the most important 
phase I metabolism enzymes and play a central role in oxidative 
metabolic reactions of drugs and other xenobiotics [4, 5]. Affinity of drugs 
and metabolites towards CYPs can result in unwanted drug-drug 
interactions (DDIs) at the level of drug metabolism. Phase II metabolism 
can also result in adverse drug reactions. The phase II metabolic 
enzymes, among which are the glucuronosyl transferases (UGTs), 
sulfotransferases (STs) and glutathione S-transferases (GSTs), add 
substituents to functional groups in compounds usually resulting in 
strongly increased hydrophilicity and facilitated excretion. Of these phase 
II metabolic enzymes, GSTs are the most important enzymes catalyzing 
the detoxication of electrophilic compounds by conjugation to glutathione 
(GSH) [6]. As metabolism of drugs can thus result in the formation of 
pharmacologically active, drug-drug interacting and/or reactive 
metabolites and metabolites causing toxicological effects, it renders them 
essential for early consideration in drug discovery and development 
programs [7]. The screening process of compounds often employs High 
Throughput Screening (HTS) methodologies [8]. However, most HTS-
methodologies used as yet do not allow the identification of individual 
ligands in mixtures. Mixtures have to be separated chromatographically 
before affinity screening of individual compounds can occur [9, 10].  
Several years ago, a novel on-line High Resolution Screening 
(HRS) concept was developed that enabled the identification of individual 
ligands in complex mixtures [11]. HRS is based on continuous-flow 
biochemical detection assays coupled on-line to HPLC. Until now, bio-
affinity detection systems have been described for e.g. the estrogen 
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receptor [12], phosphodiesterases [13, 14], acetylcholine esterases [15] 
and angiotensin converting enzymes [16]. This thesis describes the use 
of HRS for screening of biologically active metabolites and for screening 
CYP and GST affinity of individual compounds in mixtures. 
The general introduction (Chapter 1) of this thesis focuses on the 
background, applications and the present status of the HRS concept as 
well as on drug metabolism enzymes, bioactivation and receptor- and 
enzyme targets in drug discovery.  
 
Part I of this thesis deals with the development and validation of 
newly developed HRS-methodologies for the interaction of drugs and 
drug metabolites with CYPs.  
Part II describes the use of HRS-methodologies for estrogen 
receptor (ERα) affinity screening of individual metabolites in metabolic 
mixtures. Moreover, a CYP-containing bioreactor unit, developed in a 
concomitant with Van Liempd et al, was coupled on-line to HRS and 
used for fully automated generation and subsequent HRS screening of 
metabolic mixtures for ERα affinity. The automated HRS-technology 
allows the rapid and efficient monitoring of parent compounds as well as 
their metabolites in terms of metabolic stability and bioactivity. 
Part III of this thesis describes a novel HRS-methodology for the 
screening of affinities to GSH-S-Transferases (GSTs). Non-specific and 
specific GST ligands and substrates in mixtures could individually be 
detected with this HRS-methodology. Another important aspect of 
metabolism is the formation of reactive oxygen species (ROS) [17]. Part 
III also describes a HRS-methodology for the measurement of ROS 
resulting from individual compounds in mixtures. This HRS-methodology 
is capable of simultaneously identifying antioxidants in these mixtures. 
Part IV provides a summary and the conclusions of the work 
described in this thesis. Some future prospects are also given. 
 
 
Part I: High Resolution Screening of Cytochrome P450 affinities 
 
Chapter 2 deals with the development of a novel HRS-system with 
CYP bio-affinity detection coupled on-line to gradient reversed-phase 
HPLC. For this purpose, an Enzyme Affinity Detection (EAD) system was 
first optimized and validated with 7 known ligands of mammalian CYP1A 
enzymes in rat liver microsomes. IC50-values were subsequently 
determined both on-line in Flow Injection Analysis (FIA) mode and in 
gradient HPLC mode. Finally, the inhibitory properties of individual 
ligands in mixtures were screened with the HRS-CYP-EAD system. 
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Chapter 3 describes the development of three parallel CYP EAD 
detectors coupled on-line to gradient reversed-phase HPLC. The three 
EAD detectors systems, first developed and validated individually, 
contained β-naphthoflavone (induced CYP1A)-, phenobarbital (induced 
CYP2B)- and dexamethasone (induced CYP3A) rat liver microsomes, 
respectively. IC50 values of characteristic ligands towards each of the 
respective CYPs were measured and found to be similar to those 
obtained with conventional microplate reader assays. Detection limits of 
potent CYP inhibitors ranged from 1 - 3 pmol for CYP1A, 4 - 17 pmol for 
CYP2B, and 4 - 15 pmol for CYP3A isozymes of rat liver. Finally, a triple 
CYP EAD HRS-system was constructed in which the three different CYP 
EAD systems were coupled on-line, in parallel, to gradient HPLC. This 
system enabled rapid and simultaneous profiling of individual 
components in complex mixtures for inhibitory activity to the three 
different CYP isoenzymes. Although very sensitive and capable of 
identifying CYP inhibitors in mixtures, the rat liver microsomal fractions 
are not representative for the specificities of the human CYPs. These 
specificities can be obtained, however, when using heterologous 
expression systems for human CYPs. Therefore, Chapter 4 describes 
the development of two CYP EAD systems using human CYP1A2 and  -
2D6. Under optimized conditions, both CYP EAD systems were validated 
with known ligands. IC50 values obtained in FIA mode were well 
comparable with those measured in microplate reader formats. Detection 
limits of 0.4 - 1.0 pmol were obtained for potent CYP1A2 inhibitors and 
0.8 - 6.0 pmol for potent CYP2D6 inhibitors. Both EAD systems were 
finally connected to gradient HPLC and used to screen mixtures of 
compounds for the presence of CYP1A2 and -2D6 inhibitors. As an 
application, the on-line CYP2D6 EAD system was also connected to 
chiral HPLC to screen stereoisomers in a mixture of methylene-dioxy-
alkyl-amphetamines (XTC analogs) for inhibitory activity towards 
CYP2D6. It was found that the enantiomers of each analog have more or 
less the same inhibitory potency for CYP2D6. The chain-length of the N-
substituent, however, affected the affinity of the ligand giving higher 
inhibitory potencies with longer chain-lengths. 
 
Part II: Cytochrome P450 based bioactivation and High Resolution 
Screening of Estrogen Receptor binding metabolites 
 
For the demonstration of HRS-based metabolic profiling with off-
line bio-reaction, a HRS technology suited for the measurement of 
Estrogen Receptor-α (ERα) active compounds was used in Chapter 5 to 
screen affinity profiles of metabolic mixtures of the anti-breast cancer 
drug tamoxifen. Tamoxifen was used as a model compound because it is 
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metabolized by CYPs into multiple metabolites with known and unknown 
affinities for the ERα. Mass Spectrometry (MS) was used for parallel on-
line identification of metabolites. Rat and pig liver microsomal 
incubations were shown to produce at least 14 mono-, di- and tri-
oxygenated as well as N-demethylated tamoxifen metabolites. Relative 
rates of ERα-binding metabolite formation could rapidly and easily be 
determined. The affinities of most of the metabolites were at least as 
high as that of the parent tamoxifen. This study showed that in addition 
to the known metabolites of tamoxifen with affinity for the ERα, α-
hydroxytamoxifen, at least three di-oxygenated, two tri-oxygenated 
tamoxifen metabolites and one unidentified metabolite showed affinity for 
ERα. The generation, trapping and subsequent delivery of metabolic 
mixtures to HRS methodologies would allow an efficient way of 
screening parent compounds and their metabolites for biological activity 
in a rapid and fully automated manner. Therefore, in cooperation with 
Van Liempd et al, an integrated CYP-containing bioreactor was coupled 
on-line to the ERα affinity detection system in gradient HPLC mode. The 
complete system was used to metabolize, trap and subsequently screen 
metabolic mixtures of tamoxifen and raloxifen for ERα affinity. The 
results are described in Chapter 6 and show that the CYP-bioreactor on-
line integrated in a HRS-ERα screening system is able to provide 
simultaneous information on the time-dependent formation as well as on 
the ERα-affinity of CYP generated metabolites of tamoxifen and raloxifen 
in a fully automated manner. For raloxifen, six ERα-binding metabolites 
were identified of which three were not described before. The raloxifen 
metabolites included metabolites that were hydroxylated on the 
piperidine ring. 
 
Part III: High Resolution Screening methodologies for Glutathione 
S-Transferase inhibition and for pro- and antioxidants  
 
GSTs play an important role in the detoxication of electrophilic 
drugs, metabolites and other compounds. Therefore, metabolism by 
GSTs may increase or decrease the toxic potential of these compounds. 
In Chapter 7 we investigated the on-line post-column biochemical 
detection of GST inhibitors in complex mixtures. More specifically, the 
parallel coupling of two EAD systems for substrates and inhibitors of 
mammalian cytosolic GSTs and purified GST Pi to gradient HPLC was 
developed. The cGST and GST Pi EAD systems were optimized first in 
FIA mode and subsequently on-line with 9 known cGST and GST Pi 
ligands. IC50-values were compared with those obtained with microplate 
reader assays and found to be in accordance. For the high affinity ligand 
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ethacrynic acid, IC50-values of 1.8 ± 0.4 μM and 6.0 ± 2.9 μM were 
obtained with the cGST and the GST Pi EAD system in FIA mode, 
respectively. A parallel GST EAD system in HPLC mode, consisting of 
both a cGST and a GST Pi EAD system, was successfully used to 
screen individual compounds in mixtures for affinities for cGSTs and 
GST Pi. It was concluded that the novel parallel cGST/GST Pi EAD 
system in HPLC mode constitutes a valuable new bio-analytical tool for 
rapid and sensitive screening of individual components in complex 
mixtures for GST inhibition in general and for GST Pi specific inhibitors. 
In Chapter 8, the HRS technology was applied to the detection of 
reactive oxygen species (ROS) producing compounds and antioxidants 
in mixtures. The inclusion of a CYP biotransformation system allowed the 
screening of compounds that need to be bioactivated in order to produce 
ROS. The ROS detection method developed is based on the continuous 
on-line oxidation of 4-hydroxyphenylacetic acid into its fluorescent dimer 
by H2O2 and horseradish peroxidase. While eluting antioxidants 
temporarily reduce this oxidative dimerisation, ROS producing 
compounds increase this process. We were able to separate mixtures of 
antioxidants and ROS producing compounds and to detect them 
individually and on-line. This detection methodology is thus of added 
value in drug discovery and toxicology and possibly also in food research 
for rapid screening of metabolic mixtures and food extracts. 
 
 
Conclusions 
 
The primary aim of this thesis was the development and evaluation 
of the HRS-concept as possible new screening technology i) for 
compounds in mixtures with affinity towards biotransformation enzymes 
(CYPs and GSTs)  ii) for bioactive metabolites in metabolic mixtures and 
iii) for ROS producing compounds and antioxidants. In most of these 
applications, novel on-line biochemical detection systems had to be 
developed. 
 
The High Resolution Screening concept for screening metabolic 
enzyme inhibition 
 
The on-line coupling of a novel CYP enzyme affinity detection 
(EAD) system to gradient HPLC enabled for the first time CYP affinity 
screening of individual compounds in mixtures. Laborious preparative 
HPLC separation of compounds from mixtures and then followed by 
microplate reader based bioassays of the individual compounds [9, 10] 
can now be replaced by a single run with HRS coupled to an on-line CYP 
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EAD system. In contrast to previous on-line HRS-assays, novel methods 
were employed to prevent band broadening and to obtain stable 
baselines for longer time periods. By a parallelized configuration of 
different CYP EAD systems, a HRS-methodology was devised which is 
capable of simultaneous affinity screening of individual compounds in 
mixtures towards a panel of up to three relevant CYPs. In contrast to 
previously developed HTS-methodologies [18, 19] and fluorescence- or 
MS–based systems [20-22], the present HRS-methodology is able to 
screen for individual compounds in mixtures against a panel of relevant 
CYPs. By using HRS-CYP EAD systems containing human CYPs, the 
measurement of affinities of individual compounds (e.g. metabolites) in 
mixtures towards these human CYPs was achieved. This can be of 
significant value in the drug discovery and development area in general 
and in the lead finding and lead optimization process specifically [23]. 
Lower resolutions obtained with the CYP2A, -3A and -2D6 EAD systems 
as compared to the CYP1A and 1A2 EAD systems are due to a lower 
rate of formation of fluorescent product by the latter CYP EAD systems. 
Rapid formation of fluorescent product, as is seen for the CYP1A and -
1A2 EAD systems as described in Chapter 2 and 3, results in HRS assay 
formats with high resolution. As a consequence, the latter assays are 
usually a good alternative in terms of speed and resolution compared to 
their HTS counterparts [20, 24, 25] used after chromatographic 
separation. However, when the rate of formation of fluorescent product in 
CYP EAD systems is lower, the resolution of detected CYP inhibitors 
also declines as longer reaction times are needed to create sufficient 
signal to noise ratios. Increasing the CYP concentration in these cases is 
usually not an option as this results in clogging of the reaction coils, 
which results in increased tailing of eluting compounds and instable 
baselines. Moreover, this also results in more costly assay systems 
when human (expressed) CYPs are used. Addition of different additives 
to reduce tailing effects and clogging of the systems might be used [26, 
27], but usually at the cost of enzyme stability. Recently developed MS 
based pulsed ultrafiltration assays [19, 28] might also be implemented 
after HPLC in a similar way as done with the present HRS technologies, 
but similar problems (like enzyme stability, tailing effects and resolution) 
will probably be encountered. As these factors are common for HRS 
methodologies, enzymatic or receptor based HRS systems giving rapid 
and sensitive responses [16, 29] are essential for HRS systems to be 
competitive with HTS systems. Less stable and/or complex enzyme or 
receptor systems are therefore usually less suitable for HRS 
applications. An example of an enzyme system that is cumbersome to be 
used in HRS methodologies concerns protein kinases as their rate of 
product formation is usually very low [30-32]. HTS assay formats for 
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kinases therefore commonly employ very long incubation times, which is 
not an option for HRS systems.  
In addition to the present HRS methodologies for screening CYP 
interactions, GST interaction screening with similar methodologies can 
aid the drug discovery and development process as well. Since GSTs 
scavenge reactive intermediates and electrophilic compounds, HRS-GST 
EAD methodologies might find use in identifying glutathione-conjugates 
and electrophilic compounds in mixtures. The development of a parallel 
HRS-GST EAD methodology also allowed the screening for iso-enzyme 
specific GST inhibitors in mixtures. Therefore, the HRS methodology can 
also be of great advantage in the search for specific GST Pi inhibitors 
[33] that might find their way as chemotherapy assisting drugs [34]. One 
of the problems of the HRS-GST EAD methodology is the severe tailing 
of apolar compounds that elute at higher concentrations of organic 
modifier (see Chapter 7). This is probably caused by precipitation of 
apolar compounds after mixing the post-column, counteracting gradient 
to reduce the organic modifier concentration. However, compounds with 
affinity that elute shortly after each other appear superimposed and can 
still be distinguished (see Chapter 3 and 5). For HTS approaches, tailing 
effects in the collected fractions are smaller as post-column 
counteracting gradients are not applied. The lowered solubility of apolar 
compounds in HRS assays as compared to HTS assays that result in 
tailing and in lower compound concentrations in the assays, however, is 
counteracted by the possibility to identify compounds with affinity on 
fluctuating baselines as eluting compounds with affinity are measured 
directly on-line on the fluctuating baselines [26, 35]. Other 
methodologies, like high temperature liquid chromatography (HTLC) or 
size exclusion chromatography (SEC) can be used to reduce organic 
modifier concentrations, but the resolutions obtained are still inferior as 
compared to HPLC [36, 37]. For HTLC, precipitation of apolar 
compounds after cooling down the eluent before HRS analysis might still 
be a problem. 
 
High Resolution Screening as a new screening concept for 
metabolic profiling 
 
Metabolites of drugs may have pharmacological and/or 
toxicological properties. Therefore, it is not only important to identify the 
pharmacological and toxicological properties of the parent compounds, 
but also of the metabolites formed. Most receptor affinity screening 
technologies [38, 39] do only allow screening of the combined affinity of 
all compounds in mixtures. Several reported receptor affinity screening 
strategies concern the binding of active metabolites to receptors followed 
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by off-line centrifugal ultrafiltration to release the active metabolites [40, 
41], but they are usually not capable of detecting low affinity compounds 
in the presence of high affinity compounds. In this thesis, a successful 
HRS-methodology was used to demonstrate on-line ERα affinity 
screening and MS identification of individual metabolites in metabolic 
mixtures of a model drug like tamoxifen. It must be stated, however, that 
ERα-affinity responses can be measured very rapidly due to fast 
receptor-ligand kinetics hence resulting in a successful HRS 
methodology [26]. Apart from the items discussed above for the CYP and 
GST EAD systems, a low stability of enzymes or receptors towards 
organic modifiers used may render them less suitable for HRS purposes. 
In this regard, one can think of GPCRs, which need very delicate assay 
formats [42] that prevent loss of activity due to receptor destruction or 
solubilisation from membranes or functional (cell-based) assay formats 
that are more informative than primary screens, but are also more 
cumbersome [43]. Moreover, for many primary screens suitable 
fluorescent ligands are needed that show fluorescence enhancement in 
binding sites and not in surrounding membranes or fluorescent ligands 
that only interact with binding sites and not with surrounding membranes 
(for e.g. fluorescence polarization measurements [44]). As organic 
modifiers (methanol or acetonitrile) are often needed for the HPLC 
separations of HRS systems, these organic modifiers are consequently 
introduced in the HRS assays and may cause problems with unstable 
enzymes or receptors. In HTS assay formats, in contrast, separated 
fractions are usually concentrated and subsequently dissolved in enzyme 
and receptor friendly solvents, such as DMSO. As DMSO is generally 
more compatible with bioassays in terms of enzyme or receptor stability, 
it allows longer reaction times with functional enzymes and receptors 
thus resulting in higher signal to noise ratios and sensitivities. Alternative 
fluorescent ligands with high affinity or probe substrates with high 
conversion rates into highly fluorescent products and/or purified enzymes 
or receptors, however, can make HRS methodologies                   
with unstable enzymes or receptors feasible.  
The production of metabolite mixtures often impels procedures for 
incubation of compounds and subsequent extraction and isolation of 
metabolites, which is a very elaborate and cumbersome process [45]. An 
on-line bioreactor coupled to solid-phase extraction and HPLC, as 
developed by Van Liempd et al [46], may therefore be very useful. By on-
line coupling of a CYP bioreactor to the ERα-HRS technology, it was 
shown that this fully automated and rapid system is capable of 
generating metabolites that are individually screened on-line for ERα 
affinity. When comparing this successful fully automated on-line system 
to off-line strategies commonly used nowadays [45], it must be noted that 
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the latter systems are usually better suited for handling large numbers of 
samples. They can metabolize samples in 96 to 1536 well formats 
followed by automatic SPE cleanup of the metabolites, finally followed by 
introduction into separation methodologies like HPLC for further 
processing and metabolite identification [47]. The main advantage of the 
currently developed CYP-bioreactor coupled to HRS (Chapter 6) lies in 
small numbers of fully automated studies towards metabolic profiling of 
minor amounts of drugs and xenobiotics [48]. The CYP-bioreactor is an 
easily implantable, robust and cheap system which can automatically 
generate metabolic mixtures with a high sensitivity and reproducibility 
and the system is very versatile. In principle, the CYP-bioreactor and 
SPE collection unit can also be coupled to other chromatographic and 
spectrometric detection systems (e.g. MS) and is thus a good candidate 
system for more universal applications in drug development studies 
aiming at the metabolism of lead compounds as well as their active 
metabolites. It thus shows very interesting perspectives for metabolic 
profiling compared to methodologies nowadays commonly used [9].  
   
High Resolution Screening as a screening technology for pro- and 
antioxidants 
 
With the development of a HRS-methodology for ROS-producing 
compounds and antioxidants, the rapid screening of such compounds in 
mixtures can be performed in a single run. ROS-producing compounds, 
sometimes generated upon bio-activation, are generally regarded as 
hazardous compounds. As the products of ROS-producing compounds 
can react with antioxidants in the same mixtures, false negatives might 
result from traditional batch assays [49, 50] usually conducted with 
mixtures. In principle, on-line HPLC-based assays that measure 
individual antioxidants in mixtures already exist [51, 52], however, these 
assays are not suited for the simultaneous screening of both pro-
oxidants and antioxidants in mixtures. The currently developed HRS 
methodology is capable of detecting the individual pro-oxidants and 
antioxidants in complex mixtures and moreover it can utilize a CYP 
bioactivation system, which also allows the measurement of compounds 
that need to be bioactivated to exert their pro-oxidant effects. Therefore, 
this novel HRS methodology is of added value to drug discovery and 
development and food research by screening e.g. metabolic mixtures or 
food extracts for such properties. 
To summarize, the results presented in this thesis clearly show the 
excellent potential of the HRS technology for screening of individual 
compounds and metabolites in complex mixtures with affinity towards 
relevant metabolic enzymes (e.g. CYPs and GSTs). This can facilitate 
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the rapid and efficient screening of affinities towards these enzymes in 
drug discovery and development. Moreover, the screening of active 
metabolites in metabolic mixtures together with prior (i.e. off-line and on-
line) generation of these mixtures can be used efficiently in HRS format 
and allows active metabolite profiling in a rapid and sensitive way. 
Finally, the HRS-methodology for screening ROS and antioxidants in 
mixtures is of added value in drug discovery, in toxicology and in food 
research as individual compounds in mixtures can be measured for their 
ROS producing and/or antioxidant properties in a single analysis. 
 
 
Future prospects  
 
In order to cope with state of the art separation technologies, 
efficient sample pre-fractionation, clean-up and concentration is needed 
prior to analysis with HRS-methodologies. For this purpose, the HRS-
methodologies must also be adapted to these separation technologies. 
Only then complex samples can successfully be transferred to modern 
separation techniques which are nowadays more and more miniaturized 
[53, 54]. Thus, novel on-line and at-line pre-fractionation, concentration 
and clean-up technologies (such as SPE or IEF) that are suitable for 
hyphenation to modern separation techniques like microLC, nanoLC and 
UPLC could further be employed with the current HRS methodologies 
developed for small molecules. When bioactive peptides are to be 
analyzed, multidimensional LC, CE and CIEF may be used for 
separation together with the necessary sample pre-treatment steps [55, 
56] prior to connection to miniaturized HRS formats and (MS based) 
identification technologies. The coupling of miniaturized on-line 
bioassays to these separation technologies to create miniaturized HRS 
formats, however, is still a great challenge. As successful on-line 
coupling of biochemical assays to separation technologies with very high 
analysis speed and resolution demands extensive miniaturization, the 
concomitant fluorescence detection technologies must also be adapted, 
miniaturized and integrated. Other fluorescence (e.g. confocal 
spectroscopy [57] and laser induced fluorescence [58]) as well as some 
MS technologies are still to be examined for their suitability as detection 
systems for HRS formats. The on-line coupling of bioassay formats to 
modern separation technologies and their miniaturization is not the only 
issue, but also the coupling of bioanalysis methodologies that are difficult 
to couple in such a way. Enzymes with slow reaction kinetics, unstable 
enzymes or receptors, receptors with complex characteristics, receptors 
with intrinsically low affinities or slow on/off kinetics, and bioassay 
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systems in which only low concentrations of enzyme or receptor are 
available, often result in bioassays that will be difficult to couple in HRS 
formats. For this, however, chip-based on-line bioanalysis and in some 
cases semi-on-line or even at-line technologies could be examined 
instead [59-61]. The latter technologies could overcome problems such 
as slow bioreaction parameters, active compound concentration 
problems, loss of resolution after prolonged post-column reaction times 
and destruction of target proteins. Moreover, the chip-based or semi-on-
line approaches could reduce the amount of very expensive target 
proteins needed and could also allow access to cell-based assay formats 
used to screen for second messengers or other functional responses in 
signal transduction cascades, which are often more relevant than the 
measurement of the initial interactors, but more cumbersome and time 
costly to measure.  
 
In conclusion, the results presented in this thesis clearly show the 
excellent potential of HRS for metabolic profiling, i.e. affinity screening of 
individual compounds and metabolites in complex mixtures towards 
relevant metabolic enzymes and pharmaceutical targets. This may be of 
great importance to drug discovery, drug development, drug safety 
assessment and other areas, such as food research, in which bioactive 
compounds (often in mixtures) are of importance. With the development 
and incorporation of above mentioned methodologies and 
miniaturization, HRS might become one of the key screening 
technologies in these areas of research. 
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Hoge Resolutie Screening (HRS) van biologisch 
actieve verbindingen en metabolieten 
 
 
Biotransformatie enzymen spelen een cruciale rol in het 
metabolisme van zowel lichaamseigen als lichaamsvreemde 
verbindingen. Normaal gesproken levert biotransformatie van 
verbindingen door deze enzymen minder schadelijke stoffen op die door 
hun verhoogde wateroplosbaarheid vervolgens makkelijker 
uitgescheiden kunnen worden. In sommige gevallen echter levert 
biotransformatie metabolieten op die schadelijker zijn dan hun 
moederverbindingen. Hetzelfde geldt voor geneesmiddelen. 
Geneesmiddelen kunnen geactiveerd worden tot toxische reactieve 
metabolieten die irreversibel kunnen reageren met eiwitten, RNA of 
DNA, maar kunnen ook geactiveerd worden tot farmacologisch actieve 
metabolieten die reversibele affiniteit vertonen voor enzymen, receptoren 
of andere macromoleculen. Hoge affiniteit van geneesmiddelen of hun 
metabolieten voor de Cytochrome P450 enzymen (CYPs) kan resulteren 
in gevaarlijke geneesmiddel-geneesmiddel interacties, ook wel drug-drug 
interacties (DDIs) genaamd. De CYPs spelen een centrale rol in fase I 
metabolisme reacties van geneesmiddelen en andere exogene 
verbindingen. De potentiële farmacologische en toxicologische effecten 
als gevolg van metabolisme maken het noodzakelijk dat ze in een zeer 
vroeg stadium van medicijnontwikkeling onderzocht moeten worden op 
hun potentiële positieve of negatieve effecten. Fase II metabole 
enzymen, waartoe Glutathion S-transferases (GSTs), Glucuronyl-
transferases (GTs) en Sulfo-transferaces (STs) behoren, koppelen 
lichaamseigen functionele groepen toe aan de verbindingen, hetgeen 
gewoonlijk resulteert in metabolieten met een verhoogde hydrofiliciteit 
ten opzichte van hun moederverbindingen en in een gefaciliteerde 
uitscheiding. De GSTs katalyseren de conjugatie van electrofiele 
verbindingen met Glutathion (GSH) en zijn daarom belangrijke enzymen 
voor de detoxificatie van dergelijke stoffen. 
Voor het screenen van mengsels van stoffen, zoals 
synthesemengsels en extracten van planten, op affiniteit of activiteit voor 
farmaceutisch relevante enzymen of receptoren, worden vaak “High 
Throughput Screening” (HTS) screenings-technieken gebruikt. De 
meeste HTS technieken hebben echter als groot nadeel dat ze niet in 
staat zijn om de individuele actieve stoffen te identificeren in mengsels 
van stoffen waarin activiteit gevonden is. Hiervoor moeten de individuele 
verbindingen in het mengsel allereerst (meestal chromatografisch) 
gescheiden worden, waarna een her-screening van de gescheiden 
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individuele stoffen uit het mengsel plaats vindt. Een aantal jaren geleden 
echter is een nieuw concept genaamd Hoge Resolutie Screenen (HRS) 
gelanceerd, waarin een chromatografische scheiding direct gekoppeld 
wordt aan een activiteit-assay voor een relevant farmaceutisch enzym of 
receptor. Met deze HRS-technologie is het mogelijk geworden om de 
individuele actieve verbindingen in complexe mengsels te identificeren. 
Inmiddels zijn er HRS-methodologiën ontwikkeld voor bijvoorbeeld de 
estrogene receptor, fosfodiesterases, acetylcholine esterases en 
angiotensine converterende enzymen.  
Aangezien het bij de ontwikkeling van nieuwe geneesmiddelen erg 
belangrijk is om snel de farmacologisch of toxicologisch relevante 
metabolieten met affiniteit voor relevante enzymen en receptoren te 
achterhalen, staat in dit proefschrift onderzoek naar de toepasbaarheid 
van de HRS-technologie voor het screenen van actieve metabolieten in 
complexe mengsels van stoffen centraal. Ook is onderzoek gedaan naar 
methoden voor snelle en geautomatiseerde vorming van 
metabolietmengsels en naar methodes om deze vervolgens at-line aan 
te sluiten op HRS screeningsmethoden voor deze metabolietmengsels. 
Verder hebben we HRS methoden ontwikkeld voor het screenen van 
individuele verbindingen in mengsels die affiniteit vertonen voor 
verschillende metabole enzymen, met name de CYPs en de GSTs. 
Hierdoor kunnen potentiële DDI verbindingen (en andere stoffen die met 
deze enzymen interfereren) opgespoord worden. Ook is er gekeken naar 
HRS systemen om pro-oxidanten en anti-oxidanten in mengsels op te 
kunnen sporen. Pro-oxidanten kunnen schadelijke effecten vertonen in 
het lichaam, terwijl anti-oxidanten deze effecten weg kunnen vangen. 
Behalve voor de farmaceutische industrie kunnen de in dit proefschrift 
beschreven HRS-methodologiën ook gebruikt worden voor 
milieuonderzoek en in de voedingsindustrie. 
 
De algemene introductie van dit proefschrift behandelt 
metabolisme enzymen, farmacologisch relevante enzymen en 
receptoren, bio-activering en bio-inactivering, en het HRS-concept. Deel 
I van het proefschrift gaat vervolgens in op de ontwikkeling en validatie 
van HRS methodologiën om interacties van individuele verbindingen in 
mengsels met CYPs te kunnen screenen. CYPs zijn verreweg de 
belangrijkste biotransformatie enzymen voor geneesmiddelen. Deel II 
behandelt het screenen van complexe metabole mengsels op affiniteit 
voor de estrogene receptor. Bovendien wordt in dit deel een volledig 
geautomatiseerde biokatalyse unit beschreven die geschikt is om 
metabole mengsels van geneesmiddelen te genereren en direct te 
koppelen aan HRS-methodologiën. Hierdoor kunnen on-line 
gegenereerde metabolieten snel en efficiënt gescreend worden op 
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mogelijke bioaffiniteit voor relevante farmaceutische target enzymen of 
receptoren. Deel III van dit proefschrift beschrijft een HRS methodologie 
om snel en efficient individuele GST liganden en substraten in mengsels 
te identificeren. Een ander mogelijk belangrijk gevolg van 
biotransformatie door CYPs is de vorming van reactieve zuurstof 
intermediaren tijdens het metabolisme van endogene en exogene 
verbindingen. Deel III van dit proefschrift beschrijft ook een HRS 
methode om verbindingen die reactieve zuurstof intermediaren kunnen 
genereren op te sporen. Deze HRS methode is niet alleen geschikt om 
dergelijke pro-oxidanten aan te tonen, maar ook om anti-oxidanten te 
detecteren. De ontwikkelde HRS methodologie is speciaal geschikt om 
dergelijke verbindingen individueel aan te tonen in mengsels van stoffen. 
In Deel IV van het proefschrift staan een samenvatting alsmede de 
algemene conclusies en een toekomst visie. 
 
Al met al geven de resultaten in dit proefschrift de uitstekende 
mogelijkheden van HRS aan voor het screenen van verbindingen in 
mengsels die affiniteit vertonen voor metabole enzymen. Dit is van 
essentieel belang om potentiële DDI verbindingen op te sporen, die 
negatieve bijwerkingen van geneesmiddelen kunnen veroorzaken. Ook 
is duidelijk aangetoond dat HRS een zeer goede techniek is voor het 
screenen van actieve metabolieten in metabole mengsels. Deze 
bevindingen kunnen van groot belang zijn bij de ontwikkeling van 
medicijnen, onderzoek naar de veiligheid van medicijnen en in 
voedselonderzoek, waarbij bioactieve verbindingen (vaak aanwezig in 
mengsels) een belangrijke rol spelen. Met de verdere ontwikkeling van 
de hierboven genoemde technieken kan HRS een van de belangrijke 
screening technologieën worden in de genoemde onderzoeksgebieden.  
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